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1 Introduction 
1.1  Gene transfer into eukaryotic cells by lentiviral vectors 
Lentiviral vectors allow stable long-term transgene expression in non-dividing cells 
and tissues. This property has made them ideal gene delivery vehicles for research 
and therapeutic applications (Cockrell and Kafri, 2007), including clinical trials 
(Levine et al., 2006). However, further efforts in vector design are required to improve 
safety and efficacy of lentiviral mediated gene transfer. Special attention has to be 
given to measures that restrict gene transfer to the cell type relevant for a particular 
therapeutic application. Ideally, gene transfer into non-target populations is already 
restricted at the step of cell entry. However, an effective and universally applicable 
system for cell entry targeting of lentiviral vectors is still not available. Therefore, this 
thesis deals with the development of an efficient cell entry targeting system for 
lentiviral vectors. 
1.1.1 Lentiviral  vectors 
Lentiviral vectors are derived from lentiviruses which belong to the family 
Retroviridae. Lentiviruses, with their most famous member the human 
immunodeficiency virus-1 (HIV-1), are enveloped viruses of about 100 nm in 
diameter with a diploid, positive sense, single stranded RNA genome of 7 to 13 kb 
per monomer. They replicate through a DNA intermediate that becomes integrated 
into the host cell genome (Goff, 2007). The envelope, consisting of host cell 
membrane and viral envelope proteins (Env), surrounds the capsid, a protein core, 
harbouring the viral replication enzymes and the RNA genome (Figure 1). The Env 
protein interacts specifically with the viral receptor(s) on the host cell surface, which 
triggers conformational changes in Env resulting in pH-independent fusion of the viral 
and the cellular membrane. Therefore, the host range (tropism) of a given lentivirus is 
determined by the Env protein. 
The lentiviral genome consists mainly of the genes gag/pol and env. All structural 
proteins like the membrane associated matrix protein, the core forming capsid protein 
and the nucleocapsid protein, which binds to the viral RNA, are encoded in the gag Introduction 
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region. The pol gene provides all viral enzymes, namely the protease, the reverse 
transcriptase and the integrase, whereas the env gene encodes the Env. 
 
Figure 1: Schematic representation of HIV-1 as an example for a typical lentivirus. The following 
features are indicated: the membrane associated matrix, the capsid composed of the capsid protein 
p24 harbouring the viral RNA genome, associated with nucleocapsid proteins as well as the reverse 
transcriptase and the surrounding cell-derived lipid membrane with inserted viral envelope proteins, 
consisting of the surface unit (gp120) and the non-covalently bound transmembrane unit (gp41). 
(modified after Karlsson Hedestam et al. 2008, Nature Reviews Microbiology (Karlsson Hedestam et 
al., 2008)). 
 
The viral genome is flanked by two identical long terminal repeats (LTRs) which carry 
the promoter, the transcription termination, the poly-adenylation signals and at the 
ends the attachment sites necessary for viral integration. The encapsidation signal 
psi (Ψ) mediates the packaging of the genomic RNA into viral particles. This genome 
structure is common to all of the seven genera of the Retroviridae family, to which 
also the simple γ-retroviruses with their prototype murine leukaemia virus (MLV) 
belong. But in contrast to γ-retroviruses, lentiviruses like HIV-1 have additional 
accessory genes, namely tat, rev, nef, vif, vpu and vpr  (Freed and Martin, 2007) 
(Figure 2).  
 
Figure 2: Schematic representation of the MLV and HIV-1 genome. LTR: long terminal repeat, Ψ: 
encapsidation signal psi (modified after Breckpot et al. 2007, Gene Therapy (Breckpot et al., 2007)). Introduction 
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An important feature of lentiviruses, which further discriminates them from γ-
retroviruses, is their ability to infect not only dividing but also non-dividing and 
terminally differentiated cells (Lewis et al., 1992). They do not need the mitotic 
dissolution of the nuclear membrane, instead they most likely rely on the cellular 
nuclear import proteins to pass through the nuclear pore (Bukrinsky, 2004). An 
exception are e.g. quiescent primary human lymphocytes that require a minimal 
stimulation with cytokines or other factors to become transduced by lentiviral vectors 
(Korin and Zack, 1998; Serafini et al., 2004; Unutmaz et al., 1999). 
The main advantages in using retroviral vectors in gene therapy, which means gene 
delivery into cells with the purpose of a therapeutic benefit, are efficient gene transfer 
and their ability to integrate the foreign gene into the host`s chromosome thereby 
achieving transmission of the transgene to the progenies of the modified cells. Due to 
their relative simple genome structure (Figure 2) first retroviral vectors were derived 
from MLV (Miller, 1997). Accordingly, MLV derived vectors were also the first to be 
used in human gene therapy trials for the efficacious treatment of so far incurable 
inherited diseases, as e.g. severe combined immunodeficiency (Cavazzana-Calvo et 
al., 2000; Cavazzana-Calvo and Fischer, 2007). However, because of their ability to 
mediate gene transfer into mitotically inactive cells, like neurons, lentiviral vectors are 
becoming more and more popular (Cockrell and Kafri, 2007). In contrast to 
lentiviruses, lentiviral vectors have packaged therapeutic or marker genes instead of 
the viral genome. Consequently, they are replication deficient, which means that they 
do not form progeny viruses, but are able to transfer any type of genetic information 
into mammalian cells and to integrate it into the cellular genome. This process is 
called transduction, in contrast to infection mediated by replication competent viruses 
(Figure 3) (Buchholz et al., 2008).  
To generate lentiviral vectors basically three components must be provided in so 
called packaging cells: a transfer vector consisting of the gene of interest, the Ψ-site 
and the two LTRs and additionally the core and the envelope proteins to form 
particles that have packaged the transfer vector (Figure 3b). To avoid the occurrence 
of replication competent lentiviruses through recombination events (Hu and Temin, 
1990), the genes encoding the core (gag/pol) and the envelope proteins (env) are 
usually split onto two separate plasmids that both lack a functional Ψ-site, for which 
reason they are not packaged into the vector particles. Since for the generation of 
lentiviral vectors, from all accessory proteins, only Tat and Rev are essential Introduction 
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(Zufferey et al., 1997), all other accessory proteins are deleted from the packaging 
plasmid, just leaving gag/pol, tat and rev (Figure 3b). Tat activates the LTRs leading 
to more efficient viral RNA production and Rev interacts with the Rev responsive 
element of the viral RNA in order to deliver unspliced viral RNA from the cell nucleus 
to the cytoplasm (Nekhai and Jeang, 2006). Different designs are possible for the 
transfer vector, e.g. the transcription of the transfer gene can be directly under the 
control of the viral LTRs or under the control of any additional heterologous promoter 
of interest. Thereby, insertions of up to a total size of about 7.5 kb are possible 
(Verma and Somia, 1997). 
 
Figure 3: Lentivirus versus lentiviral vector. (a) After transfection of the whole virus genome into so 
called packaging cells, lentiviruses are released into the supernatant and can be used for infection of 
target cells. Due to the chromosomal integration of their genome into the target cell population, they 
enable the cells to produce viral progeny. (b) The DNA constructs required for lentiviral vector 
production are the transfer vector plasmid, encoding the transfer gene (top), the packaging plasmid 
harbouring the gag/pol,  tat and rev genes under the control of a heterologous promoter (prom.) 
(middle) and the Env expression plasmid (bottom). The presence (Ψ) or absence (∆Ψ) of the 
packaging signal is indicated. Packaging cells transfected with these three plasmids release lentiviral 
vectors that have two RNA copies of the transfer vector packaged which can be transferred and after 
reverse transcription integrated into the target cell (transduction). The expressed protein encoded by 
the transfer gene is shown as green triangles. As none of the viral proteins is expressed in the target 
cells, no vector progeny is released. LTR: long terminal repeat; polyA: polyadenylation signal. Introduction 
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For particle formation, the two plasmids encoding the structural components and the 
transfer vector plasmid are co-expressed after transient or stable transfection in 
packaging cells. Then, the vector particles, which have packaged the transfer vector 
RNA but not the genetic information of the core and envelope proteins, bud from the 
cell membrane. Hence, their envelope consists of the cellular lipid-bilayer and viral 
Env, which is expressed on the cell surface (Figure 3b). After release into the cell 
culture supernatant, the vector particles can be used directly or upon concentration 
for transduction of target cells.  
The choice of envelope glycoprotein determines which cell type will be preferentially 
entered. Lentiviral vectors offer the possibility to incorporate not only homologous 
glycoproteins but also heterologous ones derived from other enveloped viruses, an 
approach termed pseudotyping. Moreover, engineering of the glycoproteins can be 
performed to restrict the tropism to a target cell population of interest.  
1.1.2 Pseudotyping  of  lentiviral vectors 
The host range of lentiviral vectors can be easily altered by incorporation of 
heterologous glycoproteins into the lentiviral envelope, a process called 
pseudotyping. Such particles possess the tropism of the virus from which the 
envelope glycoprotein is derived (Cronin et al., 2005). Two mechanisms have been 
suggested by which the glycoproteins become incorporated into the lentiviral 
particles. In the passive model of incorporation no direct interactions between the 
glycoproteins and the viral core proteins are necessary, but sufficient amounts of 
glycoproteins must be provided at the site of budding (Pickl et al., 2001) and their 
cytoplasmic tail may not sterically interfere with viral assembly or virion morphology 
(Swanstrom and Wills, 1997). Accordingly, glycoproteins with short cytoplasmic tails, 
like the one of the vesicular stomatitis virus (VSV), are more likely passively 
incorporated than glycoproteins with a long cytoplasmic tail. In contrast, in the active 
model of incorporation the glycoprotein cytoplasmic tail interacts directly with the viral 
core proteins or indirect via a cellular factor, which leads to successful pseudotyping. 
Although the exact mechanism of glycoprotein incorporation is not fully understood, 
there is abundant evidence in literature supporting the importance of the cytoplasmic 
tail in lentiviral assembly (Cosson, 1996; Freed, 1998; Murakami and Freed, 2000). 
Not only Env proteins of the Retroviridae family can heterologously pseudotype Introduction 
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lentiviral vectors (Liu et al., 2004; Reiser et al., 1996; Stitz et al., 2000). Up to date, 
glycoproteins from almost any family of mammalian enveloped viruses have been 
functionally incorporated into lentiviral particles. Examples include, but are not limited 
to orthomyxoviruses, filoviruses, alphaviruses and baculoviruses (Cronin et al., 2005; 
McKay et al., 2006). There is also one example in which envelope proteins derived 
from a paramyxovirus were incorporated into lentiviral particles (Kobayashi et al., 
2003). Among the first and still most widely used glycoprotein for pseudotyping of 
lentiviral vectors is the glycoprotein of vesicular stomatitis virus (VSV-G) (Cronin et 
al., 2005). Due to their high stability and broad tropism that covers amongst others all 
human cell types, such vectors have become effectively the standard for evaluating 
the efficiency of other pseudotypes.  
In some cases, pseudotyping can only be achieved upon modifying the cytoplasmic 
tail of the protein of interest. For example, the relatively short 30-40 amino acids long 
cytoplasmic tails of mammalian γ- and δ-retroviral Env proteins harbour a 15-20 
amino acid long carboxy-terminal peptide, named R peptide, that renders the Env 
protein fusion inactive unless being cleaved off by the viral protease during particle 
budding (Bobkova et al., 2002). While the R-peptide of the MLV Env becomes 
cleaved by the HIV-1 protease thus allowing straight forward pseudotyping of HIV-1 
particles, failure of R-peptide cleavage was determined as main reason preventing 
pseudotyping of HIV-1 particles with the Env proteins of the gibbon ape leukaemia 
virus (GALV) or the RD114 virus (Merten et al., 2005; Christodoulopoulos and 
Cannon, 2001; Sandrin et al., 2004; Stitz et al., 2000). In an other example, the two 
glycoproteins of the paramyxoviral Sendai virus, namely fusion (F) and 
hemagglutinin-neuraminidase (HN) protein, became incorporated into a simian 
immunodeficiency virus (SIV) derived lentiviral vector after truncation of the F protein 
cytoplasmic tail and by addition of the cytoplasmic tail of SIV Env to the cytoplasmic 
tail of the HN protein, respectively (Kobayashi et al., 2003). 
In most cases, the lentiviral tropism is broadened through pseudotyping and 
sometimes the heterologous glycoproteins allow a preferential gene transfer into 
specific tissues. For example envelope proteins of viruses that infect via the airway 
epithelia, like Ebola virus or influenza virus, are useful for the transduction of this kind 
of cells (Kobinger et al., 2001; Medina et al., 2003; McKay et al., 2006). But there are 
only few glycoproteins that allow selective transduction of a special cell population, 
like HIV-1 Env, which is specialised for CD4-positive T cells. Therefore, attempts to Introduction 
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engineer viral glycoproteins in terms of receptor usage were initiated over 15 years 
ago. However, this protein engineering task proved to be difficult, especially in 
respect of glycoproteins that combine the receptor attachment and membrane fusion 
function, such as the lentiviral Env or VSV-G (Buchholz et al., 2008; Sandrin et al., 
2003; Verhoeyen and Cosset, 2004). 
1.1.3 Envelope  engineering  of retroviral vectors 
Since lentiviral vectors allow stable integration of a transgene and its propagation into 
daughter cells as well as the transduction of non-dividing cells, they are the most 
promising tools for gene therapy. But due to their genome integration, also serious 
adverse effects, like insertional mutagenesis, can occur (Loewen and Poeschla, 
2005). Furthermore, is it often not desirable to express the therapeutic protein in 
healthy cells, especially when a suicide gene like the one of the herpes simplex virus 
thymidine kinase is transferred.  
Therefore, altering receptor usage by envelope engineering has become an 
important research field. In principle, envelope engineering in contrast to envelope 
substitution is not restricted by the availability of viral glycoproteins evolved by nature 
but should allow the universal generation of retargeted vectors. Initial approaches to 
alter receptor usage consisted of the insertion of various ligand types, like growth 
factors, hormones, peptides or single-chain antibodies (scAb) in several locations on 
the retroviral Env such that instead of, or in addition to the natural receptor a chosen 
cell surface molecule mediates cell entry (Buchholz et al., 2008; Sandrin et al., 2003; 
Verhoeyen and Cosset, 2004). In particular scAbs are favorable polypeptides for 
display on glycoproteins. They are composed of the variable domains of the heavy 
and the light chain of an antibody molecule connected via a long glycine-serine 
linker, thus forming a single antigen binding site (Figure 4). By choosing a scAb with 
a target antigen expressed exclusively on the relevant cell type, in principle, 
redirection of gene transfer to any desired cell fraction should be possible.  
Many of the above mentioned chimeric Env proteins folded correctly, were stably 
incorporated into the retroviral vectors and allowed efficient binding of the vectors to 
the respective cell surface molecule. However, cell entry into the desired cell 
population via the retargeted receptor was either absent or very inefficient, which is Introduction 
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most likely due to a loss of coupling between retargeted binding and fusion activity 
(Sandrin et al., 2003). 
 
Figure 4: Schematic representation of an antibody and the derived single-chain antibody 
(scAb). An antibody of the IgG class consists of two identical heavy (H) and two identical light (L) 
chain polypeptides which are linked by disulfide bonds. The variable domains of the heavy and light 
chains (VH and VL) form the two identical antigen binding sites, whereas the constant regions (CH1-3 
and CL) mediate the immune effector functions of the antibody. The scAb consists only of one of the 
VH and VL domains linked by a long glycine-serine-linker.  
 
Alternative targeting strategies have been developed based on specific requirements 
such as the surface expression or release of a special protease by the target cell 
(Hartl et al., 2005; Szecsi et al., 2006). Thereby, the displayed ligand is used as 
blocking domain that prevents cell entry via the native receptor. The linker between 
ligand and glycoprotein contains a protease cleavage site, so that cell entry proceeds 
upon cleavage and release of the blocking domain from the glycoprotein. Targeting is 
determined by the proteases expressed, e.g. matrix metalloproteases, which are over 
expressed in certain tumor cells. The disadvantage of this system is the limited 
availability of proteases restricted to distinct cell populations.  
Recently, lentiviral vectors have been pseudotyped with engineered Sindbis virus 
glycoproteins unable to recognise their natural receptor and modified to either non-
covalently bind a monoclonal antibody directed against a surface antigen, or to 
become co-incorporated into vector particles together with a complete antibody 
molecule (Morizono et al., 2005; Yang et al., 2006). In these approaches, the 
membrane fusion is mediated by the low pH in the endosomes after endocytosing of Introduction 
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the lentiviral vector upon antigen binding. Although such vector particles showed 
indeed promising targeting capabilities, these strategies suffer from the non-covalent 
linkage to the antibody, or the requirement for the targeted receptor to become 
endocytosed upon vector binding to activate the membrane fusion function of the 
Sindbis virus glycoprotein by low pH. In conclusion, until now no universal cell entry 
targeting strategy for lentiviral vectors that allows the redirection of gene transfer to 
any desired cell population is available. 
1.2   Measles virus cell entry 
Measles virus (MV), a member of the genus Morbillivirus in the family 
Paramyxoviridae, is the causative agent for measles, a disease characterised by 
fever, cough, conjunctivitis and a generalised maculopapular rash. The infection also 
causes a transient immunosuppression which begins just after the rash and lasts 
until the virus is cleared by the immune system after about two weeks. Apart from 
acute measles, in about one in 100,000 cases, a late (several years after acute 
infection) and severe disease, triggered by MV after asymptomatic persistence in the 
central nervous system, occurs and is known as subacute sclerosing panencephalitis 
(SSPE) (Yanagi et al., 2006). MV is an enveloped virus with a non-segmented, 
negative-strand RNA genome of about 16 kb which is tightly bound to nucleocapsid 
proteins and the viral polymerase complex. It also possesses the envelope 
associated matrix protein and the two envelope glycoproteins, namely the fusion (F) 
and the hemagglutinin (H) protein (Figure 5a) (Schneider-Schaulies and ter Meulen, 
2002), which are of utmost importance for this thesis and will be described in detail 
later on.  
MV was first isolated in 1954 using a primary culture of human kidney cells (Enders 
and Peebles, 1954). This first isolate, the attenuated Edmonston strain, is the 
progenitor of the currently used live vaccine strains. In 1993, CD46 (membrane 
cofactor protein; MCP), a type I transmembrane protein and complement regulatory 
molecule that is ubiquitously expressed on all human cells except erythrocytes, was 
shown to act as a cellular receptor for the Edmonston strain of MV. However, 
wildtype MV clinical isolates are unable to enter cells via CD46. Their receptor is the 
signaling lymphocyte activation molecule (SLAM or CD150) (Yanagi et al., 2006). 
SLAM, which can also be used by the vaccine MV strains as receptor, is a type I Introduction 
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transmembrane protein of the immunoglobulin superfamily. It is expressed on various 
cells of the immune system, namely immature thymocytes, memory T cells, B cells, 
macrophages and mature dendritic cells. Stimulation with antigens or mitogens 
upregulates SLAM expression on T and B cells (Veillette, 2006). SLAM signalling, 
together with T cell receptor engagement, regulates the production of TH2 cytokines 
such as interleukin (IL)-4 and IL-13 by CD4-positive T cells (Yanagi et al., 2006). 
 
Figure 5: Schematic representation of the MV particle and the mechanism of membrane fusion. 
(a) MV is a pleomorphic particle of about 200 nm in diameter consisting of the RNA genome tightly 
bound to nucleocapsid proteins (N) and the viral polymerase complex, namely the large protein (L) 
and the phosphoprotein (P). The matrix protein (M) covers the inner side of the lipid envelope from 
which the two viral glycoproteins, the fusion (F) and the hemagglutinin (H) protein, project. The M 
protein is also thought to interact with the cytoplasmic tails of the viral glycoproteins. (b) Model of MV-
induced membrane fusion and conformational changes within the F protein. The H protein mediates 
attachment to the cellular surface receptor and also provides a fusion helper function. Interaction of 
the H protein with its cellular receptor (CD150 is shown here) triggers conformational changes within 
the F protein that lead to insertion of the hydrophobic fusion domain (N-terminus of F; represented by 
arrowheads) into the cell membrane. Then intramolecular rearrangements leading to the formation of 
a coiled-coil structure within this subunit occur, caused by the interaction of two α-helical domains. In 
this way, the membranes to be fused are brought into close proximity, which is a prerequisite for the 
mixing of the outer leaflets (hemifusion) and subsequent fusion (modified after Schneider-Schaulies 
and ter Meulen 2002, Expert. Rev. Mol. Med. (Schneider-Schaulies and ter Meulen, 2002)). Introduction 
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The MV envelope glycoproteins are responsible for MV receptor interaction and 
adjacent membrane fusion: The F protein, a type I transmembrane protein, is 
synthesised as a precursor protein (F0), and is proteolytically cleaved and activated 
by the furin protease in the trans-Golgi compartment into the disulphide-bonded F1-F2 
heterodimer (Bolt and Pedersen, 1998). The F protein is responsible for fusion 
between the virus and the host cell membrane. In contrast, the H protein, a type II 
transmembrane protein, has a dual role: it mediates the attachment of the virus to the 
cell surface through interaction with the MV receptors and it provides a helper 
function for membrane fusion, for which residues in the membrane proximal part of 
its cytoplasmic tail are essential (Moll et al., 2002). The membrane fusion is pH-
independent, takes place directly at the cell surface and requires a complex of an H 
protein tetramer and an F protein trimer (Plemper et al., 2001). Thus, in contrast to 
the lentiviral Env, which provides both, the fusion and the receptor binding function, 
these two mechanisms are separated on two proteins in MV. 
After receptor binding of the H protein, a conformational change in H causes a 
subsequent conformational change within the F protein (Yanagi et al., 2006) which 
leads to the insertion of its hydrophobic fusion domain into the cell membrane and to 
pairing of two amphipatic α-helical domains, thereby bringing the membranes to be 
fused into close proximity (Figure 5b). Consequently, the cell and viral membrane 
fuse (Schneider-Schaulies and ter Meulen, 2002). The viral particle context is not 
required for membrane fusion as infected cells or cells only expressing the MV H and 
F glycoproteins on their cell surface can mediate cell-cell fusion, when at least one 
MV receptor is present. Thereby a multinucleate cellular mass, called syncytium, is 
produced (Herschke et al., 2007; Moll et al., 2002). In conclusion, MV, like 
lentiviruses, belongs to the virus class that mediates pH-independent fusion directly 
at the cell membrane which discriminates it from the viruses that depend on receptor-
mediated endocytosis for productive entry into their host cell, such as Sindbis virus 
and VSV (Roche et al., 2008; Yang et al., 2006).  
1.3  Engineering measles virus cell entry 
In contrast to the lentiviral vector system, a very efficient cell entry targeting system 
was recently established for MV (Nakamura et al., 2005). With no loss in cell entry 
capacity this method seems to allow retargeting of MV to any desired cell type. Introduction 
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As described above, cells infected with MV mediate cell-cell fusion resulting in strong 
syncytia formation leading to cell death. Hence, attenuated vaccine MV is emerging 
as a promising oncolytic platform. To avoid unwanted damage to non-cancer tissues 
that would also become infected via CD46 and SLAM, the H protein was engineered 
to restrict and retarget MV cell entry (Nakamura et al., 2005). In a first step, SLAM 
and CD46 contact residues were mutated to generate an H protein that is blind for 
these receptors. The respective substitutions are R533A to restrict entry via SLAM 
and Y481A, S548L and F549S to ablate CD46 interaction. Then, different scAbs 
were fused to the H ectodomain (C-terminus). These modified H proteins were 
cloned into the MV genome to generate fully retargeted oncolytic MVs. Such 
retargeted MVs infect MV receptor-negative cell lines when these cells express the 
cognate cell surface antigen whereas they are unable to infect MV receptor-positive 
but antigen-negative cells (Nakamura et al., 2005). Thereby, the efficiency of 
retargeted cell entry is comparable to that of unmodified MV (Figure 6). Furthermore, 
retargeted MVs selectively spread through antigen-positive tumor cells in vivo 
(Hammond et al., 2001; Nakamura et al., 2005; Paraskevakou et al., 2007; 
Ungerechts et al., 2007).  
As attenuated MV has shown therapeutic potential as a replicating oncolytic virus in 
models of non-Hodgkin`s lymphoma (Grote et al., 2001) also a scAb directed against 
CD20, which is overexpressed on most B cell lymphomas, was displayed on the MV 
H protein (Bucheit et al., 2003; Ungerechts et al., 2007). Although Bucheit et al. used 
an H protein as display platform that could still recognise the MV receptors, they 
demonstrated with MV receptor-negative but CD20-positive cell lines for the first time 
that MV entry can be mediated through interaction with a receptor with four 
membrane-spanning domains, like CD20 (Bucheit et al., 2003). The native MV 
receptors are single transmembrane domain proteins. MVs with targeted entry to 
CD20, which is exclusively expressed on B cells (Cragg et al., 2005), might represent 
a useful tool in therapy of lymphomas. Besides scAbs also ligands can be displayed 
on the MV H protein. For example, H proteins displaying on their ectodomain 
epidermal growth factor (EGF) mediated MV cell entry through the EGF receptor 
(EGFR), which is overexpressed on many cancer tissues (Schneider et al., 2000).  Introduction 
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Figure 6: Retargeted MVs infect cell lines via the targeted receptor in vitro. (left) Schematic 
representation of the recombinant MV genome showing the modified H protein. The scAb, directed 
against CD38 or the epidermal growth factor receptor (EGFR), is flanked by SfiI/NotI restriction sites 
and is displayed as a C-terminal extension of the mutated H glycoprotein. White triangle, circle, square 
and diamond represent Y481A, R533A, S548L and F549S mutations in the H protein that ablate entry 
via SLAM and CD46, respectively. Also indicated is a factor Xa (Fxa) cleavage site in front of the scAb 
and a six-histidine peptide (Hx6) at its C-terminus. Furthermore, the MV genome carries an additional 
transcription unit coding for the enhanced green fluorescent protein (eGFP) marker gene. (right) CHO 
cells that express no MV receptors and no targeted receptor and CHO transfectands positive for an 
anti-His antibody (αHis), CD46, SLAM, CD38 or EGFR were infected with the retargeted or control 
MVs and were photographed 2 d later. Obviously, the retargeted MVs infect MV receptor-negative cell 
lines when these cells express the respective cell surface antigen whereas they are unable to infect 
MV receptor-positive but antigen-negative cells (modified after Nakamura et al. 2005, Nature 
Biotechnology (Nakamura et al., 2005)). 
1.4 Objective 
The aim of this thesis was the development of an efficient and compliant cell entry 
targeting system for lentiviral vectors. It was hypothesised that the retargeting system 
of measles virus (MV) can be transferred to lentiviral vectors, by pseudotyping HIV-1 
vector particles with the MV glycoproteins. To test this hypothesis, plasmids encoding 
the MV glycoproteins F and H, respectively, or a native receptor blind H protein with 
a displayed single-chain antibody (scAb) directed against the B cell surface marker 
CD20 were available. 
For the establishment of MV-HIV pseudotypes, cytoplasmic tail truncation mutants of 
the H and F protein had to be screened, to identify variants that allow efficient 
pseudotyping of lentiviral vectors. Then, these MV pseudotyped HIV-1 particles 
should be characterised in terms of glycoprotein incorporation, mediation of stable Introduction 
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gene transfer and expression and receptor usage. Furthermore, the titers of these 
pseudotypes should be optimised on MV receptor-positive cell lines.  
In a next step, retargeted lentiviral vector particles should be generated. Therefore, 
SLAM and CD46 blind H proteins with an optimally truncated cytoplasmic tail that 
allows incorporation into HIV-1 vector particles, displaying at their ectodomain either 
the epidermal growth factor (EGF) ligand or a scAb directed against CD20 had to be 
generated. Together with the optimally cytoplasmic tail truncated F protein HIV-1 
vector particles retargeted to the EGF receptor or CD20 should be produced.  
The targeting capability of these vectors should be determined on different target 
receptor-positive and -negative cell lines either in separate approaches or in mixed 
cell culture. Also the question if the CD20-retargeted vector can mediate selective 
cell killing should be addressed. As transduction of primary human cells is a crucial 
feature for a clinical application, finally, the ability of the CD20-retargeted HIV-1 
vector particles to selectively transduce primary human B cells had to be 
investigated. Also unstimulated primary human B cells should be included to address 
if the new entry pathway via CD20 eventually enables transduction of quiescent B 
cells. This will be of special importance as until now, quiescent lymphocytes had 
been resistant to transduction by any type of retro- or lentiviral vector.    
Such CD20-retargeted HIV-1 vectors will be of great use for a number of applications 
ranging from the genetic modification of B cells for investigating basic questions in 
immunology to therapeutic strategies such as the treatment of inherited B-cell 
disorders or lymphomas. Furthermore, as this novel targeting strategy for lentiviral 
vectors should be easily adaptable to many target molecules of interest by extending 
the H protein with appropriate ligands or scAbs, such retargeted vectors may improve 
safety and efficacy of lentiviral mediated gene transfer in gene therapy. Material and Methods 
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2  Material and Methods 
2.1 Material 
2.1.1  Chemicals and consumables 
Unless otherwise noted, all used chemicals were obtained in p.a. quality from the 
companies Merck, Sigma-Aldrich, Roth, Fluka or Serva. The consumables for cell 
culture and molecular biology were obtained from the companies Greiner, Nunc, 
Eppendorf, BD
TM or Sarstedt. 
2.1.2 Enzymes,  inhibitors,  antibiotics and cytokines 
enzymes  source of supply 
restriction endonucleases  New England Biolabs 
T4-DNA-ligase  New England Biolabs 
Taq-DNA-polymerase 5  PRIME 
PfuUltra
TM High-Fidelity (HF)-DNA-
polymerase  Stratagene 
deoxyribonuclease I (DNase I)  Invitrogen 
 
inhibitors  source of supply 
azidothymidine (AZT)  Sigma-Aldrich 
fusion-inhibiting peptide (FIP)   
Z-D-Phe-Phe-Gly-OH  Bachem 
protease inhibitor cocktail complete  Roche 
 
antibiotics  source of supply 
ampicillin Roche 
geneticin (G418)  Gibco 
puromycin Sigma-Aldrich 
penicillin Biochrom  AG 
streptomycin Biochrom  AG 
 
 
The used cytokines IL-2, IL-4 and IL-10 as well as CD40 ligand were obtained from 
R&D Systems. 
 Material and Methods 
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2.1.3 Kits 
kits  source of supply 
QIAprep
® Spin Miniprep Kit  Qiagen 
EndoFree
® Plasmid Maxi Kit  Qiagen 
Jetstar 2.0 Mega Kit  Genomed 
Geneclean
® Turbo Kit  Q-Biogene 
DNeasy
® Blood and Tissue Kit  Qiagen 
Dynal
® B cell negative isolation Kit  Invitrogen 
 
2.1.4  Antibodies and antisera   
name  dilution 
application  source of supply 
F431 rabbit anti-F 
polyclonal serum 
1:1,000  
western blot  R. Cattaneo, Mayo Clinic, USA 
H606 rabbit anti-H 
polyclonal serum 
1:2,000  
western blot  R. Cattaneo, Mayo Clinic, USA 
mouse anti-HIV-1 p24 mAb   1:1,000 
western blot  ZeptoMetrix 
HRP conjugated rabbit anti-
mouse Immunoglobulins 
1:2,000 
western blot  DakoCytomation 
HRP conjugated goat anti-rabbit 
Immunoglobulins 
1:2,000 
western blot  DakoCytomation 
Y503 mouse anti-F mAb  1:100  
FACS  R. Cattaneo, Mayo Clinic, USA 
K83 mouse anti-H mAb 
supernatant of hybridoma K83 
1:10 
FACS 
J. Schneider-Schaulies, 
University of Würzburg 
R-Phycoerythrin (PE) conjugated 
anti-mouse IgG (whole molecule) 
F(ab´)2 fragment 
1:50 
FACS  Sigma-Aldrich 
PE conjugated mouse anti-
human CD19 mAb 
1:10 
FACS  DakoCytomation 
PE-Cy5, FITC or PE  conjugated 
mouse anti-human CD20 mAb 
1:10 
FACS  BD Pharmingen
TM 
FITC conjugated mouse anti-
human CD69 mAb 
1:10 
FACS  DakoCytomation 
PE conjugated mouse anti-
human CD69 mAb 
1:10 
FACS  BioLegend 
PE conjugated mouse anti-
human CD71 mAb 
1:10 
FACS  BD Pharmingen
TM 
PE conjugated mouse anti-
human CD86 mAb 
1:10 
FACS  BD Pharmingen
TM 
PE conjugated mouse anti-
human CD25 mAb 
1:10 
FACS  BD Pharmingen
TM 
PE conjugated mouse anti-
human CD34 mAb 
1:10 
FACS  EuroBioSciences Material and Methods 
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PE-Cy5, FITC or PE conjugated 
mouse IgG2b,κ isotype control 
1:10 
FACS  BD Pharmingen
TM 
FITC or PE conjugated mouse 
IgG1,κ isotype control 
1:10 
FACS  BD Pharmingen
TM 
PE conjugated mouse IgG2a,κ 
isotype control 
1:10 
FACS  BD Pharmingen
TM 
 
2.1.5 Plasmids 
name  characterisation  source of supply 
peHc∆14 
shuttle vector with the coding region 
for MV H with a truncated 
cytoplasmic tail (ct) of 14 aa  
R. Cattaneo, Mayo 
Clinic, USA 
(Cathomen et al., 1998) 
p(+)MV-Fc∆24 
full-length MV genomic plasmid with 
the coding region for F with a 
truncated ct of 24 aa 
R. Cattaneo, Mayo 
Clinic, USA 
(Cathomen et al., 1998) 
pE-Mo 
full-length MoMLV genomic plasmid 
with the EGF ligand DNA fused to 
the N-terminal coding region of Env 
C.J. Buchholz, 
Paul-Ehrlich-Institut 
(Buchholz et al., 1998) 
  glycoprotein expression plasmids   
pCG-H (10.2)  encodes MV H under control of the 
CMV promoter 
R. Cattaneo, Mayo 
Clinic, USA 
(Cathomen et al., 1995) 
pCG-F (10.1)  encodes MV F under control of the 
CMV promoter 
R. Cattaneo, Mayo 
Clinic, USA 
(Cathomen et al., 1995) 
pCG-Hc∆14 
encodes MV H with a truncated ct 
of 14 aa under control of the CMV 
promoter 
this thesis 
pCG-Hc∆15 to 
pCG-Hc∆24 
encodes MV H with a truncated ct 
of the indicated number of aa under 
control of the CMV promoter 
A. Maisner, Philipps 
University of Marburg 
(Moll et al., 2002) 
pCG-Hc∆21+A 
pCG-Hc∆24+4A 
pCG-Hc∆26+6A 
pCG-Hc∆30+10A  
encodes MV H with a truncated ct 
of 21, 24, 26 or 30 aa and one, four, 
six or ten added alanine after the 
start methionine of the MV H 
protein 
A. Maisner, Philipps 
University of Marburg 
(Moll et al., 2002) 
pCG-Fc∆24 
encodes MV F with a truncated ct of 
24 aa under control of the CMV 
promoter 
this thesis 
pCG-Fc∆30 
encodes MV F with a truncated ct of 
30 aa under control of the CMV 
promoter 
A. Maisner, Philipps 
University of Marburg 
(Moll et al., 2002) 
pCG-Hmut-6His 
encodes MV H with the four point 
mutations Y481A, R533A, S548L, 
F549S 
R. Cattaneo, Mayo 
Clinic, USA 
pCG-Hmut∆18  encodes MV H with the four point 
mutations Y481A, R533A, S548L,  this thesis Material and Methods 
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F549S and a truncated ct of 18 aa 
pCG-
HmutXαCD20-
6His 
encodes MV H with the four point 
mutations Y481A, R533A, S548L, 
F549S and the αCD20-scAb fused 
to its C-terminus  
R. Cattaneo, Mayo 
Clinic, USA 
(Ungerechts et al., 2007)
pCG-H-αCD20 
(10.7) 
encodes MV H with the four point 
mutations Y481A, R533A, S548L, 
F549S, a truncated ct of 18 aa and 
the αCD20-scAb fused to its C-
terminus  
this thesis 
pCG-H-αEGFR 
(10.8) 
encodes MV H with the four point 
mutations Y481A, R533A, S548L, 
F549S, a truncated ct of 18 aa and 
the ligand EGF fused to its C-
terminus  
this thesis 
pMD.G2 (10.5)  encodes VSV-G  D. Trono, Tronolab, 
Switzerland 
pHIT123  encodes the Env of the Moloney 
MLV  (Soneoka et al., 1995) 
  packaging plasmids   
pCMV∆R8.9 
(10.3)  HIV-1 packaging plasmid 
U. Blömer, University 
Hospital Kiel 
(Zufferey et al., 1997) 
pHIT60  MLV packaging plasmid 
A.J. Kingsman, 
University of Oxford, UK 
(Soneoka et al., 1995) 
SIV10+  SIVmac packaging plasmid 
F.-L. Cosset, University 
of Lyon, France 
(Negre et al., 2000) 
  transfer vector plasmids   
pHR`-CMV-GFP 
(10.4) 
HIV-1 packagable vector encoding 
GFP under control of the CMV 
promoter 
U. Blömer, University 
Hospital Kiel 
(Miyoshi et al., 1997) 
pSEW (10.6) 
HIV-1 packagable vector encoding 
GFP under control of the SFFV 
promoter 
M. Gretz,  
Georg-Speyer-Haus 
(Demaison et al., 2002) 
pS-CD34TK39-W 
(10.9) 
HIV-1 packagable vector encoding 
the CD34TK39 fusion protein under 
control of the SFFV promoter 
this thesis 
pM71tCD34tk39m 
MPSV packagable vector encoding 
the CD34TK39 fusion protein under 
control of the viral LTRs 
M. Gretz,  
Georg-Speyer-Haus 
(Junker et al., 2003) 
pSFG-eGFP  MLV packagable vector encoding 
GFP under control of the viral LTRs 
A. Schwantes, 
Paul-Ehrlich-Institut 
GAE-sffv-gfp-
wpre 
SIVmac packagable vector 
encoding GFP under control of the 
SFFV promoter 
D. von Laer,  
Georg-Speyer-Haus 
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2.1.6 Oligonucleotides 
All oligonucleotides were synthesised from the company Eurofins MWG Operon. 
 
name 5`Æ 3`sequence 
PR-CD34TK-for  AGGCGCGCCAGTCCTCCGATTGACTGAGTCGCCCGGGGG 
GGATCCACCGGTCGCCACCATGCCGCGGGGCTGGACC 
PR-CD34TK-rev GTGCCTGCAGGTCAGTTAGCCTCCCCCATC 
ALUs AAACCCACGCATGACACAACACTG 
HIV-AluPCRas CGGGCGCCACTGCTAGAGATTTT 
SEW-LTR1s ACTGGAAGGGCTAATTCACTCC 
SEW-LTR1as TGCTAGAGATTTTCCACACTGACT 
β-Act-for ATGATATCGCCGCGCTCGTCGTC 
β-Act-rev TTCTCGCGGTTGGCCTTGGGGTTCAG 
 
2.1.7 Bacterial  strains and culture media 
name genotyp  source of 
supply 
Top10 
F
-, mcrA, ∆(mrr-hsdRMS-mcrBC), Ф80lacZ∆M15, ∆lacX74, 
deoR, recA1, araD139, ∆(ara-leu)7697, galU, galK, rpsL (Str
R), 
endA1, nupG  
Invitrogen 
 
Luria-Bertani (LB) medium     S.O.C.  medium  (Invitrogen) 
Bacto-Trypton   1.0%  (w/v)   Tryptone    2.0%  (w/v) 
yeast  extract    0.5%  (w/v)   yeast  extract    0.5%  (w/v) 
N a C l      1 . 0 %   ( w / v )    N a C l      1 0   m M  
pH 7.0        K C l      2 . 5   m M  
       M g C l 2     10 mM 
       M g S O 4    10  mM 
       g l u c o s e     2 0   m M  
2.1.8  Cell lines and culture media 
name  characterisation  source of supply 
HEK-293T 
human embryonic kidney cell line 
genetically engineered to express the 
large T antigen 
ICLC HTL04001 
HT1080  human fibrosarcoma cell line  ATCC CCL-121 
HT1080-CD20  human fibrosarcoma cell line genetically 
engineered to express CD20 
R. Cattaneo, Mayo 
Clinic, USA 
CHO-K1  chinese hamster ovary cell line  ATCC CCL-61 
CHO-SLAM  chinese hamster ovary cell line 
genetically engineered to express 
Y. Yanagi, Kyushu 
University, Japan Material and Methods 
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human SLAM 
CHO-CD46 
(previously termed 
CHO-BC1) 
chinese hamster ovary cell line 
genetically engineered to express 
human CD46 
C.J. Buchholz, 
Paul-Ehrlich-Institut 
CHO-CD20 
chinese hamster ovary cell line 
genetically engineered to express 
human CD20 
R. Cattaneo, Mayo 
Clinic, USA 
CHO-EGFR 
chinese hamster ovary cell line 
genetically engineered to express 
human EGFR 
R. Cattaneo, Mayo 
Clinic, USA 
A-431  human epidermoid carcinoma cell line  ATCC CRL-1555 
Daudi  human Burkitt`s lymphoma cell line  ECACC 85011437 
Raji  human Burkitt`s lymphoma cell line  ATCC CCL-86 
K-562  human chronic myelogenous leukaemia 
cell line  ATCC CCL-243 
A3.01  continuous human T cell line  (Folks et al., 1985) 
 
Culture medium for HEK-293T, HT1080, A-431 and CHO-K1 cells 
Dulbecco`s modified Eagle medium (DMEM) obtained from Biochrom AG 
supplemented with 10% fetal calf serum (FCS; Biochrom AG) and 2 mM L-glutamine 
(Biochrom AG) 
 
Culture medium for Daudi, Raji, K-562 and A3.01 cells 
RPMI 1640 medium obtained from Biochrom AG supplemented with 10% FCS and 2 
mM L-glutamine 
 
Culture medium for CHO-SLAM cells 
RPMI 1640 medium supplemented with 10% FCS, 2 mM L-glutamine and 0.5 mg/ml 
G418 
 
Culture medium for CHO-CD46, CHO-EGFR, CHO-CD20 and HT1080-CD20 cells 
DMEM supplemented with 10% FCS, 2 mM L-glutamine and 1.2 mg/ml G418 (CHO-
CD46) or 1.0 mg/ml G418 (CHO-EGFR) or 3 µg/ml puromycin (CHO-CD20, HT1080-
CD20) Material and Methods 
 
  21
2.2  Methods of molecular biology 
2.2.1  Cultivation of bacteria 
Liquid culture 
Bacteria were grown in LB medium supplemented with 0.1 mg/ml ampicillin (LBAmp) 
either at 37°C over night or at 25°C for 72 h and 180 rpm in a bacteria shaker 
(innova
TM 4200, New Brunswick scientific). 
 
Culture plate 
The cultivation on LBAmp plates (1% (w/v) Bacto-Trypton, 0.5% (w/v) yeast extract, 
1% NaCl, 50 µg/ml ampicillin, 1.5% (w/v) agar agar) was performed by applying 
bacteria onto the plates and subsequent incubation at 37°C or 25°C in a bacteria 
incubator (innova
TM 4200, New Brunswick scientific) until bacteria colonies were 
visible. The overgrown plates were stored for up to one month at 4°C. 
2.2.2  Restriction and ligation of plasmid DNA 
All DNA restrictions were performed using commercially available type II restriction 
endonucleases from New England Biolabs (NEB) according to the manufacturer’s 
instructions. 
 
Standard restriction reaction for preparative purposes 
10 µg DNA 
10 U (units) restriction enzyme (each, in case of a double digest) 
5 µl 10x buffer (NEB buffer 1-4, corresponding to the used restriction enzyme/s) 
5 µl 10x BSA (NEB, only if required by the applied enzyme/s) 
ad 50 µl aqua bidest 
 
The restriction sample was incubated for three hours or over night at the temperature 
optimum of the used restriction enzyme. In case of a double digest with restriction 
enzymes needing different NEB buffers, the optimal buffer for the double digest was 
chosen. In case of different optimal temperatures, the enzymes were added 
sequentially and incubation was performed at the respective temperature optimum 
for three hours each. Then, the restriction sample was applied to agarose gel Material and Methods 
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electrophoresis (2.2.5) and the desired DNA fragment was purified from the gel 
(2.2.6). 
 
Standard restriction reaction for analytic purposes 
1 µg DNA 
5 U restriction enzyme (each, in case of a double digest) 
2 µl 10x buffer (NEB buffer 1-4, corresponding to the used restriction enzyme/s) 
2 µl 10x BSA (NEB; only if required by the applied enzyme/s) 
ad 20 µl aqua bidest 
 
Incubation was performed for 90 min or over night at the temperature optimum of the 
applied enzyme. Double digests were performed as described for preparative 
purposes. Then, the restriction sample was analysed by agarose gel electrophoresis 
(2.2.5). 
 
Ligation of DNA fragments 
Recombination of DNA is usually performed by ligation of two double stranded 
nucleic acid molecules exhibiting complementary overhangs or blunt ends, which is 
the case, when the DNA fragments of interest were digested with the same restriction 
endonucleases. For ligation, the T4-DNA-ligase, which catalyses the formation of 
phosphodiester bonds between the fragments under consumption of ATP was used. 
The following reaction mixture has been used as standard sample: 
 
approximately 0.1 µg DNA (molar ratio of backbone to insert = 1:3) 
1 µl 10x ligase buffer (NEB) 
400 U T4-DNA-ligase 
ad 10 µl aqua bidest 
 
The reaction mix was incubated at 16°C over night. Then, the ligated DNA was 
directly used for the transformation of competent bacteria or was frozen at -20°C. 
2.2.3  Generation and transformation of competent bacteria 
Transformation of E. coli (K12-derived safety strains) is the method of choice to 
amplify plasmid DNA through cellular replication. For this purpose, bacteria have to Material and Methods 
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be pretreated in a special manner to become competent for introduction of foreign 
DNA. 
For the generation of chemically competent Top10 bacteria 2.5 ml of an over night 
culture were used to inoculate 100 ml LB medium, which were subsequently 
incubated at 37°C and 180 rpm in a bacteria shaker (innova
TM 4200, New Brunswick 
scientific). Cells were allowed to grow to an OD550 of about 0.5 - 0.55 reaching the 
logarithmic growth phase. Then the culture was incubated on ice for 5 min, divided 
into two portions and pelleted at 4,000 rpm for 10 min at 4°C (Multifuge 3S-R, 
Heraeus). Next, the pellets were each resuspended in 20 ml TFB1 buffer (sterile 
filtrated solution of 30 mM KOAc, 100 mM RbCl2, 10 mM CaCl2, 50 mM MnCl2, 15% 
glycerine, pH adjusted to 5.8 with HAc), incubated on ice for 5 min and once again 
pelleted as above. Subsequently the cells were resuspended each in 2 ml TFB2 
buffer (sterile filtrated solution of 10 mM MOPS, 75 mM CaCl2, 10 mM RbCl2, 15% 
glycerine, pH adjusted to 6.5 using KOH-solution) and incubated on ice for 15 min. 
Afterwards the suspension was portioned á 100 µl into 1.5 ml reaction tubes and 
frozen at -80°C. 
To transform the chemically competent E. coli bacteria, the cells were thawed on ice 
and approximately 50 ng DNA or the whole 10 µl ligation reaction (2.2.2) were added 
to one aliquot. After further incubation on ice for 30 min, a heat shock at 42°C for 45 
sec was performed in a thermoblock (eppendorf). Then 500 µl of pre-warmed (37°C) 
S.O.C. medium were added and the sample before it was incubated at 600 rpm for 
60 min at 37°C in a thermoblock (eppendorf). Then the bacteria suspension was 
applied to LBAmp plates (2.2.1) and incubated at 37°C over night or at 25°C for 72 h. 
2.2.4 Plasmid  preparation 
Preparation of plasmids from transformed bacteria was performed using the 
QIAprep
® Spin Miniprep kit, the EndoFree
® Plasmid Maxi kit or the Jetstar 2.0 Mega 
kit according to the manufacturer’s instructions. The basic principle of these kits is 
binding of DNA to silica gel membranes in the presence of a high concentration of 
chaotropic salt or to anion exchange columns. Thus, all cellular compounds such as 
proteins can be washed away, whereas the DNA is retained within the columns from 
which it can be diluted with water or appropriate buffers.  Material and Methods 
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For purification of low amounts of DNA (Miniprep), 5 ml LBAmp medium were 
inoculated with one bacteria clone and incubated over night at 37°C (2.2.1). The next 
day, bacteria were harvested at 3,000 rpm for 10 min at RT (Multifuge 3S-R, 
Heraeus). The resulting pellet was used for the preparation of plasmid DNA 
according to the manufacturer’s instructions of the QIAprep
® Spin Miniprep kit. 
For extraction of larger amounts of DNA (Maxiprep or Megaprep) 200 ml or 2 l LBAmp 
medium were inoculated and cultivated over night at 37°C or for 72 h at 25°C (2.2.1). 
Bacteria were harvested at 4,000 rpm for 10 min at RT (Sorvall RC 26 plus). The 
resulting pellets were used for the preparation of plasmid DNA according to the 
manufacturer’s instructions of the EndoFree
® Plasmid Maxi kit or Jetstar 2.0 Mega 
kit. Finally, the concentration of the isolated plasmid DNA was determined 
photometrically (GeneQuant pro, Amersham Biosciences) at absorption A260. 
2.2.5 Agarose  gel  electrophoresis 
Agarose gel electrophoresis allows the separation of DNA molecules by their size. 
Polymerised agarose acts like a molecular sieve, for which reason the negatively 
charged DNA migrates through agarose gels in a size dependent manner after 
applying an electric current. 
For fragments >1 kb, 0.7% - 1% agarose gels were used, whereas 1.5% - 2% 
agarose gels were used for smaller fragments. The gels were produced by adding 
the corresponding amount of agarose to 100 ml TAE buffer (40 mM Tris-Acetat, 1 
mM EDTA, pH 7.5) and heating of the emulsion in a microwave oven until the solid 
agarose became solved. Afterwards, 50 µg/ml ethidium bromide that intercalates into 
DNA strands and can be visualised under UV light, were added and the gel was 
casted into a tray, in which it polymerised within about 20 min.  
DNA samples were mixed with 0.2 volumes 5x sample buffer (30% glycerine and 1% 
brome phenol blue and xylenxyanol in 5x TAE buffer) and applied to the gel. As 
marker, 1.0 µg 2-log ladder (NEB) was used. Electrophoresis was performed at 100 
V for approximately 45 min in a Bio-Rad WIDE MINI-SUB
® cell GT chamber. 
Afterwards the fragments were photographically documented under UV light. If 
desired, DNA fragments were isolated from the gel as described below.  Material and Methods 
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2.2.6  Isolation of DNA fragments from agarose gels 
Purification of DNA fragments from agarose gels was performed using the 
Geneclean
® Turbo kit according to the manufacturer’s instructions. This kit is based 
on binding of DNA to silica gel membranes in the presence of a high concentration of 
chaotropic salt. After electrophoretic separation, the DNA fragment of interest was 
cut out of the gel, transferred into a 1.5 ml reaction tube and purified according to the 
manual. 
2.2.7 Nucleic  acid  sequencing 
Nucleic acid sequencing was performed at the company Eurofins MWG Operon. For 
this purpose, DNA samples containing approximately 1 µg plasmid DNA were 
lyophilised in a Speedvac sc 100 (Savant) and sent via regular mail together with 
appropriate primers of 10 pmol/µl to the company.  
2.2.8  DNase I digestion of vector particles 
Vector particles used for the transduction of adherent eukaryotic cell lines or primary 
human B cells, from which afterwards genomic DNA was isolated, were incubated 
with DNase I in advance. This way plasmid DNA from the vector particle producing 
cells that might be attached to the vector particles was digested and could not lead to 
false positive results in PCR of the isolated genomic DNA. The following reaction 
mixture has been used as standard sample: 
 
30 µl vector particles 
4 µl 10x DNase I reaction buffer (Invitrogen) 
1 U DNase I (Invitrogen) 
ad 40 µl PBS (Biochrom AG) 
 
The reaction sample was incubated for 1 h at RT and then directly used for 
transduction (2.3.8; 2.3.9). Material and Methods 
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2.2.9  Isolation of genomic DNA 
Genomic DNA was isolated from adherent eukaryotic cell lines or primary human B 
cells using the DNeasy
® Blood and Tissue kit according to the manufacturer’s 
instructions. The kit is based on binding of DNA to silica gel membrane columns in 
the presence of a high concentration of chaotropic salt. Thus, DNA is retained, 
whereas all other cellular components are washed away. 
Adherent cells were trypsinised (PBS (Biochrom AG), 100 mM EDTA, 0.25% Trypsin-
Melnick) within the well of a 48 well plate and the resulting cell suspension was 
centrifuged at 3,000 rpm, RT, for 3 min (Heraeus Fresco 17). Then, the cells were 
resuspended in 1 ml PBS (Biochrom AG) and centrifuged as described above. 
Approximately 2x10
5 - 5x10
5 detached cells or primary human B cells (centrifuged as 
described above) were resuspended in 200 µl PBS and applied to the purification 
procedure described in the manual with the following modification: For elution of the 
DNA from the columns 100 µl of buffer AE were used instead of 200 µl to increase 
the DNA concentration. Finally, the concentration of the DNA was determined 
photometrically (GeneQuant pro, Amersham Biosciences) at absorption A260. 
2.2.10  Polymerase chain reaction (PCR) 
PCR allows the amplification of specific DNA sequences from different origins, such 
as plasmid, genomic or complementary DNA (Mullis and Faloona, 1987; Saiki et al., 
1985). The amplified fragment can be used for further molecular biological methods. 
One of the most used DNA-dependent DNA-polymerases is the thermally stable Taq-
DNA-polymerase isolated from Thermophilus aquaticus. Using appropriate buffers, 
oligonucleotides (primers), deoxynucleotides and cycling conditions, the Taq-DNA-
polymerase can amplify a DNA fragment (template) bordered by the forward and 
reverse primer in an exponential manner. A typical PCR cycle contains a 
denaturising step at 94°C or 95°C, leading to the dissociation of the double stranded 
template. The following hybridisation step allows primer annealing to the 
complementary sequences on the single stranded template. The hybridisation 
temperature TH is adjusted according to length and G/C-A/T content of the primers. It 
can be calculated roughly corresponding to the Wallace rule (Suggs et al., 1981): TH 
= 4x(G+C) + 2x(A+T) - 5. After hybridisation, DNA elongation is performed at the Material and Methods 
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temperature optimum of the used DNA-polymerase. The elongation time is chosen 
according to the length of the amplificate, for the DNA-polymerases used in this 
thesis approximately 1 min / 1 kb. By repeating this cycle sequence, the template is 
amplified in an exponential manner. 
In this thesis, the Taq-DNA-polymerase and the PfuUltra
TM HF-DNA-polymerase 
were used. In contrast to the Taq-DNA-polymerase, the PfuUltra
TM HF-DNA-
polymerase has an 3´-5´exonuclease activity that reduces the error rate.   
For amplification of the cd34tk39-gene a standard PCR mix (100 µl) containing the 
following ingredients and a standard PCR protocol was used:   
 
0.5 µg template (pM71tCD34tk39m) 
10 µl 10x  PfuUltra
TM HF reaction buffer (Stratagene)  94°C  2 min 
10 pmol PR-CD34TK-for (forward primer)  94°C  20 sec 
10 pmol PR-CD34TK-rev (reverse primer)  55°C  30 sec        15x 
200 µM of each deoxynucleotid  72°C  125 sec 
5 U PfuUltra
TM HF-DNA-polymerase (Stratagene)  72°C  7 min 
ad 100 µl aqua bidest  subsequent cool down to 4°C 
 
To verify chromosomal integration of vector sequences transferred by MVαCD20-HIV 
vectors or VSV-G-HIV vectors, a two-step PCR amplification assay (two-step Alu-
PCR) was performed (Chun et al., 1997).  
For integration analysis, isolated genomic DNA from transduced and untransduced 
cells was used as template. In the first step, the primers ALUs and HIV-AluPCRas 
that bind to cellular genomic Alu and proviral gag sequences (ψ-site coding region in 
the transfer vector), respectively, were used, for which reason only after integration of 
the transfer vector sequences, amplificates were obtained. As these amplificates 
were of different sizes, due to different integration sites in the genomic DNA, a 
second transfer vector specific PCR was performed. For this purpose, in the second 
step, 1/10 of the PCR product from the first step was used as template and the 
transfer vector-specific primers SEW-LTR1s and SEW-LTR1as binding in the LTR 
were applied. Integration of vector DNA was indicated, if a significant increase in the 
transfer vector-specific signal was obtained by two steps of amplification, compared 
to that attained without a preceding Alu-PCR. β-Actin sequences were amplified to 
demonstrate the integrity of isolated genomic DNA. The following PCR protocols 
were performed: Material and Methods 
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1. step: Alu-PCR  
90  ng  genomic  DNA      
10 pmol ALUs (forward primer)     95°C    3  min   
10 pmol HIV-AluPCRas (reverse primer)    95°C  30 sec           
5 µl 10x Taq buffer advanced (5 PRIME)    60°C  30 sec      35x 
2.5 U Taq-DNA-polymerase (5 PRIME)     68°C  2 min 
200 µM of each deoxynucleotid         68°C  7 min 
300 µM MgCl2        subsequent cool down to 4°C 
ad 50 µl aqua bidest 
 
2. step: transfer vector-specific PCR 
5 µl PCR product from step 1      
or 9 ng genomic DNA          95°C  3 min 
10 pmol primer SEW-LTR1s (forward primer)    95°C  30 sec 
10 pmol primer SEW-LTR1as (reverse primer)   60°C  30 sec       30x 
5 µl 10x Taq buffer advanced (5 PRIME)    68°C  40 sec 
2.5 U Taq-DNA-polymerase (5 PRIME)     subsequent cool down to 4°C 
200 µM of each deoxynucleotid  
ad 50 µl aqua bidest 
 
β-Actin PCR 
90 ng genomic DNA 
12.5 pmol β-Act-for (forward primer)  94°C  3 min 
12.5 pmol β-Act-rev (reverse primer)  94°C  1 min 
5 µl 10x Taq buffer advanced (5 PRIME)  58.8°C   1 min      35x   
2.5 U Taq-DNA-polymerase (5 PRIME)  68°C  2 min   
200 µM of each deoxynucleotid 68°C  7  min 
ad 50 µl aqua bidest          subsequent cool down to 4°C 
 
All PCR reactions were performed using an Eppendorf Mastercycler gradient 
(Eppendorf) or DNA Engine Peltier Thermal Cycler (Bio-Rad) and were subsequently 
analysed by agarose gel electrophoresis (2.2.5) or stored at -20°C. Material and Methods 
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2.3  Cell culture and virological methods 
2.3.1  Cultivation of cell lines 
Cell lines were cultivated in the appropriate medium (2.1.8) in an incubator (BBD 
6220, Heraeus) at 37°C, 5% CO2 and saturated water atmosphere and were 
passaged twice a week. For this purpose, adherent cells were trypsinised (PBS 
(Biochrom AG), 100 mM EDTA, 0.25% Trypsin-Melnick) before an appropriate 
fraction of the resulting suspension was seeded into a new culture flask with fresh 
medium. 
2.3.2 Freezing  and  thawing of cultured cells 
For storage, cells were kept in liquid nitrogen. 
 
Freezing 
Adherent cells were trypsinised (PBS (Biochrom AG), 100 mM EDTA, 0.25% Trypsin-
Melnick) and resuspended in the appropriate medium before they were, like 
suspension cells, centrifuged (800 rpm for 5 min at 4°C in a Varifuge 3.0 RS) to pellet 
the cells. These were then resuspended in 4°C cold freezing medium (50% FCS, 
10% DMSO and 40% DMEM or 40% RPMI, steril filtrated), aliquoted á approximately 
1.5x10
6 cells into cryotubes and frozen in a 5100  Cryo 1°C Freezing Container 
(Nalgene) at -80°C. After 24 h the cells were transferred into liquid nitrogen. 
 
Thawing 
Cryotubes were incubated in a water bath at 37°C until the ice thawed. Then the cell 
suspension was immediately transferred into a 15 ml falcon tube with 15 ml pre-
warmed medium. To exclude the cytotoxic DMSO, cells were subsequently 
centrifuged (800 rpm for 4 min at RT, Varifuge 3.0 RS), resuspended in fresh 
medium (2.1.8) and seeded into appropriate cell culture flasks. Material and Methods 
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2.3.3  Isolation of human peripheral blood mononuclear cells (PBMC) 
PBMCs were isolated from human blood (Buffy Coats obtained from the 
Blutspendedienst Hessen, Frankfurt a. M.) by density centrifugation using 
Histopaque
®-1077 (Sigma-Aldrich). For this purpose, in a 50 ml falcon tube, 15 ml 
cold Histopaque (4°C) were overlaid with 25 ml of a 1:1 mixture of human blood and 
PBS (Biochrom AG). Through centrifugation at 1,800 rpm and RT for 30 min (without 
break; Varifuge 3.0 RS) the red blood cells and granulocytes were pelleted. Above 
the Histopaque solution the lymphocytes, monocytes and macrophages concentrated 
within the whitish “lymphocyte-ring” above which the plasma resided. The 
“lymphocyte-ring” was collected into 50 ml falcon tubes (5 ml per falcon) and 
resuspended in 45 ml PBS per tube. A centrifugation step at 1,500 rpm, 10 min, RT 
(Varifuge 3.0 RS) followed. The cells were once more washed with 50 ml PBS 
(centrifugation at 1,200 rpm, 10 min, RT, Varifuge 3.0 RS) and then collected into 
one single 50 ml falcon tube, in which they were washed again with 50 ml PBS (see 
above). Next, remained erythrocytes were lysed through incubation in 10 ml 0.86% 
ammonium chloride solution at 37°C for 20 min. Then, the cells were washed twice 
with PBS as described above. Finally, they were resuspended in 50 ml PBS and 
counted in a Neubauer counting chamber, before they were applied for B cell 
isolation. 
2.3.4 Isolation  and  activation of primary human B cells 
Primary human B cells were isolated from fresh human PBMCs with the Dynal
® B-cell 
negative isolation kit following the manufacturer’s instructions. With this kit, 
untouched B cells were isolated from PBMCs by depleting T cells, natural killer cells, 
monocytes, granulocytes and erythrocytes. For this purpose, a mixture of monoclonal 
antibodies against unwanted cells was added to the PBMCs, followed by magnetic 
Dynabeads
® that bind to the antibodies. Then, the cells were applied to a magnetic 
field, which catches the Dynabeads
® bound cells, only leaving the B cells in solution. 
These were pelleted at 1,500 rpm and RT for 10 min (Varifuge 3.0 RS). Then, 
isolated B cells were either activated for 48 h in RPMI 1640 supplemented with 10% 
FCS, 2 mM L-glutamine, 50 mg/ml streptomycin, 100 U/ml penicillin, 25 mM HEPES 
as well as 300 ng/ml CD40 ligand, 50 ng/ml IL-2, 10 ng/ml IL-4 and 10 ng/ml IL-10 or Material and Methods 
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used directly for transduction. In the latter case, cells were transferred into RPMI 
1640 supplemented with 10% FCS, 2 mM L-glutamine, 50 mg/ml streptomycin, 100 
U/ml penicillin, 25 mM HEPES without any cytokines. The respective media were 
also used during transduction (2.3.9). 
2.3.5  Isolation of mixed primary human B and T cells 
A mixture of primary human CD20/CD19 double-positive B and CD3-positive T cells 
was obtained from U. Köhl (Goethe-University Hospital Frankfurt a. M.) by 
immunomagnetic purification of peripheral blood stem cells from healthy donors. 
Briefly, apheresis products were harvested after granulocyte-colony stimulating factor 
stimulation and performed using a COBE Spectra (Gambro, Lakewood, USA). After 
platelet reduction, cells were labeled with anti-CD3 and anti-CD19 antibodies (CD3
+ 
CD19
+ Microbeads, Miltenyi/Biotec) for 30 min. Then, T and B cells were depleted 
immunomagnetically on the CliniMacs system (Miltenyi/Biotec) under GMP 
conditions according to the manufacturer’s instructions (positive selection of B and T 
cells). While the fraction including stem cells, monocytes, natural killer and dendritic 
cells was used for haploidentical stem cell transplantation, the fraction consisting of a 
mixture of highly purified CD19-positive B and CD3-positive T cells was provided for 
this thesis. The lymphocytes were activated as described above (2.3.4) and used for 
transduction experiments (2.3.9). Informed consent was given by the donors and use 
of the samples has been approved by the Goethe-University Hospital Ethics 
Committee.    
2.3.6 Production  and  concentration of vector particles 
Vector particles were generated by transient transfection of HEK-293T cells with the 
packaging plasmid, the transfer vector plasmid and the glycoprotein expression 
plasmid/s. The plasmid DNA was introduced into the cells by calcium phosphate 
transfection. The procedure is based on slow mixing of HEPES-buffered saline (HBS) 
containing sodium phosphate with a CaCl2 solution containing the DNA. A DNA-
calcium phosphate co-precipitate forms, which adheres to the cell surface and is 
taken up by the cell, presumably by endocytosis.  Material and Methods 
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Twenty-four hours before transfection, 6.5x10
6 HEK-293T cells were seeded into a 
T75 flask. One hour before transfection the medium was replaced by 7 ml fresh 
medium (DMEM supplemented with 10% FCS and 2 mM L-glutamine). In total, 8 µg 
of the two plasmids encoding either a F or a H protein variant of MV (unless 
otherwise noted, for the experiments described in chapters 3.1 to 3.1.5 4 µg of each 
plasmid were used, apart from that, for production of MV-HIV vectors 1 µg H protein 
variant encoding plasmid and 7 µg pCG-Fc∆30 were used and for the production of 
targeting vectors 2 µg H protein variant encoding plasmid and 6 µg pCG-Fc∆30 were 
used), 10.72 µg of the packaging plasmid and 11.27 µg of the transfer vector plasmid 
were mixed. The plasmid DNA was filled up with H2O (Sigma-Aldrich W-3500; this 
special water was also used for the generation of the CaCl2 solution and the 2x HBS 
buffer) to 450 µl. Then, 50 µl 2.5 M CaCl2 solution were added. While vortexing the 
DNA-CaCl2 solution, 500 µl 2x HBS Buffer (281 mM NaCl; 100 mM HEPES; 1.5 mM 
Na2HPO4, pH 7.12) were added dropwise. Afterwards the solution was vortexed for 
an additional minute. Then, the precipitate was added to the cells. After 17 h medium 
was replaced by 12 ml fresh medium. Twenty-four hours afterwards, the cell 
supernatant, containing the pseudotyped lentiviral vector particles, was filtered (0.45 
µm filter) and 300 µl thereof were directly used for transduction. The remaining 
supernatant was concentrated by centrifugation at 3,600 rpm and 4°C for at least 24 
h (Varifuge 3.0 RS). The pellet was resuspended in 120 µl FCS-free medium or PBS 
(Biochrom AG). Vector particle aliquots were stored at -80°C. Vector particles 
pseudotyped with the VSV-G protein or the Env protein of Moloney MLV were 
produced by co-transfection of 4.55 µg of the plasmid pMD.G2 encoding VSV-G or 
pHIT123 encoding MoMLV Env, 8.45 µg of packaging plasmid and 13.00 µg of 
transfer vector plasmid. 
2.3.7  Transfection of cells in six well plates 
Transfection of cells in six well plates was also performed by calcium phosphate 
transfection. Twenty-four hours before transfection, 8x10
5 cells were seeded into a 
single well of a six well plate. One hour before transfection, the medium was replaced 
by 1 ml fresh medium per well. In total, 8 µg plasmid DNA was added with H2O 
(Sigma-Aldrich W-3500) to 180 µl. If needed DNA content was filled up to 8 µg with 
empty pCG-1 vector. The transfection was performed as described above (2.3.6) with Material and Methods 
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20 µl CaCl2 solution and 200 µl 2x HBS buffer. Twenty-four hours later, transfected 
cells were analysed. 
2.3.8  Transduction of adherent cell lines and titration of vector 
particles  
For transduction about 5.8x10
4 cells were seeded into a single well of a 48 well plate. 
On the next day, vector particle stocks were serially diluted in 1:10 steps with 
medium and a total of 250 µl of the dilutions, including 8 µg/ml of the cationic polymer 
polybrene (hexadimethrine bromide; Sigma-Aldrich) that enhances transduction 
efficiency by neutralising the charge repulsion between the vector particles and cell 
surface (Davis et al., 2004), were added per well. In advance the old medium was 
removed from the cells. After incubation for 2.5 - 3 h, the transduction reaction mix 
was replaced by 1 ml of fresh medium (2.1.8). After 48 - 72 h titers were calculated 
by determining the number of GFP-fluorescent cells under the fluorescence 
microscope. The counted cells per well were multiplied by the dilution factor and the 
factor 4.0 (used 250 µl x 4.0 = 1 ml) to obtain transducing units (t.u.)/ml. Alternatively, 
titers were determined by FACS analysis based on the indicated percentage of green 
fluorescent cells. For both methods dilutions were chosen, in which about 10-20% of 
the cells were transduced.  
2.3.9 Transduction  of  suspension cells and primary human 
lymphocytes 
Twenty-four hours before transduction, a 48 well plate was coated with the 
extracellular matrix molecule fibronectin (BD
TM) to enable co-adhesion of vector 
particles and target cells to fibronectin resulting in a large increase in local virus titer 
presented to the cells (Moritz et al., 1996). For this purpose, 500 µl 5 µg/ml 
fibronectin containing medium were added into a single well of the 48 well plate and 
incubated for 24 h at 37°C in an incubator (BBD 6220, Heraeus). For transduction, 
the fibronectin was pre-coated with half of the vector particles used for transduction 
diluted in 120 µl medium by centrifugation of the plate at 2,000 rpm and 4°C for 20 
min (Multifuge 3S-R, Heraeus). The other half of the vector particles was diluted in 
180 µl medium supplemented with 4 µg/ml protamine sulfate (Sigma-Aldrich) that is a Material and Methods 
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polycation exhibiting the same function as polybrene (2.3.8) but is less cell toxic. If 
not otherwise noted, 1.0x10
5 cells of a suspension cell line or 5.0x10
4 primary human 
lymphocytes were added before the transduction mix was added to the respective 
wells pre-coated with the vector particles. A centrifugation step at 1,000 rpm and 
32°C for 90 min (Multifuge 3S-R, Heraeus) followed. After 1 h incubation at 37°C in a 
cell culture incubator (BBD 6220, Heraeus), 700 µl medium per well were added. 48 
h or 72 h after transduction the cells were analysed by FACS. The used media are 
depicted in chapters 2.1.8 and 2.3.4. 
2.3.10  Fluorescence activated cell sorting (FACS) 
FACS analysis allows to assay cell populations for surface expression of proteins or 
GFP-expression. The method makes use of scattered light and fluorescence of GFP 
or fluorofor labelled antibodies directed against cell surface proteins. The cells are 
excited with a laser beam and the fluorescence that is dependent from the used 
fluorofore or GFP is detected. 
FACS analysis was performed on the Galaxy flow cytometry system (Dako). For this 
purpose, adherent cells were detached by incubation with PBS-Trypsin solution (PBS 
(Biochrom AG), 100 mM EDTA, 0.25% Trypsin-Melnick). Approximately 1x10
5 - 
5x10
5 cells in suspension were pelleted by centrifugation at 3,500 rpm, 4°C, 3 min 
(Heraeus Fresco 17). Then they were washed in 1 ml FACS washing buffer (PBS, 
1% FCS, 0.1% NaN3; centrifugation as described above) and incubated with the 
appropriate antibody/antibodies (2.1.4) diluted in PBS (Biochrom AG) for 30 min at 
4°C in the dark. If the antibody was not directly labelled with a fluorofor, after two 
washing steps with FACS washing buffer, the cells were incubated with the labelled 
secondary antibody for 30 min at 4°C in the dark. After antibody incubation, the cells 
were washed twice in 1 ml FACS washing buffer and were finally fixed in 200 µl 
PBS/1% paraformaldehyde. If only GFP-fluorescence was detected, the cells were 
directly fixed after the first washing step. The samples were either directly use for 
FACS analysis or stored up to one week at 4°C in the dark. Data were analysed with 
the FloMax program version 2.0 (partec). To determine the rate of unspecific staining 
by the antibodies, cells were also incubated with isotype controls conjugated with the 
same fluorofor as the applied antibody. By using differently labelled antibodies, 
multiple cell surface proteins were detected simultaneously on one cell. Material and Methods 
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2.4  Methods of protein biochemistry 
2.4.1 SDS-polyacrylamide-gelelectrophoresis 
The SDS-polyacrylamide-gelelectrophoresis (SDS-PAGE) (modified after (Laemmli, 
1970)) allows the separation of protein mixtures according to the molecular weight of 
the proteins. The basic principle includes binding of multiple molecules of the anionic 
detergent sodium dodecyl sulfate (SDS) via hydrophobic interactions to denatured 
protein molecules. That way, irrespective of their native charges, the denatured 
proteins acquire an excess of negative charge on their surface and can thus be 
applied to electrophoresis. For this purpose, the samples were loaded on 
polyacrylamid gels, which act like molecular sieves, similar to agarose gels (2.2.5).  
To denature the proteins and allow binding of SDS, the samples were mixed with the 
appropriate amount of 2x urea sample buffer (5% SDS, 8 M urea, 200 mM Tris-HCl, 
0.1 mM EDTA, 0.03% bromphenol blue, 2.5% dithiothreitol, pH 8.0) and heated for 
10 min at 95°C. Then, they were loaded on 10% SDS polyacrylamid gels within a 
Bio-Rad Mini Protean II chamber filled with SDS running buffer (36 g glycine, 7.75 g 
Tris, 1.25 ml 20% SDS, ad 250 ml aqua bidest). As protein standard 10 µl of the 
Precision Plus Protein
TM Standard Kaleidoscope
TM marker from Bio-Rad were used. 
 
Ingredients of a 10% SDS polyacrylamid gel       
ingredients  resolving gel  stacking gel 
30% acrylamide Roti-gel (Roth)  5 ml  1.65 ml 
1 M Tris pH 8.8  5.85 ml  - 
1 M Tris pH 6.8  -  1.25 ml 
50% glycerine  1.3 ml  - 
10% SDS  0.17 ml  0.1 ml 
aqua bidest  2.68 ml  7 ml 
Temed   12.5 µl  12.5 µl 
20% APS  40 µl  40 µl 
 
SDS-PAGE was performed at 80 V until the samples entered the resolving gel using 
a Bio-Rad Power Pac 200. Then, 130 V were applied until the dye front had left the 
resolving gel. Material and Methods 
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2.4.2 Western  blot  analysis 
The western blot technique is a method which enables the transfer of proteins onto 
protein-binding surfaces such as nitrocellulose membranes (Towbin et al., 1979). 
This transfer, also termed blot, enables the specific visualisation of proteins of 
interest by immunostaining. Usually, proteins which have been separated by SDS-
PAGE are applied to western blot analysis. 
The transfer of the proteins from the SDS polyacrylamid gels onto nitrocellulose 
membranes (Amersham Biosciences) was performed electrophoretically within a Bio-
Rad Trans-Blot
® SD Semi-Dry transfer cell according to the manufacturer’s 
instructions. In advance, six 3 mm Whatman filter papers (Schleicher & Schuell), 
membrane/s and SDS polyacrylamid gel/s were shortly incubated in transfer buffer 
(48 mM  Tris, 39 mM  glycine, 20 % methanol, ad 1,000 ml aqua bidest). After 
blotting at 110 mA for 90 min (1 blot) or 200 mA for 90 min (2 blots), unspecific 
binding sites were blocked with 10% horse serum in TBST (10 mM Tris pH 8.0, 150 
mM NaCl, 0.1% Tween 20) for 1 h at RT. For specific protein staining, antibodies 
diluted in 5% horse serum in TBST have been used (2.1.4). Staining was performed 
over night at 4°C. Then, the membranes were washed three times for 10 min at RT 
with TBST before they were incubated for 1 h at RT with the appropriate horseradish 
peroxidase (HRP) conjugated secondary antibodies (2.1.4) diluted in 5% horse 
serum in TBST. After washing as described above, detection of H and F proteins was 
performed using the SuperSignal West Pico Luminol kit (Pierce) according to the 
manufacturer’s instructions. For detection of p24, the Amersham ECL Plus Western 
Blotting detection reagent (GE Healthcare) was used according to the manufacturer’s 
instructions. The reagents contain a HRP substrate that emits light during conversion 
into the product by the HRP conjugated secondary antibodies. Hence the signal can 
be visualised, using chemiluminescence films (Amersham Biosciences). The latter 
ones were exposed to the substrate-incubated membrane/s for 5 sec - 30 min 
depending on the signal intensities. 
2.4.3  Preparation of cell lysates 
Thick grown cells in T75 culture flasks were washed ones with 5 ml ice-cold PBS 
(Biochrom AG). Then, carefully 1.6 ml ice-cold lysis buffer (50 mM Tris pH 8.0, 62.5 Material and Methods 
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mM EDTA, 1% NP-40, 0.4% sodium-deoxycholate, 40 µl/ml protease inhibitor 
cocktail complete (25x)) was added to the cells (nuclei should remain intact on the 
flask bottom). After incubation for 5 min at 4°C, the lysate was transferred into a 2 ml 
reaction tube and centrifuged at 13,000 rpm, 4°C for 2 min (Heraeus Fresco 17) to 
get rid of the cell debris. The supernatant was transferred into a new 2 ml reaction 
tube and either directly used for Bradford assay or frozen at -20°C. 
2.4.4 Bradford  assay 
To determine the protein concentration in cell lysates the Quick Start
TM Bradford Dye 
reagent from Bio-Rad was used according to the manufacturer’s instructions for 1 ml 
cuvetts with the exception that sample and 1x dye was mixed in 1:1 ratio. The 
Bradford assay is a protein quantification method that involves the binding of 
Coomassie Brilliant Blue G-250 dye to proteins (Bradford et al., 1976). The dye exists 
in three forms: cationic (red), neutral (green), and anionic (blue) (Compton and 
Jones, 1985). Under acidic conditions, the dye is predominantly in the doubly 
protonated red cationic form (Amax = 470 nm). However, when the dye binds to 
proteins, it is converted to a stable unprotonated blue form (Amax = 595 nm) (Sedmak 
and Grossberg, 1977). This blue protein-dye form was detected at 595 nm using a 
spectrophotometer (GeneQuant pro, Amersham Biosciences). With the absorption at 
595 nm and a standard curve the protein concentration was determined. Cell lysates 
were diluted 1:100 before they were applied to the assay. Results 
 
  38
3 Results 
This thesis describes the development of an efficient cell entry targeting system for 
lentiviral vectors, which allows in principle retargeting to every cell surface molecule 
of interest. The very competent MV targeting system was transferred to lentiviral 
vectors by pseudotyping them with the MV H and F glycoproteins. To achieve 
pseudotyping, in a first step, the cytoplasmic tails of the H and F proteins were 
specifically truncated. Then, for proof of principle, lentiviral vectors that entered 
selectively epidermal growth factor (EGF) receptor-positive or CD20-positive cells 
were generated by using native receptor blind H proteins with an optimally truncated 
cytoplasmic tail and the EGF ligand or a CD20-specific scAb displayed at their 
ectodomain. 
3.1 Pseudotyping  of  retroviral vector particles with the MV 
glycoproteins 
The first step for the generation of retargeted retroviral vector particles was the 
pseudotyping with MV glycoproteins. For this purpose, the MV H and F genes 
derived from the NSe variant of the recombinant attenuated MV vaccine strain 
Edmonston B were used (Cathomen et al., 1995).  
For the production of lentiviral vector particles, HEK-293T cells are transiently 
transfected with a packaging plasmid, a transfer vector plasmid and an envelope 
expression plasmid (1.1.1 Figure 3). To adapt this procedure for MV pseudotyped 
particles, the commonly used VSV-G expression plasmid was initially substituted by 
equal amounts of the F and H expression plasmids pCG-F (10.1) and pCG-H (10.2). 
Besides lentiviral HIV-1 vector particles also retroviral MLV vector particles were 
generated. For the production of HIV-1 vectors the following plasmids were co-
transfected into HEK-293T cells: the HIV-1 packaging plasmid CMV∆R8.9 (10.3), the 
green fluorescent protein (GFP) transfer vector plasmid HR´-CMV-GFP (10.4), pCG-
F and pCG-H. For the production of MLV vectors pHIT60, pSFG-eGFP, pCG-F and 
pCG-H were co-transfected. In parallel, as positive control, HIV-1 and MLV vector 
particles pseudotyped with VSV-G were generated by co-transfection of the VSV-G 
encoding pMD.G2 (10.5) along with the packaging and transfer plasmids. After 48 h, 
vector particle containing cell supernatants were harvested as described (2.3.6) and Results 
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used for the transduction of HT1080 cells, either directly or after concentration 
(2.3.8).  
Twenty-four hours after transfection all HEK-293T packaging cells that were co-
transfected with pCG-F and pCG-H showed strong syncytia formation (Figure 7 and 
data not shown), which is typical for cells expressing both MV glycoproteins and at 
least one MV receptor.  
 
Figure 7: Syncytia formation of HEK-293T packaging cells. CD46-positive HEK-293T cells were 
co-transfected with the HIV-1 packaging plasmid CMV∆R8.9, the GFP transfer vector plasmid HR’-
CMV-GFP and plasmids encoding the MV F and H glycoproteins, respectively. After 24 h, syncytia 
formation was detected by (a) reflected-light and (b) fluorescence microscopy (100x magnification). 
 
HIV-1 as well as MLV vector particles that were released from these F/H transfected 
cells were unable to mediate any detectable gfp-gene transfer into the CD46-positive 
HT1080 cells, while particles pseudotyped with VSV-G reached titers of 10
9 
transducing units (t.u.)/ml (Figure 8 and data not shown). 
 
Figure 8: Transduction of HT1080 cells. Concentrated cell supernatants of HIV-1 vector particle 
producing HEK-293T cells were used for the transduction of HT1080 cells. After 48 h, cells incubated 
with HIV-1 particles produced in the presence of (a) the unmodified MV glycoproteins and (b) VSV-G, 
respectively, were analysed under the fluorescence microscope for GFP-expression (100x 
magnification). 
 Results 
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Hence, although the MV H and F glycoproteins were able to form functional fusion 
complexes in HEK-293T packaging cells, they did not pseudotype HIV-1 or MLV 
vectors.  
3.1.1  Truncation of the MV H and F protein cytoplasmic tails and 
screening for variants that pseudotype lentiviral vectors 
As it was not possible to produce retroviral vectors pseudotyped with the unmodified 
MV glycoproteins, it was assumed that sequences in the cytoplasmic tail of the MV H 
and F proteins prevent pseudotyping. For this reason, MV glycoprotein cytoplasmic 
tail variants (Figure 9) that were characterised previously in terms of fusion function 
(Moll et al., 2002; Cathomen et al., 1998) were screened for their ability to 
pseudotype retroviral vectors. Thereby, all H protein variants with stepwise 
cytoplasmic tail truncations by less than 21 amino acids (aa) still own fusion helper 
function in a cell-cell fusion assay with CD46-positive Vero cells, whereas H proteins 
with truncations by more than 20 aa showed impaired cell-cell fusion when they were 
co-expressed with the F protein (Moll et al., 2002). In variants Hc∆21+A and 
Hc∆24+4A the fusion helper function was restored by substituting the critical aa with 
alanine (Moll et al., 2002) (Figure 9). 
The plasmids pCG-Hc∆14 and pCG-Fc∆24, encoding MV H or F protein variants with 
cytoplasmic tails truncated by 14 and 24 aa, respectively, were generated by 
replacing the respective glycoprotein gene in pCG-H or pCG-F after PacI/SpeI and  
NarI/PacI digestion, respectively, with the Hc∆14 or Fc∆24 coding region removed 
from peHc∆14 and p(+)MV-Fc∆24 (Cathomen et al., 1998), respectively. The 
production of all other plasmids encoding cytoplasmic tail variants was described 
previously (Moll et al., 2002).  
The 15 H protein variants carrying stepwise truncations and amino acid exchanges in 
their cytoplasmic tails and the two F protein variants (Figure 9) were screened in all 
combinations for their ability to pseudotype HIV-1 vector particles. Because it was 
speculated that the absence of syncytia formation in the packaging cells might be of 
advantage for pseudotype production, also the fusion helper function impaired H 
protein variants were included into the screen. Furthermore, the impairment of fusion 
helper function might be less pronounced for particle-cell fusion than for cell-cell 
fusion. Results 
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Figure 9: Overview on the MV F and H protein variants used for the pseudotyping screen. 
Amino acid sequences of the cytoplasmic tails of the (a) F protein and (b) H protein variants are 
shown. Note that H is a type II transmembrane protein. Presence (+) or absence (-) of the fusion 
helper function of each H variant as determined by Moll et al. (Moll et al., 2002) is indicated. 
 
For the screen, pseudotyped HIV-1 particles were produced by co-transfection of 
HEK-293T cells with the HIV-1 packaging plasmid CMV∆R8.9, the GFP transfer 
vector plasmid HR`-CMV-GFP and the two plasmids encoding the modified H and F 
proteins, respectively. Thereby all combinations of MV H and F protein variants were 
assayed for pseudotype generation. Forty-eight hours after transfection, the vector 
particle containing cell supernatants were used directly or after concentration for the 
transduction of HT1080 cells and after further 48 h the respective titers were 
determined under the fluorescence microscope (2.3.8).  Results 
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Figure 10: Screening for MV H and F protein variants that efficiently pseudotype lentiviral 
vector particles. HEK-293T cells were co-transfected with pCMV∆R8.9, pHR’-CMV-GFP and 
plasmids encoding the indicated F and H protein variant, respectively. After 48 h, cell supernatants 
were used for the transduction of HT1080 cells either directly or upon concentration and after further 
48 h the respective titers were determined under the fluorescence microscope. (a) The best titer of 
unconcentrated pseudotyped HIV-1 vectors for each possible F/H combination that was tested is 
shown (screening titer [t.u./ml]). Presence (+) or absence (-) of the fusion helper function of each H 
variant as determined by Moll et al. (Moll et al., 2002) is indicated. Variants used for further studies are 
depicted in bold. (b) Screening titers of selected unconcentrated and concentrated pseudotype vectors 
are shown. The arrows indicate titers below 10 t.u./ml. (c) Representative pictures of HT1080 cells 
transduced by the indicated pseudotypes (concentrated particles) are shown (100x magnification) (d) 
HEK-293T cells were co-transfected with the SIVmac packaging plasmid SIV10+, the SIVmac transfer 
vector plasmid GAE-sffv-gfp-wpre and the two plasmids encoding the Hc∆18 and Fc∆30 protein 
variants, respectively. After 48 h, concentrated cell supernatants containing Hc∆18/Fc∆30 
pseudotyped SIVmac vector particles were used for the transduction of HT1080 cells. A representative 
picture of gfp-transduced HT1080 cells is shown (100x magnification). Transduced cells were 
quantified by fluorescence microscopy and FACS analysis. The titer is indicated. 
 
Twenty-four hours after transfection, all vector particle producing HEK-293T cells 
showed strong syncytia formation, except when an H protein variant with impaired 
fusion helper function (Figure 9) was used (data not shown). But only when the 
cytoplasmic tails of both glycoproteins were truncated, pseudotyped HIV-1 vector 
particles, mediating transfer of the gfp-gene into HT1080 cells, were produced 
(Figure 10a, b). Highest titers were obtained when the F protein cytoplasmic tail was 
truncated by 30 residues just leaving three aa, two of which being positively charged. Results 
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Among the H protein variants, there was a clear peak of optimal truncation when 18 
or 19 residues were deleted (variants Hc∆18 and Hc∆19). Further truncation reduced 
titers, although replacing some of the deleted residues by alanine could restore 
optimal titers in case of variant Hc∆24+4A.  
All three H protein variants that allowed most efficient pseudotype formation are also 
active in fusion helper function (Moll et al., 2002) (Figure 10a). Thus, the screening 
identified three combinations, namely Hc∆18/Fc∆30, Hc∆19/Fc∆30 and 
Hc∆24+4A/Fc∆30 that allowed most efficient pseudotyping of HIV-1 vector particles 
with titers of about 10
5 t.u./ml on HT1080 cells. After concentration, titers above 10
6 
t.u./ml were obtained (Figure 10b, c). Also other lentiviral vectors, like simian 
immunodeficiency virus (SIVmac) derived ones, could be pseudotyped with the 
identified Hc∆18 and Fc∆30 protein variants with a titer of 1x10
6 t.u./ml on HT1080 
cells (Figure 10d), demonstrating the flexibility of the system.  
Apparently, the cytoplasmic tail of the MV H and F protein contains sequences that 
prevent pseudotyping of lentiviral vectors. Only after optimal truncation of both 
cytoplasmic tails efficient pseudotyping of lentiviral vectors with the MV glycoproteins 
was possible. Highest titers with above 10
6 t.u./ml, using concentrated vector 
particles, were obtained with the combinations Hc∆18/Fc∆30, Hc∆19/Fc∆30 and 
Hc∆24+4A/Fc∆30. Obviously, the critical step was the identification of H protein 
cytoplasmic tail truncation mutants that allowed pseudotyping while retaining the 
fusion helper function. Below, HIV-1 vector particles pseudotyped with the MV 
envelope proteins will be referred to as MV-HIV vectors. 
3.1.2  Screening for MV H and F protein variants able to efficiently 
pseudotype MLV vector particles 
Next, the MV glycoprotein cytoplasmic tail truncation mutants were assayed to 
pseudotype MLV vectors. 
The screen was performed as described above for HIV-1 vectors with the exception 
that the H protein variants with impaired fusion helper function were not included. For 
production of vector particles, HEK-293T cells were co-transfected with the MLV 
packaging plasmid HIT60, the GFP transfer vector pSFG-eGFP and the two plasmids 
encoding the H and F protein variants, respectively. Forty-eight hours after 
transfection, cell supernatants were collected and used for the transduction of Results 
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HT1080 cells. After further 48 h the respective titers were determined under the 
fluorescence microscope.  
As described before for the HIV-1 vectors, 24 h after transfection, syncytia formation 
of the vector particle producing cells was observed (data not shown). However, in 
contrast to MV-HIV vector particles, which reached titers above 10
5 t.u./ml, MLV 
particles were not efficiently pseudotyped with any of the tested glycoprotein 
combinations. The best titer of only 3x10
3 t.u./ml was observed for the combination 
Hc∆24+4A/Fc∆24 (Figure 11).  
 
Figure 11: Screening for MV H and F protein variants that efficiently pseudotype MLV particles. 
HEK-293T cells were co-transfected with pHIT60, pSFG-eGFP and the plasmids encoding the 
indicated F and H protein variants, respectively. After 48 h, the cell supernatants were used for the 
transduction of HT1080 cells. Screening titers of unconcentrated pseudotype vectors are shown. The 
arrows indicate titers below 10
2 t.u./ml. For comparison, the titer of Hc∆18/Fc∆30 pseudotyped HIV-1 
vectors, obtained in the screen depicted in Figure 10, is shown. 
 
Thus, MV H and F cytoplasmic tail truncation mutants were identified that could 
pseudotype HIV-1 vector particles. However, the same variants as well as all other 
tested MV glycoprotein variants could not efficiently pseudotype MLV vector 
particles. Obviously, the restriction factors for the formation of lentiviral and γ-
retroviral MV pseudotypes, respectively, are different. All further experiments were 
performed with HIV-1 vector particles. Results 
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3.1.3  Biochemical analysis confirmed the formation of HIV-1 
pseudotypes  
HIV-1 vector particles pseudotyped with the Hc∆18/Fc∆30 protein variants mediated 
efficient gene transfer into HT1080 cells, whereas HIV-1 particles produced in the 
presence of the unmodified MV glycoproteins did not. Thus, it was now investigated if 
the cytoplasmic tail truncations had enabled or enhanced the incorporation of the MV 
glycoproteins into the viral particles. 
For this purpose, MV-HIV vector particles were generated in presence of the 
truncated Hc∆18 and Fc∆30 protein variants or the unmodified H and F proteins. 
They were concentrated and purified over a 20% sucrose cushion (2 ml) by 
centrifugation at 3,450xg and 4°C for at least 24 h. In parallel, the respective HEK-
293T packaging cells were lysed and their protein content determined by Bradford 
assay (2.4.3; 2.4.4). The purified particles as well as the cell lysates were then 
applied to SDS-polyacrylamide-gelelectrophoresis and analysed by western blot 
(2.4.1; 2.4.2). For standardisation of the vector particles, p24, which builds the HIV-1 
capsid, was analysed besides F and H. In parallel, cell surface expression of the MV 
glycoproteins, which is essential for their incorporation into vector particles, was 
determined by FACS analysis of HEK-293T cells, co-transfected in a six well plate 
with the Hc∆18 and Fc∆30 or the unmodified H and F proteins (2.3.7). As 
transfection control, 0.5 µg of a GFP-encoding plasmid was added to each well. To 
avoid syncytia formation, 0.2 mM fusion-inhibiting peptide (FIP)-containing medium 
was added to the cells 4 h after transfection. FIP interacts with the MV F protein, 
thereby inhibiting its fusion capability (Firsching et al., 1999; Richardson and 
Choppin, 1983). Twenty-four hours after transfection the cells were stained with a 
primary antibody directed against the H or F protein and anti-mouse PE-conjugated 
secondary antibody and were analysed by FACS (2.3.10).  
In the cell lysates, the truncated proteins Hc∆18 and Fc∆30 as well as the 
unmodified MV H and F proteins were readily detectable and migrated according to 
their expected molecular weights (Figure 12a). Although especially for Fc∆30, the 
western blot analysis suggested increased protein expression levels upon 
cytoplasmic tail truncation (Figure 12a), there was no significant difference in cell 
surface expression levels between H and Hc∆18 or F and Fc∆30, respectively 
(Figure 13). Differences in transfection efficiencies were excluded, as similar GFP-Results 
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expression levels were obtained (data not shown). In HIV-1 vector particles, only low 
amounts of unmodified H protein and no unmodified F protein were detectable. The 
Hc∆18 and Fc∆30 proteins, in contrast, were present in significant amounts, 
demonstrating that cytoplasmic tail truncation had enhanced particle incorporation 
(Figure 12b). 
 
Figure 12: Incorporation of modified MV glycoproteins into HIV-1 vector particles. Western blot 
analysis of (a) cell lysates of HEK-293T packaging cells and (b) the respective produced HIV-1 vector 
particles pseudotyped with the indicated proteins. The blotted proteins were analysed utilizing anti-F, 
anti-H and anti-p24 antibodies, respectively. Either cell lysate or concentrated cell supernatant from 
untransfected HEK-293T cells were loaded as negative control (ut). Results 
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Figure 13: Cell surface expression of unmodified versus modified MV glycoproteins. In a six 
well plate, HEK-293T cells were co-transfected with 3 µg pCG-F and 3 µg pCG-H or 3 µg pCG-Fc∆30 
and 3 µg pCG-Hc∆18. As transfection control also 0.5 µg of a GFP-encoding plasmid were added to 
each well. To avoid syncytia formation, 4 h after transfection 0.2 mM FIP-containing medium was 
added to the cells. Twenty hours later the cells were stained against (a) F and (b) H protein, 
respectively, and analysed by FACS. Transfection efficiency was similar for both approaches as 
determined by GFP-expression (not shown). MFI: mean fluorescence intensity. 
 
Hence, sequences in the cytoplasmic tail of H and especially F seem to prevent 
incorporation of the unmodified MV glycoproteins into the vector particles. Their 
truncation enhanced particle incorporation. Thus, reduced or absent particle 
incorporation can be concluded as most likely reason for absence of pseudotyping 
with the unmodified H and F proteins. 
3.1.4  MV-HIV vectors show the same tropism as MV 
So far, it has been demonstrated that concentrated HIV-1 particles pseudotyped with 
selected modified MV glycoproteins can mediate efficient gene transfer into HT1080 
cell with titers above 10
6 t.u./ml (3.1.1). Next, the question if MV pseudotyped HIV-1 
vector particles have the same receptor usage as MV was addressed. 
For this purpose, concentrated MV-HIV vector particles pseudotyped with the 
Hc∆18/Fc∆30, Hc∆19/Fc∆30 or Hc∆24+4A/Fc∆30 proteins, respectively, were used Results 
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for the transduction of cell lines being positive or negative for the MV receptors 
(Table 1).  
The transduction of the different cell lines revealed that receptor usage of the 
pseudotyped particles is identical to that of MV (Figure 14; Table 1), e.g. CHO-K1 
cells that express neither of the MV receptors (Nakamura et al., 2005) remained 
untransduced, whereas CHO cells stably transfected with SLAM or CD46 (Buchholz 
et al., 1996; Tatsuo et al., 2000) became GFP-positive (Figure 14). 
Thus, by pseudotyping HIV-1 particles with the MV glycoproteins, MV receptor usage 
was transferred to these particles. 
 
Figure 14: Receptor specificity of HIV-1 vector particles pseudotyped with the modified MV 
glycoproteins. CHO cells stably expressing (a) SLAM or (b) CD46 or (c) the parental CHO-K1 cells 
expressing neither of the two receptors were transduced with concentrated HIV-1 particles 
pseudotyped with the Hc∆18/Fc∆30 glycoproteins. Cells were analysed by fluorescence microscopy 
48 h after transduction and representative pictures were taken at 100x magnification.  
 
Table 1: Transduction of different cell lines with MV-HIV vector particles
a  
envelope 
proteins 
HEK-
293T
b 
[t.u./ml] 
A-431
b 
[t.u./ml] 
Daudi
c 
[t.u./ml] 
A3.01
c 
[t.u./ml] 
CHO-
SLAM 
[t.u./ml] 
CHO-
CD46 
[t.u./ml] 
CHO-
K1
d 
[t.u./ml]
Fc∆30  
Hc∆18  1.2x10
6 8.5x10
5f nd 6.0x10
4 7.3x10
6  5.4x10
5 <30
e 
Fc∆30  
Hc∆19  2.0x10
5 nd 1.1x10
6e  2.0x10
5 nd  nd  <30 
Fc∆30  
Hc∆24+4A  1.6x10
6 4.1x10
5  nd nd nd nd  <30 
 
a concentrated cell supernatants were used   
e average of  two experiments 
b cell lines expressing CD46       
f  average of four experiments 
c cell lines expressing CD46 and SLAM    
nd not determined 
d CHO-K1 cells do not express CD46 and SLAM Results 
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3.1.5  Stable gene transfer by MV-HIV vector particles 
MV-HIV vectors showed high titers on different cell lines expressing the MV receptors 
CD46 and/or SLAM. To exclude that the observed titers were due to 
pseudotransduction, which means GFP-protein transfer from the producer to the 
target cells, instead of viral integration, the sensitivity of gene transfer towards a 
reverse transcriptase inhibitor (Liu et al., 1996) was determined. A contribution of 
pseudotransduction to the titers was not unlikely because of syncytia formation and 
thus enhanced vesicle production of the vector particle producing cells. During 
azidothymidine (AZT) incubation reverse transcription of the gfp-transfer vector in 
transduced cells,  and thus GFP-expression, is prevented whereas GFP-protein 
transfer is unaffected.  
HT1080 cells were transduced with concentrated MV-HIV vector particles 
pseudotyped with Hc∆18/Fc∆30, Hc∆19/Fc∆30 and Hc∆24+4A/Fc∆30, respectively, 
or as positive control VSV-G-HIV vectors either in the presence or absence of 10 µM 
AZT in the medium. The respective HT1080 cells were also pre-incubated for one 
hour in 10 µM AZT-containing medium. Forty-eight hours after transduction, titers 
with and without AZT incubation were compared and the relative titer reduction in 
presence of AZT was determined.  
In presence of AZT, the titers of the MV pseudotyped HIV-1 particles decreased by 
90-97%, which was in the same range as the 99% titer reduction observed for VSV-G 
pseudotyped vector particles (Figure 15a).  
To further verify gene expression stability, the suspension B cell line Daudi was 
transduced by HIV-1 particles pseudotyped with the Hc∆18/Fc∆30 proteins (2.3.9) 
and adjacent, the number of GFP-positive cells was determined over a period of 15 
days. For this experiment, the applied vector particles were not produced in presence 
of the lentiviral transfer vector plasmid HR`-CMV-GFP, but in presence of the transfer 
vector plasmid SEW (10.6), encoding GFP. This plasmid is optimised for expression 
in hematopoietic cells (Demaison et al., 2002). 
A constant level of 12% - 20% GFP-positive Daudi cells was detectable over the 
whole observation period (Figure 15b). Results 
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Figure 15: Stable gene transfer by MV-HIV vector particles. (a) HT1080 cells were transduced in 
the presence or absence of 10 µM AZT by concentrated HIV-1 vector particles pseudotyped with the 
indicated glycoproteins. The relative titer reduction in presence of AZT is shown. (b) To follow the 
stability of gene integration and expression, Daudi cells were cultivated for 15 days after transduction 
with HIV-1 vector particles pseudotyped with the Hc∆18 and Fc∆30 protein. The percentage of GFP-
positive cells was determined by FACS analysis at the indicated time points. 
 
Because a titer reduction of almost 100% was observed in presence of AZT, the data 
demonstrate that pseudotransduction contributed negligibly to the titers of the MV 
pseudotyped HIV-1 particles. Furthermore, the stability of gene integration and 
expression mediated by the pseudotypes was confirmed by the long-lasting GFP-
expression in transduced Daudi cell over a period of 15 days. 
3.1.6  Identification of an optimal H to F ratio 
Concentrated MV-HIV vector particles reached titers above 10
6 t.u./ml on HT1080 
cells (3.1.1). Next, it was tried to enhance titers to enable even more efficient gene 
transfer. During MV infection less H than F mRNA is produced (Cattaneo et al., 1987; 
Plumet et al., 2005), therefore it was expected that altering the ratio of the amounts 
of H and F plasmids in the packaging cells might lead to titer enhancement. All MV 
pseudotyped HIV-1 particles that were used for the experiments described above Results 
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were produced by co-transfection of the same amounts of H and F protein encoding 
plasmids, respectively.  
To determine the optimal H to F ratio in the packaging cells, HEK-293T cells were co-
transfected with pCMV∆R8.9, pHR`-CMV-GFP and different ratios of pCG-Hc∆19 
and pCG-Fc∆30, respectively. Forty-eight hours later, the respective cell 
supernatants containing the Hc∆19/Fc∆30 pseudotyped HIV-1 particles were used 
for the transduction of HT1080 cells. After 48 h, the titer of the pseudotypes was 
determined under the fluorescence microscope and normalised to that obtained after 
transfection of a 1:1 ratio of pCG-Hc∆19 and pCG-Fc∆30.    
Compared to vector particles generated upon transfection of equivalent amounts of 
both plasmids, increasing the relative level of pCG-Hc∆19 reduced titers. In contrast, 
higher levels of pCG-Fc∆30 considerably increased titers. The optimal ratio was 
determined to be seven-fold more F than H plasmid, which resulted in a more than 
ten-fold increase in titer (Figure 16). 
Thus, it was possible to enhance the titer of Hc∆19/Fc∆30 pseudotyped HIV-1 vector 
particles on HT1080 cells just by varying the ratio of the Hc∆19 and Fc∆30 encoding 
plasmids during vector particle production. It is noteworthy that for optimal 
pseudotyping more F protein than H protein mRNA is needed, which reflects the 
natural situation in MV.  
 
Figure 16: Titer optimisation of Hc∆19/Fc∆30 pseudotyped HIV-1 particles. The ratio of the 
plasmids encoding the Hc∆19 or Fc∆30 protein variant, used for vector particle production in HEK-
293T cells, was varied as indicated. Each produced pseudotyped vector was titrated on HT1080 cells 
and its titer normalised to that obtained after transfection of a 1:1 ratio of pCG-Hc∆19 and pCG-Fc∆30 
(100%).  Results 
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In this first part of the thesis, MV H and F cytoplasmic tail truncation mutants, namely 
Hc∆18/Fc∆30, Hc∆19/Fc∆30, Hc∆24+4A/Fc∆30 were identified that efficiently 
pseudotyped HIV-1 vector particles. The incorporation of the glycoprotein variants 
Hc∆18/Fc∆30 was verified by western blot analysis and stable gene transfer, 
mediated by the MV-HIV vector particles, was confirmed by reverse transcriptase 
inhibition and long-term cultivation. As no detectable difference between the three H 
protein cytoplasmic tail truncation mutants in respect of pseudotyping efficiency was 
observed, all further experiments were performed with the Hc∆18 variant.  
3.2  Retargeting of MV-HIV vector particles 
In the first part of the results section it was demonstrated that HIV-1 vector particles 
can be pseudotyped with the MV glycoproteins after optimal truncation of their 
cytoplasmic tails. These particles mediated efficient and stable gene transfer into MV 
receptor-positive but not MV receptor-negative cell lines. Titers were enhanced, 
when an optimal ratio of 1:7 for plasmids encoding the H and F protein variants, 
respectively, was used during vector particle production. Now, based on the 
described pseudotyping with the MV glycoprotein variants, retargeted HIV-1 vector 
particles were generated. For proof of principle, the EGF receptor (EGFR) and the B 
cell surface marker CD20 (Cragg et al., 2005) were chosen as targets.   
3.2.1  Generation of MV-HIV targeting vectors 
For the production of targeting vectors specific for the EGFR or human CD20, the 
cytoplasmic tail of the H protein variant that was mutated in the CD46 (Y481A, S548L 
and F549S) and SLAM (R533A) interaction regions (Nakamura et al., 2005), thus 
unable to recognise its native receptors, was truncated by 18 amino acids 
(Hmut∆18). At its ectodomain either EGF or a scAb directed against human CD20 
(αCD20-scAb) was displayed, resulting in the constructs H-αEGFR and H-αCD20, 
respectively (Figure 17).  
The pCG-Hmut∆18 plasmid and the pCG-H-αCD20 plasmid (10.7) were constructed 
by subcloning the PacI/NheI fragment of pCG-Hc∆18, coding for the truncated H 
cytoplasmic tail, into pCG-Hmut-6His and pCG-HmutXαCD20-6His (Ungerechts et 
al., 2007), respectively. To generate pCG-H-αEGFR (10.8), the αCD20-scAb coding Results 
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region in pCG-H-αCD20 was replaced upon SfiI/NotI digestion by the EGF ligand 
coding region removed from pE-Mo (Buchholz et al., 1998).  
 
Figure 17: Schematic drawing of the modified H protein variants that were used for retargeting. 
The following modifications in the H protein are indicated: four point mutations in the ectodomain (ED) 
ablating CD46 and SLAM interaction, truncation of the cytoplasmic tail by 18 amino acids (CT∆18), a 
factor Xa cleavage site (Xa) and the displayed polypeptide with a C-terminal His6-Tag (6His). The 
position of the transmembrane domain (TM) is also indicated as well as the position of the restriction 
sites for SfiI and NotI, respectively. 
 
For the generation of the targeting vectors MVαEGFR-HIV and MVαCD20-HIV, the 
plasmids pCG-H-αEGFR and pCG-H-αCD20, respectively, were co-transfected with 
pCG-Fc∆30, pCMV∆R8.9 and pHR`-CMV-GFP into HEK-293T cells. After 48 h, the 
vector particle containing cell supernatants were concentrated and then used for the 
transduction of target receptor-positive and -negative cell lines (3.2.2 and 3.2.4). 
3.2.2  Transduction of EGFR-positive and -negative cell lines 
After generation of the plasmid encoding the H-αEGFR protein (Figure 17) that 
should specifically interact with the EGFR through its displayed EGF ligand, now, the 
targeting potential of HIV-1 vectors, pseudotyped with H-αEGFR and Fc∆30 was 
investigated. 
For the production of MVαEGFR-HIV vector particles the same amounts of pCG-H-
αEGFR and pCG-Fc∆30 were co-transfected with the HIV-1 packaging and transfer 
vector plasmid into HEK-293T cells. The untargeted MV-HIV vector was produced as 
control, using the optimised ratio of seven times more pCG-Fc∆30 than pCG-Hc∆18 
for vector particle generation (3.1.6). To evaluate the targeting potential of the 
MVαEGFR-HIV vector, transduction of a panel of CHO cell lines stably expressing Results 
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EGFR, CD46 or SLAM as well as the human cell line A-431 naturally overexpressing 
EGFR (Blakely et al., 2000; Haigler et al., 1978) was performed. Therefore, in a first 
step, both vector types were titrated on A-431 cells (2.3.8), which are susceptible for 
both vector types. Then, serial dilutions containing equivalent amounts of A-431 
transducing units of MVαEGFR-HIV or MV-HIV vectors were applied to the above 
mentioned cell lines. Titers were calculated under the fluorescence microscope, 
based on dilutions in which significantly less than every cell expressed GFP. 
The background level of transduction (5x10
2 t.u./ml) was defined by applying the 
same amounts of HIV-1 vectors pseudotyped with the Env protein of the ecotropic 
Moloney MLV, which lacks a receptor on human and CHO cells (data not shown). 
Also Hmut∆18/Fc∆30 pseudotyped HIV-1 vectors did not show transduction above 
background on any of the cell lines tested (data not shown). 
The MVαEGFR-HIV vector transduced CHO-EGFR cells, while transduction of CHO-
CD46 and CHO-SLAM cells remained at background levels even when the highest 
possible amount of vector particles was applied (Figure 18). In contrast, MV-HIV 
vector particles efficiently transduced all cell lines expressing MV receptors, while 
CHO-EGFR cells were only transduced at background level (Figure 18). 
 
Figure 18: Targeting of EGFR-positive cell lines. Concentrated HIV-1 vector particles pseudotyped 
with H-αEGFR and Fc∆30 were used for the transduction of EGFR-positive and -negative cell lines. As 
control, vector particles pseudotyped with Hc∆18 and Fc∆30 were used. The titers are mean values 
from four independent experiments with standard deviation. The arrow indicates a titer below 10
2 
t.u./ml. 
 Results 
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These data clearly demonstrate that cell entry of the MVαEGFR-HIV vectors occurred 
via the retargeted receptor as EGFR-positive cell lines were transduced about 10
3-
fold more efficiently by the targeting vectors than EGFR-negative cell lines. Even by 
the lowest applied dilution (highest vector dose) no transduction above background 
was detected for the MVαEGFR-HIV vector on CHO-SLAM and CHO-CD46 cells. 
Accordingly, the display of a ligand like EGF on a CD46 and SLAM blind H protein 
can mediate cell entry of the respective pseudotyped particles through the retargeted 
receptor.  
3.2.3  Identification of an optimal H-αCD20 to Fc∆30 ratio 
Having shown that MVαEGFR-HIV vector particles can mediate selective gene transfer 
into EGFR-positive cell lines, the targeting potential of MVαCD20-HIV vector particles 
was investigated next. As demonstrated for Hc∆19/Fc∆30 pseudotyped HIV-1 
particles in chapter 3.1.6 a fine tuned balance of the relative amounts of F and H 
encoding plasmids has to be maintained in the packaging cells to allow most efficient 
formation of pseudotyped HIV-1 vectors. Therefore, the titer of MVαCD20-HIV particles 
on target receptor-positive cell lines was optimised by identification of an optimal 
pCG-H-αCD20 to pCG-Fc∆30 ratio during vector particle production in a first step. It 
was assumed that the optimal ratio differs from the one obtained for Hc∆19 and 
Fc∆30, as the H-αCD20 protein showed a reduced cell surface expression compared 
to the Hc∆18 protein (diploma thesis of Inna Kneiske).  
To determine the optimal ratio, HEK-293T cells were co-transfected with 
pCMV∆R8.9, pHR`-CMV-GFP and different ratios of pCG-H-αCD20 and pCG-Fc∆30. 
The respective cell supernatants containing the CD20-retargeted HIV-1 particles 
were used for the transduction of HT1080 cells stably expressing CD20 (HT1080-
CD20 cells). Measured titers were then normalised to the one obtained upon 
transfection of the same amounts of pCG-H-αCD20 and pCG-Fc∆30. 
A clear peak in titer was observed, when a ratio of 1:3 of pCG-H-αCD20 to pCG-
Fc∆30 was used for vector generation. At this optimised ratio, the titer of MVαCD20-HIV 
vector particles on HT1080-CD20 cells had increased by about five-fold (Figure 19). 
Interestingly, titers were drastically decreased when the optimal ratio for the 
production of MV-HIV vector particles was used (1:7 H/F ratio) (Figure 19).  
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Figure 19: Titer enhancement of MVαCD20-HIV vector particles. To optimise titers, the ratio of the 
plasmids encoding H-αCD20 and Fc∆30, respectively, used for vector particle production in HEK-293T 
cells was varied as indicated. Each pseudotype vector produced was titrated on HT1080-CD20 cells. 
The titer of vector particles produced after transfection of a 1:1 ratio of pCG-H-αCD20 to pCG-Fc∆30 
was set to 100%. The titers of all other vector types were normalised to this value. 
 
Hence, the optimal H to F plasmid ratio for the production of MVαCD20-HIV particles is 
different from the one obtained for the generation of the untargeted MV-HIV vector 
particles. Obviously, relatively more H protein is needed when a scAb is fused to its 
ectodomain. This is most likely due to the reduced cell surface expression of such H 
proteins (diploma thesis of Inna Kneiske), which can be compensated by applying 
higher amounts of the corresponding expression plasmid. 
3.2.4 Transduction  of  CD20-positive and -negative cell lines 
After identification of optimal conditions for the production of MVαCD20-HIV vectors, 
the targeting capability of these vectors was investigated.  
For this purpose, MVαCD20-HIV vectors and as control MV-HIV vectors were produced 
(2.3.6). In order to apply equivalent amounts of transducing units of MVαCD20-HIV and 
MV-HIV vectors, both vector stocks were titrated on HT1080-CD20 cells. Then, CHO 
cell lines expressing CD20, CD46 or SLAM as well as HT1080 and HT1080-CD20 
cells were transduced with serial dilutions containing equivalent amounts of MVαCD20-
HIV or MV-HIV vectors, before 48 h later titers were determined (2.3.8). 
The titer of the MVαCD20-HIV vector on HT1080-CD20 cells was above 10
6 t.u./ml and 
thus almost three magnitudes higher than the titer on the parental CD20-negative Results 
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HT1080 cells (Figure 20). Similar observations were made on the CHO cell lines, 
which were only transduced when CD20 was expressed. The MV-HIV vector, in 
contrast, transduced the different MV receptor-positive cell types with similar 
efficiency but did not transduce CHO-CD20 cells (Figure 20). 
 
Figure 20: Targeting of CD20-positive cell lines. Concentrated HIV-1 particles pseudotyped with H-
αCD20 and Fc∆30 were used for the transduction of the CD20-positive and -negative HT1080 and 
CHO cell lines. As control, MV-HIV particles were used. The titers are based on mean values of four 
independent experiments with standard deviation. The arrows indicate titers below 10
3 t.u./ml. 
 
 
These data clearly demonstrate that cell entry of the MVαCD20-HIV vectors occurred 
via the retargeted receptor. CD20-positive cell lines were transduced at least 10
3-fold 
more efficiently by the targeting vectors than CD20-negative cell lines independent 
from the vector dose. Hence, also scAbs can mediate selective cell entry of MV 
pseudotyped HIV-1 particles, when they are displayed on a cytoplasmic tail 
truncated, CD46 and SLAM blind H protein. The maximal reached titers of the 
MVαCD20-HIV vector particles were even slightly higher than those of MVαEGFR-HIV 
vector particles (Figure 18, Figure 20).  
3.2.5  Fusion via CD20 is pH-independent 
It has been shown that MVαCD20-HIV particles enter specifically CD20-positive cells 
via interaction with the retargeted CD20 receptor. Upon recognition of its native 
receptors, MV mediates pH-independent membrane fusion directly at the cell Results 
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membrane. Now, the question was addressed, if also fusion via CD20 is pH-
independent. 
Therefore, HT1080-CD20 and HT1080 cells were transfected in a six well plate under 
neutral pH-conditions with the plasmids pCG-Hc∆18/pCG-Fc∆30 or pCG-H-
αCD20/pCG-Fc∆30 and pSEW, encoding GFP, as transfection control. Twenty-four 
hours later syncytium formation was documented under the microscope. 
Transfection efficiency was similar in all four samples (data not shown). Syncytia 
formation was observed in HT1080-CD20 cells but not in HT1080 cells after 
transfection with pCG-H-αCD20 and pCG-Fc∆30 (Figure 21). However, when pCG-
Hc∆18 and pCG-Fc∆30 were co-transfected, both cell lines showed extensive 
syncytia formation (Figure 21). 
Hence, fusion via CD20 was pH-independent as demonstrated by cell-cell fusion in 
CD20-positive cells at neutral pH. Furthermore, also in the cell-cell fusion model the 
membrane fusion is specific, as only the CD20-positive cell line showed syncytia 
formation after transfection with pCG-H-αCD20 and pCG-Fc∆30. 
 
Figure 21: CD20-dependent membrane fusion at neutral pH. HT1080-CD20 (upper panel) and 
HT1080 cells (lower panel) were transfected in a six well plate with plasmids (1.5 µg each) pCG-
Hc∆18/pCG-Fc∆30 or pCG-H-αCD20/pCG-Fc∆30 and 1 µg pSEW as transfection control. Twenty-four 
hours later syncytium formation (highlighted by red circles) was documented under the microscope at 
100x magnification.  
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3.2.6  Exclusion of pseudotransduction by MVαEGFR-HIV and MVαCD20-HIV 
vectors 
After confirmation of the targeting capability of the MVαEGFR-HIV and MVαCD20-HIV 
vector particles, it was now investigated, if pseudotransduction has contributed to the 
observed titers on the target receptor-positive cell lines. As already described in 
chapter 3.1.5, the reverse transcriptase inhibitor AZT was used to address this 
question.  
A-431 and HT1080-CD20 cells, respectively, were transduced by MVαEGFR-HIV or 
MVαCD20-HIV vectors, either in presence or absence of 10 µM AZT. In the first case, 
both cell lines were also pre-incubated for one hour with 10 µM AZT-containing 
medium. In addition, also MV-HIV particles and HIV-1 particles pseudotyped with 
VSV-G (VSV-G-HIV) were incubated with both cell lines with and without AZT. Then, 
titers in presence and absence of AZT were compared and the relative titer reduction 
under AZT incubation determined. 
In presence of AZT, the relative titers of MVαEGFR-HIV vector particles on A-431 cells 
(Figure 22a) and MVαCD20-HIV vector particles on HT1080-CD20 cells (Figure 22b) as 
well as the titers of MV-HIV and VSV-G-HIV vector particles on both cell lines 
decreased by 98%-100%, (Figure 22).  
Consequently, pseudotransduction contributed, if at all, negligibly to the titers. 
 
Figure 22: Exclusion of pseudotransduction by MVαEGFR-HIV and MVαCD20-HIV particles. In the 
presence or absence of 10 µM AZT in the medium (a) A-431 cells were transduced by concentrated 
MVαEGFR-HIV, MV-HIV or VSV-G-HIV vector particles and (b) HT1080-CD20 cells were transduced by 
MVαCD20-HIV, MV-HIV or VSV-G-HIV vector particles. The relative titer reduction in presence of AZT is 
shown. 
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3.2.7  Targeting of cell lines naturally expressing CD20 
The results described in chapter 3.2.4 demonstrate that MVαCD20-HIV targeting 
vectors enter selectively into cell lines that had been genetically modified to express 
CD20. Now, it was analysed, if MVαCD20-HIV vectors also mediate selective and 
stable gene transfer into cell lines that do naturally express CD20. Furthermore, the 
ability of the targeting vector to selectively transduce CD20-positive cells in mixed 
cell culture with CD20-negative cells was investigated.  
The following transductions were performed: The CD20-positive B cell line Daudi and 
the CD20-negative myeloid cell line K-562 were separately incubated with the 
MVαCD20-HIV vector particles at a multiplicity of infection (MOI) of 0.5 or as control 
VSV-G-HIV vector particles at an MOI of 5 (2.3.9). As transfer vector plasmid for 
vector particle production pSEW was used. Forty-eight hours after transduction the 
percentage of GFP-positive cells was analysed by FACS. Furthermore, to verify gene 
expression stability, the CD20-positive B cell line Raji was transduced with MVαCD20-
HIV vector particles and the number of GFP-positive cells was determined over a 
period of 19 days by FACS analysis. In a next step, a 1:1 mixture of the CD20-
positive Raji and the CD20-negative K-562 cell line was transduced with the 
retargeted vector particles or the VSV-G-HIV particles. After 48 h, the cells were 
stained against CD20 and the percentage of CD20
+/GFP
+ and CD20
-/GFP
+ cells was 
determined by FACS analysis, respectively (2.3.10). 
As expected, VSV-G-HIV particles transduced both of the separately incubated cell 
lines efficiently (Figure 23a). In contrast, the MVαCD20-HIV vectors selectively 
transduced Daudi cells, whereas K-562 cells remained largely GFP-negative (Figure 
23b). Remarkably, the transduction efficiency of Daudi cells was slightly higher with 
the MVαCD20-HIV particles than with the VSV-G-HIV particles. In addition, the Raji 
cells transduced by the MVαCD20-HIV vector showed a constant level of 17%-30% 
GFP-positive cells over the whole observation period (Figure 23c). Furthermore, also 
in the mixed cell culture the MVαCD20-HIV particles transduced nearly exclusively the 
CD20-positive Raji cells, whereas the CD20-negative K-562 cells remained mostly 
untransduced (Figure 24a). On the other side, VSV-G-HIV particles mediated gfp-
gene transfer into both cell lines (Figure 24b). 
Accordingly, also cells naturally expressing CD20 were efficiently transduced by the 
MVαCD20-HIV particles. Moreover, the targeting vector was able to discriminate 
between CD20-positive and -negative cells even in mixed cell cultures. The stability Results 
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of gene integration and expression mediated by the targeting vector was confirmed 
by stable GFP-expression in transduced Raji cells over a period of 19 days. Thus, it 
was demonstrated that CD20-retargeted HIV-1 vector particles had been generated 
that mediated efficient, selective and stable gene transfer into CD20-positive cells. 
 
Figure 23: Selective and stable transduction of CD20-positive B cell lines. Concentrated (a) VSV-
G-HIV (MOI 5) or (b) MVαCD20-HIV vector particles (MOI 0.5) were used for the transduction of CD20-
positive Daudi cells and CD20-negative K-562 cells, respectively. The indicated percentages of GFP-
positive cells were determined 72 h later by FACS analysis. (c) To follow the stability of gene 
integration and expression, Raji cells were cultivated for 19 days after transduction with MVαCD20-HIV 
vectors (MOI 0.1). The percentage of GFP-positive cells was determined by FACS analysis at the 
indicated time points. 
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Figure 24: Selective transduction of CD20-positive cells in mixed cell culture. 1x10
5 CD20-
positive Raji cells and 1x10
5 CD20-negative K-562 cells were mixed and incubated with (a) MVαCD20-
HIV (MOI 0.5) or (b) VSV-G HIV (MOI 5) particles. After 48 h, the cells were stained against CD20 and 
the percentage of CD20
+/GFP
+ and CD20
-/GFP
+ cells was determined by FACS analysis, respectively. 
 
3.3  Selective killing of CD20-positive cells in a mixed cell 
population 
Having demonstrated that the MVαCD20-HIV vector efficiently targets CD20-positive 
cells in a mixed cell population, the question raised if the targeting capability of the 
vector can be applied to selectively kill CD20-positive cells in a mixture of CD20-
positive and -negative cells. 
3.3.1  Setting up the experiment 
To allow cell killing, a suicide gene coding for a fusion protein (CD34TK39) 
composed of a hypersensitive mutant of the herpes simplex virus thymidine kinase 
(TK39) and a truncated version of the cell surface antigen CD34 was used (Junker et 
al., 2003). The thymidine kinase metabolises the inactive drug gancyclovir (GCV) into 
a chemical derivate, which is toxic for dividing cells and furthermore, transduced cells 
can be detected by CD34-expression. The beauty of the TK39/GCV system is that it 
can be used as a therapeutic agent for the treatment of e.g. cancer (Nasu et al., 
2000; Miyake et al., 2007).  
The HIV-1 transfer vector plasmid S-CD34TK39-W (10.9), encoding the fusion 
protein, was constructed by PCR amplification of the cd34tk39 coding region of the 
plasmid M71tCD34tk39m (Junker et al., 2003) with the primers PR-CD34TK-for and 
PR-CD34TK-rev (2.2.10) and subsequent ligation of the PCR fragment into the Results 
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AscI/SbfI digested lentiviral transfer vector plasmid SEW (Demaison et al., 2002), 
thereby replacing the gfp-gene.  
Next, the functionality of the fusion protein in context of the lentiviral transfer vector 
was verified and the killing capacity of MVαCD20-HIV vector particles with the 
packaged  cd34tk39-gene (MVαCD20-HIVcd34tk39) was analysed. In a first step, HEK-
293T cells were transfected in a six well plate with pSEW or pS-CD34TK39-W 
followed by incubation in 10 µM GCV-containing medium 24 h after transfection. Two 
days and five days afterwards cell propagation was monitored under the microscope.  
Twenty-four hours after transfection, about 70% of the HEK-293T cells that were 
transfected with pSEW in a six well plate were GFP-positive (data not shown). While 
in presence of GCV cell propagation was obvious for these cells (Figure 25a), the cell 
density of cd34tk39-transfected HEK-293T cells was remarkably reduced, with nearly 
all cells killed after 5 days of GCV-incubation (Figure 25b). 
 
Figure 25: The cd34tk39-gene is functional in the backbone of pS-CD34TK39-W. HEK-293T cells 
were transfected in a six well plate with (a) 3 µg pSEW or (b) 3 µg pS-CD34TK39-W. Twenty-four 
hours later, medium containing 10 µM GCV was added and changed every 24 h against fresh GCV-
containing medium. Two days and five days afterwards, the cells were analysed under the microscope 
at 100x magnification. 
 
Then, MVαCD20-HIVcd34tk39 particles were produced by co-transfection of HEK-293T 
cells with three-fold more pCG-Fc∆30 than pCG-H-αCD20 together with pCMV∆R8.9 
and pS-CD34TK39-W. After 48 h, concentrated cell supernatant was used for the Results 
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transduction of Raji cells. Because transduced cells express CD34 on their cell 
surface, they can be distinguished from untransduced cells. Thus, the percentage of 
CD34-positive cells was determined ten days after transduction by FACS analysis. 
Afterwards, half of the cells were transferred into 10 µM GCV-containing medium with 
a medium exchange every 24 h while the other half was left as control in GCV-free 
medium. After 48 h, 72 h and 96 h the cells were stained against CD34 and analysed 
by FACS (2.3.10). 
Ten days after transduction of Raji cells with MVαCD20-HIVcd34tk39 vectors, about 27% 
CD34-positive cells were observed (Figure 26; time point 0 h). After 48 h of GCV-
incubation, only about 16% CD34-positive cells were left and after four days (96 h) in 
GCV-containing medium nearly all CD34-positive cells were killed. In contrast, a 
constant level between 22% and 27% CD34-positive cells was present over the 
whole observation period in absence of GCV (Figure 26). 
 
Figure 26: Killing of CD20-positive suspension cells by MVαCD20-HIVcd34tk39 vector particles.   
Concentrated MVαCD20-HIVcd34tk39 particles that were produced by co-transfection of pCMV∆R8.9, pS-
CD34TK39-W, pCG-Fc∆30 and pCG-H-αCD20 were used for the transduction of 2x10
3 Raji cells. 
After ten days the amount of CD34-positive cells was determined by FACS analysis (time point 0 h) 
and half of the cells were transferred into 10 µM GCV-containing medium while the other half was left 
as control in GCV-free medium. Every 24 h the GCV-containing medium was exchanged. At time 
points 48 h, 72 h and 96 h the percentages of CD34-positive cells were determined by FACS analysis.  
   
These data demonstrate that the cd34tk39-gene is functional in the backbone of the 
lentiviral transfer vector, although the bystander effect of the TK39/GCV system 
(Zhang et al., 2008) might have supported the killing of the adherent HEK-293T cells. 
To avoid the influence of the bystander effect during the MVαCD20-HIVcd34tk39 vector 
mediated killing, CD20-positive suspension cells were used for this experiment. Also Results 
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here, nearly all cells transduced with the cd34tk39-gene were killed after four days of 
GCV-incubation, demonstrating the ability of the MVαCD20-HIVcd34tk39 vector to mediate 
efficient cell killing. 
3.3.2  Selective killing of CD20-positive cells 
After generation of the transfer vector encoding the fusion protein CD34TK39 and the 
demonstration of efficient cell killing by MVαCD20-HIVcd34tk39 vectors, the selectivity of 
killing was investigated next.  
Therefore, MVαCD20-HIVcd34tk39 vector particles and as control also MVαCD20-HIV vector 
particles having packaged the pSEW transfer vector RNA were produced. The 
concentrated vector particles were separately applied to a 1:1 mixture of CD20-
positive Raji and CD20-negative K-562 cells. Five days later, the percentage of 
GFP/CD20 and CD34/CD20 double-positive cells, respectively, was determined by 
FACS analysis (2.3.10). Then, half of the cells of both approaches were incubated in 
10 µM GCV-containing medium while the other half was left as control in GCV-free 
medium. At different time points after start of GCV treatment the relative number of 
GFP/CD20 and CD34/CD20 double-positive cells was determined by FACS analysis, 
respectively.  
Both CD20-retargeted vector particles selectively transduced the CD20-positive cell 
fraction. Five days after transduction, there were about 20% GFP/CD20 and 30% 
CD34/CD20 double-positive cells whereas only about 1-2.5% of the CD20-negative 
cells were transduced (Figure 27; time point 0 h). Normalised to the total cell number, 
this means that 32% and 55% of the CD20-positive cells, respectively, and 4% and 
6% of the CD20-negative cells, respectively, had become GFP- or CD34-positive. 
Without GCV, the transduction patterns remained similar over time, demonstrating 
the stable integration and expression of the transferred genes and the viability of 
transduced cells. However, there was a slight increase in the number of reporter 
gene-positive CD20-negative cells in absence of cell killing (Figure 27), suggesting 
that transduction by the MVαCD20-HIV vectors may have resulted in loss of the CD20 
surface marker in a small fraction of the cells. As expected, incubation with GCV had 
no influence on the fraction of GFP/CD20 double-positive cells (Figure 27a). In 
contrast, the CD20-positive cell fraction transduced with the cd34tk39-gene was Results 
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efficiently and selectively killed by GCV (Figure 27b): Starting with 32% double-
positive cells, after six days almost all double positive cells had disappeared. 
 
Figure 27: Selective killing of CD20-positive cells in a mixed cell population. 2x10
3 CD20-
positive Raji and 2x10
3 CD20-negative K-562 cells were mixed and then transduced with the MVαCD20-
HIV vector having packaged either (a) the gfp-gene or (b) the cd34tk39-gene. Five days after 
transduction (time point 0 h), half of the transduced cells were incubated in 10 µM GCV-containing 
medium while the other half was left as control in GCV-free medium. Every 24 h the GCV-containing 
medium was exchanged. At time point 0 h and at the indicated time points, the percentages of 
GFP/CD20 and CD34/CD20 double-positive cells (highlighted by blue circles) were determined by 
FACS analysis, respectively. 
 
Accordingly, the CD20-targeting vector can mediate selective and efficient killing of 
CD20-positive cells in mixed cell populations. This demonstrated that the targeting 
capability of MVαCD20-HIV vectors can be applied for selective transfer of a 
therapeutic gene, like cd34tk39, into target cell populations, leading to a selective 
expression and effect of the therapeutic agent.  Results 
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3.4  Transduction of primary human B cells 
Having demonstrated the selective and efficient gene transfer of MVαCD20-HIV vectors 
into different CD20-positive cell lines, the potential of the targeting vector to 
transduce primary human cells was investigated next. The efficient transduction of 
primary human cells is a crucial feature for a future application of the vector in the 
clinic. Naturally, CD20 is exclusively expressed on B cells (Cragg et al., 2005), which 
were therefore used as target population. 
3.4.1  Transduction of activated primary human B cells 
As transduction of primary human B cells with any retro- or lentiviral vector has only 
been observed after activation of these cells (Serafini et al., 2004), in a first step, also 
in this study, activated B cells were used. 
Therefore, primary human B cells were isolated by negative depletion from peripheral 
blood mononuclear cells (PBMCs) (2.3.4). Then, they were activated for 48 h with a 
cytokine cocktail consisting of 300 ng/ml CD40 ligand, 50 ng/ml IL-2, 10 ng/ml IL-4 
and 10 ng/ml IL-10 and were analysed by FACS for the presence of the early 
activation marker CD69 (Bose et al., 2008; Damle et al., 2002). Next, the B cells 
were incubated at an MOI of 2 with concentrated MVαCD20-HIV particles produced by 
co-transfection of HEK-293T cells with three times more pCG-Fc∆30 than pCG-H-
αCD20 together with pCMV∆R8.9 and pSEW. For comparison, also VSV-G-HIV 
particles with packaged gfp-gene derived from pSEW were used for the transduction 
of activated primary human B cells at an MOI of 2 and 150 (2.3.9). After 72 h, the 
cells were stained for the B cell markers CD20 and CD19 and the percentage of 
CD20/CD19/GFP triple-positive cells was analysed by FACS. 
After incubation with the cytokine cocktail, 82% of the cells were CD69-positive 
(Figure 28) and thus activated. Furthermore, most of the isolated, activated cells 
were double-positive for the B cells markers CD20 and CD19 (Figure 29). 
Remarkably, more than 70% of these B cells were GFP-positive after transduction 
with the MVαCD20-HIV vector (Figure 29a), whereas only about 20% had become 
GFP-positive with the VSV-G-HIV vector (Figure 29b). This result, of MVαCD20-HIV 
vectors being much more efficient in mediating gene transfer into primary human B Results 
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cells than VSV-G-HIV particles, was confirmed with B cells of three further donors 
(Table 2).  
 
 
Figure 28: CD69-expression of activated primary human B cells. Isolated primary human B cells 
were activated for 48 h with 300 ng/ml CD40 ligand, 50 ng/ml IL-2, 10 ng/ml IL-4 and 10 ng/ml IL-10 
and then analysed by FACS for the expression of the early activation marker CD69. left: B cells 
incubated with FITC conjugated IgG1,κ isotype control; right: B cells incubated with FITC conjugated 
anti-CD69 antibody. 
   
Figure 29: Transduction of activated primary human B lymphocytes. Primary human B cells were 
isolated from human PBMCs, activated for 48 h and then transduced with (a) the MVαCD20-HIV vector 
at an MOI of 2. In parallel, B cells were transduced with the VSV-G-HIV vector at an MOI of (b) 2 or 
(c) 150. Seventy-two hours after transduction, the percentage of CD20/CD19/GFP triple-positive cells 
and the respective GFP mean fluorescence intensity (MFI) was determined by FACS analysis. Results 
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Table 2: Transduction of activated primary human B cells from different donors 
  transduced B cells [%] 
donor  MVαCD20-HIV 
MOI 2 
VSV-G-HIV 
MOI 2 
VSV-G-HIV 
MOI 150 
1 74 19 42 
2  32  nd  8 (MOI 510) 
3 42 12 16 
4 35 3  7 
 
nd not determined 
 
Increasing the MOI of the VSV-G-HIV vector to 150 raised the fraction of GFP-
positive B cells about two-fold (Figure 29c). However, the GFP mean fluorescence 
intensity (MFI) of cells transduced by the VSV-G-HIV vector was considerably lower 
compared to the MVαCD20-HIV transduced cells (Figure 29). 
In conclusion, it has been shown, that MVαCD20-HIV particles can transduce activated 
primary human B cells with a remarkably high efficiency, which is above any 
transduction rate described before for any type of retro- or lentiviral vector (Bovia et 
al., 2003; Janssens et al., 2003). 
3.4.2  Chromosomal integration of vector sequences transferred by 
MVαCD20-HIV particles 
Having observed this unexpected high transduction efficiency of MVαCD20-HIV vectors 
on primary human B cells, the question raised if the transferred vector sequences are 
indeed integrated into the B cell genome. For this reason a two-step PCR 
amplification assay (two-step Alu-PCR) was performed (Chun et al., 1997).  
Therefore, in a first step, activated primary human B cells and as control HT1080-
CD20 cells were transduced with MVαCD20-HIV particles at an MOI of 2 and 0.7, 
respectively (2.3.8; 2.3.9). In parallel, primary human B cells were also transduced 
with VSV-G-HIV particles at an MOI of 150. To avoid contamination with the transfer 
vector plasmid DNA (pSEW) from the packaging cells, the used vector particles were 
incubated with DNase I before transduction (2.2.8). Six days after transduction, the 
genomic DNA of the cells was isolated using the DNeasy
® Blood and Tissue kit Results 
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(Qiagen) (2.2.9). For integration analysis, the isolated genomic DNA was then 
applied to a two-step Alu-PCR (2.2.10). Therefore, the primers ALUs and HIV-
AluPCRas that bind to cellular genomic Alu and proviral gag sequences (ψ-site 
coding region in the transfer vector), respectively, in the first cycle and the transfer 
vector-specific primers SEW-LTR1s and SEW-LTR1as binding in the LTR in the 
second cycle were used. Integration of vector DNA is indicated, if a significant 
increase in the transfer vector-specific signal is obtained by two steps of 
amplification, compared to that attained without a preceding Alu-PCR.  
Integration of vector sequences, transferred by MVαCD20-HIV particles, was detected 
in both, transduced primary human B cells and HT1080-CD20 cells, whereas no 
signal was detected in untransduced control cells or PCR controls (Figure 30). In 
contrast, primary human B cells transduced by the VSV-G-HIV vector were negative 
in the two-step Alu-PCR (data not shown).                       
 
Figure 30: Chromosomal integration of transfer vector DNA in cells transduced by MVαCD20-HIV 
particles. Genomic DNA of primary human B cells and HT1080-CD20 cells that were transduced by 
MVαCD20-HIV particles at an MOI of 2 and 0.7, respectively, was isolated six days after transduction 
and analysed via a two-step Alu-PCR protocol for genomic integration of transfer vector sequences. 
To avoid contamination with pSEW from the packaging cells, the used vector particles were incubated 
with DNase I before transduction. β-Actin sequences were amplified to demonstrate the integrity of 
isolated genomic DNA. Amplification products were 236 bp for transfer vector-derived sequences and 
390 bp for β-Actin sequences. ut, genomic DNA of untransduced cells; pc, positive control for the 
second amplification step (50 ng pSEW); +, two-step Alu-PCR protocol; -, transfer vector-specific PCR 
(second round) without previous Alu-PCR.  
 
Accordingly, chromosomal integration of vector sequences transferred by the 
MVαCD20-HIV particles was demonstrated in primary human B cells as well as Results 
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HT1080-CD20 cells. The weaker signal obtained for the HT1080-CD20 cells can be 
explained by the lower MOI used for the transduction of these cells. Thus, it was 
verified, that the high amount of GFP-positive primary human B cells, gained after 
transduction with MVαCD20-HIV particles, was due to viral integration and not to 
pseudotransduction. In contrast, the absence of an amplificate after the two-step Alu-
PCR for primary human B cells transduced by VSV-G-HIV particles indicates a 
significant contribution of pseudotransduction to the GFP-fluorescence obtained with 
this vector. 
3.4.3  Selective transduction of B cells in primary human lymphocytes 
Confirming the ability of the targeting vector to efficiently transduce primary human B 
cells, next, it was investigated if the MVαCD20-HIV vector discriminates between 
CD20-positive and -negative primary human cells in mixed lymphocytes.  
Therefore, CD20/CD19
 double-positive B cells and CD3-positive T cells were isolated 
from human blood via CD19 and CD3 antibody mediated immunomagnetic selection 
(2.3.5) and were activated with the same cytokine cocktail as described above. Then, 
the cell mixture containing about 70% T cells and 5% B cells (data not shown) was 
transduced with the MVαCD20-HIV vector and the VSV-G-HIV vector, respectively. 
Forty-eight hours after transduction, the lymphocyte mixture was stained against the 
B cell markers CD20 and CD19 and the percentages of CD20
+/CD19
+/GFP
+ and 
CD20
-/CD19
-/GFP
+ cells were determined by FACS analysis. 
With the MVαCD20-HIV vector about 40% of the B cells had become GFP-positive, 
while the CD20/CD19 double-negative cell fraction, mainly consisting of T cells, 
remained GFP-negative (Figure 31a). In contrast, the VSV-G-HIV vector transduced 
both cell fractions roughly at equal efficiency (Figure 31b) and did not discriminate 
between the two cell populations. These data have been confirmed with a B and T 
cell mixture of a second donor (data not shown).  
Thus, the MVαCD20-HIV vector effectively targets primary human CD20-positive cells, 
even when the target cell population is highly underrepresented. Results 
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Figure 31: Selective transduction of primary human B cells in mixed lymphocytes. Primary 
human B and T cells were isolated from human blood by positive selection and incubated with 
cytokines activating B and T cells. Then, the cell mixture was transduced with (a) the MVαCD20-HIV 
vector or (b) the VSV-G-HIV vector at an MOI of 2. Forty-eight hours after transduction, the 
percentage of CD20
+/CD19
+/GFP
+ cells (upper panels) and CD20
-/CD19
-/GFP
+ cells (bottom panels) 
was determined by FACS analysis. 
3.4.4 Transduction  of  unstimulated primary human B cells 
The unexpected highly efficient transduction of activated primary human B cells by 
the MVαCD20-HIV vector prompted to test if the vector can mediate gene transfer into 
unstimulated primary human B cells. 
For this purpose, primary human B cells were isolated from human PBMCs by 
negative depletion, were stained against the early activation marker CD69 (Bose et 
al., 2008; Damle et al., 2002) and analysed by FACS. Next, the B cells were 
transduced by MVαCD20-HIV and VSV-G-HIV particles, respectively, without ever 
coming in contact with any activating cytokines, neither before nor after transduction. 
After 48 h, the cells were stained against the B cell markers CD20 and CD19 and the 
percentage of CD20/CD19/GFP triple-positive cells was determined by FACS 
analysis. 
The unstimulated state of the isolated B cells was confirmed by the absence of the 
early activation marker CD69 (Figure 32a). As expected, these cells were completely 
resistant against transduction with the VSV-G-HIV vector even at MOIs of 150 or 
higher (Figure 32b; Table 3). Most surprisingly, the MVαCD20-HIV vector transduced 
unstimulated B cells derived from five different donors at efficiencies of around 20% 
(Figure 32c; Table 3). Results 
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Figure 32: Transduction of unstimulated primary human B lymphocytes. Primary human B cells 
were isolated from human PBMCs, shown to be negative for CD69 (a), and were then transduced with 
(b) the VSV-G-HIV vector at an MOI of 150 or (c) the MVαCD20-HIV vector at an MOI of 2. Forty-eight 
hours after transduction, the percentage of CD20/CD19/GFP triple-positive cells was determined by 
FACS analysis. 
 
Table 3: Transduction of unstimulated primary human B cells from different 
donors 
 
  transduced unstimulated B cells [%] 
donor  MVαCD20-HIV 
MOI 2 
VSV-G-HIV 
MOI 2 
VSV-G-HIV 
MOI 150 
1 19  0 0.4 
2  25  nd  0 (MOI 350) 
3 22  0.2  0.5 
4  23 0.6 nd 
5 30  0  nd 
 
nd not determined 
 
In conclusion, it was demonstrated that the MVαCD20-HIV vector transduced activated 
primary human B cells with a surprisingly high efficiency. Even in a mixture of primary Results 
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lymphocytes, with highly underrepresented B cells, the MVαCD20-HIV vector mediated 
selective gene transfer into the B cell fraction. Even more remarkably was the 
observation that the MVαCD20-HIV particles transduced unstimulated primary human B 
cells with efficiencies of around 20% although until then unstimulated (quiescent) 
primary human B cells were resistant against transduction by any type of retro- or 
lentiviral vector (Serafini et al., 2004). 
3.5  Induced activation of unstimulated primary human B cells by 
MVαCD20-HIV transduction 
Having shown that MVαCD20-HIV vectors transduce activated primary human B cells 
much more efficiently than VSV-G-HIV vectors, which were believed to be the most 
promising vectors for the transduction of primary human B cells (Bovia et al., 2003; 
Janssens et al., 2003) and above all the observation that even unstimulated primary 
human B cells can be transduced by the CD20-targeting vector, let to the question of 
the difference between the MVαCD20-HIV and other pseudotype vectors, like VSV-G-
HIV. One possible explanation for the ability of MVαCD20-HIV vectors to efficiently 
transduce unstimulated primary human B cells is a stimulatory signal induced by 
CD20-binding. Increasing evidence for a physiological role of CD20 as a regulator of 
cell growth and differentiation supports this view (Riley and Sliwkowski, 2000; Cragg 
et al., 2005). 
3.5.1 Influence  of  MVαCD20-HIV particles on different activation markers 
To answer the question if MVαCD20-HIV particles induce activating stimuli in primary 
human B cells, the expression patterns of the activation markers CD25, CD69, CD71 
(Damle et al., 2002) and CD86 (Yokozeki et al., 1996) of untransduced B cells and B 
cells transduced by MVαCD20-HIV or VSV-G-HIV particles were analysed by FACS.  
Therefore, primary human B cells were isolated from PBMCs and immediately 
transduced with MVαCD20-HIV or VSV-G-HIV particles without any pre-activation 
(2.3.9). Forty-eight hours later, the cells were stained against CD25, CD69, CD71 or 
CD86 and the expression of the different activation markers as well as the 
transduction efficiency, determined by GFP-expression, was analysed by FACS. Results 
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Again, VSV-G-HIV particles could not mediate gene transfer above background level, 
whereas the MVαCD20-HIV particles transduced 23% of the unstimulated primary 
human B cells (Table 3 donor 4). There was no detectable difference of CD25-
expression between untransduced B cells and B cells transduced by MVαCD20-HIV or 
VSV-G-HIV vectors (data not shown). In contrast, a slight enhancement of CD69 and 
CD86 and a moderate enhancement of CD71 expression of B cells transduced by 
the MVαCD20-HIV particles compared to untransduced and VSV-G-HIV transduced B 
cells was observed (Figure 33). This rise in expression was confirmed for CD69 and 
CD71 with B cells from further donors (Table 4).   
 
Figure 33: Expression of different activation markers in transduced primary human B cells. 
Unstimulated primary human B cells were incubated with VSV-G-HIV or MVαCD20-HIV particles at an 
MOI of 2. After 48 h, the expression of the activation markers (a) CD69, (b) CD86 and (c) CD71 was 
analysed by FACS for untransduced (left panel), VSV-G-HIV transduced (middle panel) and MVαCD20-
HIV transduced (right panel) B cells. 
  Results 
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Table 4: Expression of different activation markers in transduced primary 
human B cells from different donors. 
transduction 
state 
CD69
1 
[%] 
CD69
2 
[%] 
CD69
3 
[%] 
CD71
2 
[%] 
CD71
3 
[%] 
CD86
2 
[%] 
Transduction 
efficiency 
[%] 
untransduced 9.0  18.8  5.7 8.5 0.0 7.0  - 
VSV-G-HIV 8.7 18.3 5.4  8.9 0.0 8.0 0.0  -  0.6 
MVαCD20-HIV 14.0  24.2  7.2  33.4  2.9  10.0  22.0 - 30.0 
 
1 primary human B cells from donor 1 
2 primary human B cells from donor 2 
3 primary human B cells from donor 3 
 
In conclusion, three of the four tested activation markers showed an enhanced 
expression after transduction of unstimulated primary human B cells with the 
MVαCD20-HIV vectors, which indicates an influence of MVαCD20-HIV transduction on 
the activation status of primary human B cells. 
3.5.2  Co-transduction of VSV-G-HIV and MVαCD20-HIVcd34tk39 vectors 
The results described in the previous chapter indicate an activating stimulus of 
MVαCD20-HIV transduction on unstimulated primary human B cells. Consequently, 
such cells might now be transducible by VSV-G-HIV vector particles. To test this 
hypothesis, unstimulated primary human B cells were incubated with a mixture of 
VSV-G-HIV and MVαCD20-HIVcd34tk39 (3.3) vector particles.  
For this purpose, VSV-G-HIV vectors were produced by co-transfection of pMD.G2, 
pCMV∆R8.9 and pSEW, whereas MVαCD20-HIVcd34tk39 particles were generated by co-
transfection of pCG-Fc∆30 and pCG-H-αCD20 together with pCMV∆R8.9 and pS-
CD34TK39-W. In parallel, also MVαCD20-HIV particles using pSEW instead of pS-
CD34TK39-W during transfection were produced. Thus, VSV-G-HIV and MVαCD20-
HIV particles have packaged the gfp-gene, whereas MVαCD20-HIVcd34tk39 particles 
transfer the cd34tk39-gene. Next, primary human B cells were isolated from PBMCs 
by negative depletion and were immediately transduced by a mixture of VSV-G-HIV 
and MVαCD20-HIVcd34tk39 particles (both at an MOI of 2). Consequently, cells 
transduced by VSV-G-HIV
  vectors
  express GFP, whereas cells transduced by 
MVαCD20-HIVcd34tk39 vectors do not. As controls, two further B cell aliquots were Results 
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separately transduced with VSV-G-HIV (MOI 2) or MVαCD20-HIV (MOI 2) vectors. 
After 48 h, the cells were stained for the B cell markers CD20 and CD19 and the 
percentage of CD20/CD19/GFP triple-positive cells was determined by FACS 
analysis. 
While the MVαCD20-HIV particles mediated gfp-gene transfer into 50% of the 
unstimulated primary human B cells, only background transduction was observed 
after VSV-G-HIV incubation (Table 5 experiment 1). In contrast, after co-incubation 
with VSV-G-HIV and MVαCD20-HIVcd34tk39 particles, 4% of the unstimulated B cells had 
become GFP-positive (Table 5 experiment 1). More or less the same amount of 
CD20/CD19/GFP triple-positive B cells after co-transduction with VSV-G-HIV and 
MVαCD20-HIVcd34tk39 particles was observed with B cells from a second donor (Table 5 
experiment 2).  
Table 5: GFP-positive primary human B cells after co-transduction with VSV-G-
HIV and MVαCD20-HIVcd34tk39 particles. 
  transduction efficiency [%] 
vector type  experiment 1  experiment 2 
MVαCD20-HIV 50  not  done 
VSV-G-HIV 0.6  0 
VSV-G-HIV  
MVαCD20-HIVcd34tk39  4 7 
   
Taken together, these results and the results from chapter 3.5.1 indicate that 
MVαCD20-HIV particles induce an activating stimulus in unstimulated primary human B 
cells, which allowed moderate gene transfer by VSV-G-HIV particles into these cells. Discussion 
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4 Discussion 
Since lentiviral vectors allow stable integration of a transgene into the host cell 
genome and its propagation into daughter cells and furthermore the transduction of 
most non-dividing cells, they are the most promising tools for gene therapy. However, 
further efforts in vector design are required to improve safety and efficiency of 
lentiviral mediated gene transfer. One aspect is the restriction of gene transfer to the 
cell type relevant for a particular therapeutic application already at the step of cell 
entry. Furthermore, lentiviral vectors able to transduce quiescent lymphocytes are 
desirable. For this reason, the development of an efficient and compliant cell entry 
targeting system for lentiviral vectors is described in this thesis. The very competent 
MV targeting system was transferred to lentiviral vectors by pseudotyping them with 
the MV H and F glycoproteins. This novel approach allowed for the first time the 
retargeting of a lentiviral vector to a cell surface molecule of interest as well as the 
transduction of quiescent B lymphocytes. 
4.1  Setting up the system 
The first step for the generation of retargeted lentiviral vector particles was their 
pseudotyping with the MV glycoproteins. As the unmodified MV H and F proteins did 
not pseudotype HIV-1 vectors (3.1), it was assumed that sequences in their 
cytoplasmic tails prevent pseudotyping. In both postulated mechanisms of 
pseudotype formation the glycoprotein cytoplasmic tail plays an important role. In the 
passive incorporation model, in which no direct interactions between virus proteins 
and glycoproteins are needed, but sufficient amounts of glycoproteins must be 
provided at the site of budding, the glycoprotein cytoplasmic tail has no active 
function but should not sterically hinder vector particle incorporation and morphology 
(Swanstrom and Wills, 1997). In the active model, it directly interacts with the viral 
core proteins or indirectly via cellular factors, which leads to pseudotyping.  
At the beginning of this thesis there was only a single description of lentiviral 
pseudotype formation with glycoproteins of a paramyxovirus, namely Sendai virus, 
available. Thereby, truncation of the F protein cytoplasmic tail and addition of the 
cytoplasmic tail of the lentiviral Env to the cytoplasmic tail of the HN protein were 
necessary to allow pseudotyping (Kobayashi et al., 2003). For the generation of HIV-Discussion 
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1 vectors pseudotyped with the MV glycoproteins, in a first attempt, this strategy was 
adapted for this thesis. However, no MV-HIV vectors could be generated with this 
approach (data not shown). For this reason also the cytoplasmic tail of the H protein 
was truncated.  
Fifteen H protein variants carrying stepwise truncations and amino acid exchanges in 
their cytoplasmic tails and two F protein variants (3.1.1 Figure 9) were screened in all 
combinations for their ability to pseudotype HIV-1 vector particles. The screen 
identified three combinations that led to efficient pseudotype formation, namely 
Hc∆18/Fc∆30, Hc∆19/Fc∆30 and Hc∆24+4A/Fc∆30 (3.1.1). The F cytoplasmic tail 
has to be truncated by 30 aa, leaving just 3 aa, two of which are positively charged. 
In transmembrane proteins such membrane proximal, positively charged residues 
are often needed to stabilise their integration into the lipid-bilayer (Dalbey, 1990). The 
functionality of the Fc∆30 protein in respect of membrane fusion has been shown 
previously (Moll et al., 2002). Furthermore MV F proteins with a premature stop 
codon, resulting in a cytoplasmic tail truncated by 24 aa, are found in MV isolates 
from patients with SSPE (Cathomen et al., 1998).  
Among the H protein variants, there was a clear peak of optimal truncation when 18 
or 19 residues were deleted (variants Hc∆18 and Hc∆19). Further truncation reduced 
titers, although replacing some of the deleted residues by alanine could restore 
optimal titers in case of variant Hc∆24+4A. Obviously, the critical step was the 
identification of H protein cytoplasmic tail truncation mutants that allowed 
pseudotyping while retaining fusion helper function located in the membrane proximal 
region of the H protein cytoplasmic tail (Moll et al., 2002). All of the three H protein 
variants that allowed most efficient pseudotype formation are still active in fusion 
helper function (Moll et al., 2002). Apparently, the cytoplasmic tails of the unmodified 
MV H and F proteins contain sequences that prevent pseudotyping of lentiviral 
vectors. Western blot analysis of Hc∆18/Fc∆30 pseudotyped HIV-1 vector particles in 
comparison to HIV-1 particles produced in the presence of the unmodified H and F 
proteins demonstrated that these perturbing sequences in the cytoplasmic tails of H 
and especially F prevent incorporation of the unmodified MV glycoproteins into viral 
particles (3.1.3).  
Although the overall expression levels of the truncated proteins in the packaging cells 
appeared increased compared to the unmodified proteins, cell surface expression 
levels, which are regarded more relevant for pseudotyping did not differ (3.1.3). Thus, Discussion 
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the interference of cytoplasmic tail sequences with particle incorporation is most 
likely the reason for absence of pseudotyping with the unmodified H and F proteins. 
Interestingly, these same variants as well as other tested MV glycoprotein variants 
could not efficiently pseudotype MLV particles (3.1.2). Obviously, the restriction 
factors for the formation of lentiviral and γ-retroviral MV pseudotypes, respectively, 
are different. There is indeed evidence in literature for a different behaviour of MLV 
and HIV-1 vector particles in respect of pseudotype formation. For example, the 
unmodified glycoproteins of GALV and RD114 virus readily form MLV pseudotypes, 
because the MLV protease can cleave their R peptide, located in their cytoplasmic 
tails, but are unable to pseudotype HIV-1 particles. Only after truncation or 
modification of the R peptide sequence, these envelope proteins form HIV-1 
pseudotypes (Christodoulopoulos and Cannon, 2001; Merten et al., 2005; Sandrin et 
al., 2004; Stitz et al., 2000).  
A few month after our publication of the MV-HIV pseudotype formation (Funke et al., 
2008), also the group around François-Loïc Cosset published data demonstrating 
pseudotyping of HIV-1 vectors with MV glycoproteins at titers comparable to ours 
(Frecha et al., 2008). While they also used Fc∆30, they identified Hc∆24 as the best 
candidate for pseudotyping. Pseudotype formation with this H protein truncation 
mutant was very inefficient in the screen described in this thesis (3.1.1). Furthermore, 
Hc∆24 is strongly impaired in the fusion helper function (Moll et al., 2002), for which 
reason it is even more surprising that it allowed efficient pseudotype formation. 
Another discrepancy is the observation by Frecha et al. that Hc∆24/Fc∆30 also 
pseudotype MLV particles (Frecha et al., 2008). As mentioned above, in this thesis, 
for MV-MLV vector particle pseudotyping no gene transfer above background levels 
was observed, also including the Hc∆24/Fc∆30 combination (data not shown). Taken 
together, Frecha et al. confirmed the data in this thesis that MV-HIV pseudotypes are 
formed upon cytoplasmic tail truncations. In contrast to our data, a fusion helper 
function deficient H protein mutant was active and MV-MLV pseudotypes could be 
generated. Both issues are not in accordance with our results and can not be 
explained at the moment. 
An interesting observation was the increase in MV-HIV titers, when the ratio of the 
plasmids encoding Fc∆30 and Hc∆19, respectively, was optimised for vector particle 
production. The optimal ratio was determined to be seven-fold more F than H 
plasmid, which resulted in a more than ten-fold increase in titer compared to particles Discussion 
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produced in presence of the same amounts of pCG-Fc∆30 and pCG-Hc∆19 (3.1.6). 
Although it was known before that more F than H mRNA is present in MV infected 
cells (Cattaneo et al., 1987; Plumet et al., 2005), the extent of titer reduction 
observed when suboptimal H:F ratios were applied, was unexpected. Obviously, a 
fine tuned balance of the relative amounts of F and H has to be maintained in the 
packaging cells to allow most efficient formation of pseudotyped HIV-1 vector 
particles. 
In conclusion, the successful pseudotyping of HIV-1 vector particles with modified 
MV glycoproteins was demonstrated. These particles mediated efficient and stable 
gene transfer into MV receptor-positive but not MV receptor-negative cell lines. This 
paved the way for the generation of retargeted HIV-1 vector particles. For proof of 
principle, the EGF receptor (EGFR) and the B cell surface marker CD20 (Cragg et 
al., 2005) were chosen as targets.   
4.2  Cell entry targeting of lentiviral vectors 
The extensive range of target tissues/cell types transducible by lentiviral vectors in 
vitro and in vivo makes them an attractive tool for treating a number of genetic 
disorders. However, insertional mutagenesis, vector mobilization and germ-line 
transmission of vector sequences are all potential hazards that could arise as a 
consequence of the use of lentiviral vectors in gene therapy (Manilla et al., 2005). 
Accordingly, efforts in vector design are required to improve safety of lentiviral 
mediated gene transfer, for example, by restricting cell entry to the cell population 
important for a respective therapeutically application. For this reason, a lentiviral cell 
entry targeting system based on the described pseudotyping with the MV 
glycoproteins was developed in this thesis.  
For the production of MV-HIV vectors specific for EGFR or human CD20, the 
cytoplasmic tail of an H protein variant that was mutated in the CD46 (Y481A, S548L 
and F549S) and SLAM (R533A) interaction regions (Nakamura et al., 2005), thus 
unable to recognise its native receptors, was truncated by 18 amino acids 
(Hmut∆18). At its ectodomain either EGF or a scAb directed against human CD20 
(αCD20-scAb) was displayed, resulting in the constructs H-αEGFR and H-αCD20, 
respectively (3.2.1). For the generation of the targeting vectors MVαEGFR-HIV and 
MVαCD20-HIV, the plasmids pCG-H-αEGFR and pCG-H-αCD20, respectively, were Discussion 
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co-transfected with pCG-Fc∆30, the HIV-1 packaging construct pCMV∆R8.9 and the 
GFP transfer vector plasmid HR`-CMV-GFP or SEW into HEK-293T cells. The vector 
particle containing cell supernatants were concentrated and then used for the 
transduction of target receptor-positive and -negative cell lines (Figure 34). 
 
Figure 34: Production of retargeted MVαCD20-HIV vectors. For the generation of MVαCD20-HIV vector 
particles the glycoprotein expression plasmids pCG-H-αCD20 and pCG-Fc∆30, the HIV-1 packaging 
plasmid CMV∆R8.9 and the GFP transfer vector pHR`-CMV-GFP are transiently co-transfected into 
HEK-293T cells (packaging cells). Then, the packaging cells release CD20-retargeted lentiviral vector 
particles pseudotyped with Fc∆30 and H-αCD20. They have two RNA copies of the transfer vector 
packaged, which can be transferred and after reverse transcription integrated into CD20-positive cells 
(transduction). In contrast, CD20-negative cells are not transduced from these particles. The 
expressed GFP, encoded by the transfer gene, is shown as green triangles. Presence (Ψ) or absence 
(∆Ψ) of the packaging signal is indicated. LTR: long terminal repeat; CMV: cytomegalovirus promoter; 
polyA: polyadenylation signal. 
 
Use of the targeted receptors EGFR and CD20, respectively, for cell entry was 
verified by the highly increased titers (about 1,000-fold) of MVαEGFR-HIV and MVαCD20-
HIV vectors on CHO cells expressing the target receptors compared to the parental 
CHO cells or CHO cells positive for SLAM or CD46 (3.2.2; 3.2.4). Hence, the high Discussion 
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selectivity and flexibility of the novel retargeting system for lentiviral vectors was 
demonstrated by targeting two different types of cell surface molecules, namely the 
EGFR, a typical type I transmembrane protein which becomes rapidly endocytosed 
upon ligand binding, and CD20, a membrane tetraspan protein usually not 
internalised upon antibody binding (Blakely et al., 2000; Cosset et al., 1995; Cragg et 
al., 2005; Glennie et al., 2007). Furthermore, either a natural ligand (EGF) or a scAb 
can be displayed as C-terminal extension of the Hmut∆18 protein for retargeting.  
Similarly as with MV-HIV vectors (3.1.6), also the titers of MVαCD20-HIV particles were 
enhanced after identification of an optimal pCG-H-αCD20 to pCG-Fc∆30 ratio, which 
is 1:3 (3.2.3). However, the optimal H to F plasmid ratio for the production of 
MVαCD20-HIV vector particles was different from the one determined for untargeted 
MV-HIV vector particles. Obviously, relatively more H protein is needed when a scAb 
is fused to its ectodomain. This is most likely due to the reduced cell surface 
expression of such H proteins (diploma thesis of Inna Kneiske), which can be 
compensated by applying higher amounts of the corresponding expression plasmid.  
Probably, the displayed scAb destabilises the H protein leading to a higher 
degradation rate and thus reduced cell surface expression. Data obtained in our 
laboratory indicate that each displayed scAb has a different effect on H protein 
surface expression, for which reason the optimal glycoprotein plasmid ratio might 
differ between diverse H protein display constructs (Buchholz, personal 
communication).   
For MVαCD20-HIV vectors selective long-term gfp-gene transfer into cell lines naturally 
expressing CD20 was demonstrated in mixed cell culture of CD20-positive and 
negative cell lines (3.2.7). Virtual absence of background transduction of non-target 
cells with this system was demonstrated by the selective killing of CD20-positive 
human lymphocytes while co-cultured CD20-negative cells proliferated unaffectedly 
(3.3.2). This experiment also verified the ability of the MVαCD20-HIV vector particles to 
selectively transfer therapeutic genes, like a suicide gene (Nasu et al., 2000; Miyake 
et al., 2007), into the relevant cell population leading to a restricted effect of the 
expressed therapeutic agent.  
Membrane fusion via CD20 was pH-independent as confirmed by the formation of 
syncytia under neutral pH conditions in HT1080-CD20, but not HT1080 cells upon 
co-transfection of plasmids encoding H-αCD20 and Fc∆30 (3.2.5). Hence, the pH-
independent MV membrane fusion machinery is able to use totally different types of Discussion 
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cell surface proteins as receptor, and may thus be exploited for the targeting of 
lentiviral vectors to any desired cell surface molecule. Compared to another cell entry 
targeting system for lentiviral vectors (see below), MV-HIV vectors do not depend on 
receptor-mediated endocytosis of the vector upon antigen binding to mediate fusion 
via the low pH in the endosomes. 
In parallel to this thesis a lentiviral cell entry targeting system based on the co-
incorporation of a native receptor blind Sindbis virus glycoprotein, which mediates 
pH-dependent fusion, and a complete antibody molecule has been developed (Yang 
et al., 2006). Interestingly, also in this system CD20 was used as target molecule. 
Although numerous reports have demonstrated the lack of CD20 modulation after 
antibody binding, there is some evidence that it can be endocytosed with a slow 
kinetic under certain circumstances (Cragg et al., 2005; Press et al., 1989). 
Transduction of 293T-CD20 cells yielded similar titers with these vectors as with our 
MV glycoprotein-based targeting vectors on HT1080-CD20 cells. However, 
background transduction on control cells seems higher with the Sindbis vector 
pseudotypes (Yang et al., 2006). Transductions of mixed cultures of target and non-
target cell lines were not performed and the selective transduction of primary human 
B lymphocytes lacked some important controls, like the demonstration that the CD20-
negative T lymphocytes can be generally transduced with a lentiviral vector after 
stimulation with lipopolysaccharide only, which was the reagent used for activation of 
their primary lymphocytes. Lymphocytes require stimulation with cytokines or other 
factors to make them susceptible for transduction by lentiviral vectors (Serafini et al., 
2004; Unutmaz et al., 1999).  
In contrast to Yang et al. in this thesis a surprisingly efficient transduction of activated 
primary human B lymphocytes using the CD20-targeted vector was achieved, 
reaching more than 70% GFP-positive cells upon a single transduction cycle (3.4.1). 
Previously, difficulties in achieving efficient transduction of primary human B 
lymphocytes have been described. All studies agreed in VSV-G being the optimal 
envelope for B cell transduction but even under carefully optimised conditions never 
reached transduction levels higher than 20% (Bovia et al., 2003; Janssens et al., 
2003).  When the same culture and activation conditions were applied as in this 
thesis, only 2.3% transduced B cells were obtained (Bovia et al., 2003). Although in 
this thesis about 42% GFP-positive B cells were observed after applying VSV-G-HIV 
particles at an MOI of 150 (3.4.1), at such high MOIs pseudotransduction may have Discussion 
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significantly contributed to the GFP-fluorescence of VSV-G-HIV vector transduced 
cells (Gallardo et al., 1997). The considerably lower MFI of VSV-G-HIV vector 
transduced B cells, compared to B cells transduced by MVαCD20-HIV particles, 
supports this possibility.  
Thus, the MV glycoproteins modified with an αCD20-scAb are much more efficient in 
mediating gene transfer into primary human B lymphocytes than the VSV-G protein. 
Moreover, gene transfer is very selective, demonstrated by the transduction of mixed 
lymphocytes with highly underrepresented B cells. With the MVαCD20-HIV vector only 
the B cells had become GFP-positive, while the T cell fraction remained GFP-
negative. In contrast, the VSV-G-HIV vector transduced both cell fractions roughly at 
equal efficiency and did not discriminate between the two cell populations (3.4.3). 
Chromosomal integration of transfer vector sequences in primary human B cells 
transduced by the MVαCD20-HIV vector has been demonstrated by a two step Alu-
PCR (3.4.2), which verifies that the high amount of GFP-positive primary human B 
cells was due to viral integration and not to pseudotransduction. In contrast, the 
absence of an amplificate after the two-step Alu-PCR for primary human B cells 
transduced by VSV-G-HIV particles (data not shown) supports a significant 
contribution of pseudotransduction to the GFP-fluorescence obtained with this vector.  
Hence, with the novel targeting system based on the MV glycoproteins a highly 
selective gene transfer into specific target cell populations with an unprecedented 
degree of efficiency is possible. Furthermore, this system should be widely 
applicable, by displaying different scAbs or ligands on the modified H protein. In 
contrast to previously ineffective targeting strategies that used for example MLV Env 
as display platform, the reason for the success of this novel targeting system lays 
presumably in the separation of the receptor recognition and fusion functions onto 
two different proteins. 
4.3  MV-HIV vectors and the transduction of quiescent lymphocytes   
Quiescent cells reside in the G0 phase of the cell-cycle. In comparison to cells in G1 
phase, this state is characterised by lower rates of transcription, translation and 
metabolism as well as reduced cell size (Yusuf and Fruman, 2003). In quiescent 
naϊve lymphocytes, antigen recognition with appropriate co-stimulation triggers exit 
from G0 phase, increased size and metabolism and progression through the cell Discussion 
 
  86
cycle. Presumably, quiescence in naϊve lymphocytes acts to reduce the resources 
(energy and space) required to maintain a vast repertoire of T and B cells. 
Quiescence might also protect cells from accumulating metabolic damage as well as 
genetic changes that could result in malignancy (Yusuf and Fruman, 2003). Lentiviral 
vectors can transduce many types of non-proliferating cells, but primary human 
lymphocytes require stimulation with cytokines or other factors leading to exit from 
the G0 status and transition to G1b phase to become transduced by these vectors. In 
resting lymphocytes post-entry steps like completion of reverse transcription, nuclear 
import and chromosomal integration of the transgene do not occur (Korin and Zack, 
1998; Serafini et al., 2004; Stevenson et al., 1992; Unutmaz et al., 1999). 
It was therefore highly unexpected that MVαCD20-HIV vector particles transduced 
unstimulated, quiescent B cells from five different donors with efficiencies of about 
20%. VSV-G-HIV vector particles were unable to transduce these cells even if 
applied at 100-fold higher MOIs than MVαCD20-HIV vectors (3.4.4). Hence, MVαCD20-
HIV vectors do not only allow restricted transduction of CD20-positive cells but also 
transduction of unstimulated, resting primary human B cells. What is the molecular 
mechanism behind this unexpected result? Post-entry events in MV and HIV infected 
T lymphocytes as well as CD20-dependent signaling events in B cells, together with 
some initial experimental data might give an explanation: 
 
T cells  
In contrast to HIV-1 derived lentiviral vectors, HIV-1 itself can infect resting T cells in 
vivo, for which it needs beside CD4 the chemokine co-receptor CXCR4. Static 
cortical actin in quiescent T cells represents a post-entry barrier to HIV-1 infection, 
but upon binding, HIV-1 utilizes the CXCR4 signaling pathway to activate a cellular 
actin-depolymerising factor, namely cofilin, to overcome this restriction (Yoder et al., 
2008). Cofilin is the primary molecule regulating cortical actin dynamics. In cycling 
cells, cofilin is constitutively active to facilitate constant remodeling of the actin 
cytoskeleton. In contrast, in resting CD4-positive T cells cofilin is largely inactive, 
implying a less dynamic cortical actin. Cofilin dephosphorylation and thus activation 
by CXCR4 signaling and adjacent actin dynamics are required post-entry processes 
for HIV-1 infection (Yoder et al., 2008). Probably, lentiviruses use the actin 
cytoskeleton for transfer of their viral genome from the peripheral regions of the cell 
to the microtubule network for reverse transcription and nuclear import.  Discussion 
 
  87
Furthermore, Naghavi et al. showed that another cytoskeletal factor, namely moesin, 
a member of the ezrin/radixin/moesin proteins, also directly influences lentiviral 
infection of cells (Naghavi et al., 2007). Moesin, which partially resides in lipid rafts 
(Müller et al., 2006), acts as a cross-linker between plasma membrane and actin 
filaments, as well as a signal transducer in responses involving cytoskeletal 
remodeling. Moesin overexpression was found to downregulate the formation of 
stable microtubules, whereas knockdown of moesin increased stable microtubule 
formation (Naghavi et al., 2007). Naghavi et al. demonstrated that moesin 
overexpression blocks infection by HIV-1 before the initiation of reverse transcription 
while moesin knockdown enhances infection. They state that in the absence of stable 
microtubules, due to active moesin, functional reverse transcription complexes are 
not formed. Consistent with this, phosphorylation levels and activity of moesin are 
high in quiescent lymphocytes but decrease after stimulation with cytokines (Müller et 
al., 2006).  
Importantly, Müller et al. investigated the influence of MV on cofilin and moesin 
(Müller et al., 2006): In T cells that had been in contact with the MV glycoproteins 
cofilin and moesin became dephosphorylated. This way cofilin became activated 
leading to actin rearrangement and moesin became inactivated leading to enhanced 
formation of stable microtubules. As mentioned above, both processes are crucial for 
the transport of HIV-1 core particles to the cell nucleus (Naghavi et al., 2007; Yoder 
et al., 2008). 
Shortly after publication of some results of this thesis (Funke et al., 2008) also 
Frecha et al. (Frecha et al., 2008) published data about the pseudotyping of lentiviral 
vectors with MV glycoproteins (4.1). They showed that untargeted MV-HIV vectors 
are able to transduce quiescent primary human T cells. However, in contrast to B 
cells transduced by the MVαCD20-HIV vectors (3.5), Frecha et al. showed evidence 
that MV-HIV transduced T cells were not activated but remained in a quiescent state 
after transduction. Their data indicate that entry into primary human T cells happened 
primarily through SLAM. Even though SLAM and CD46 can act as co-stimulatory 
molecules for lymphocyte activation, their engagement has no mitogenic effect on 
freshly isolated T-cells (Cocks et al., 1995; Zaffran et al., 2001). Although Frecha et 
al. gave no mechanistic explanation for their observation, they confirmed our 
observation that MV glycoprotein pseudotyped HIV-1 vectors can transduce 
quiescent lymphocytes.  Discussion 
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B cells 
It is likely that also in B cells one of the blocks for quiescent B cell transduction is 
static cortical actin. Like T cells, also B cells must at least enter G1b cell-cycle phase 
for transduction by all so far known lentiviral vectors (Serafini et al., 2004). During 
this state actin rearrangements take place (Brancolini and Schneider, 1994), which 
presumably dissolve the actin block. Although it is clear that MVαCD20-HIV vectors 
bind CD20 and enter cells via CD20, interactions with the natural receptors SLAM 
and CD46 cannot be completely ruled out. It is e.g. known that R533, which is 
mutated to prevent entry via SLAM, does not directly contact SLAM, but is involved in 
the H protein conformational changes that occur after SLAM binding (Navaratnarajah 
et al., 2008). It is therefore supposed that residual binding of the MV glycoproteins to 
SLAM and/or CD46 would lead to dephosphorylation of cofilin and moesin (Hao et 
al., 2008; Müller et al., 2006; Lanemo Myhrinder et al., 2008; Masumoto et al., 1998), 
resulting in actin rearrangement and microtubule formation (Naghavi et al., 2007; 
Yoder et al., 2008). MVαCD20-HIV vector particles can then enter unstimulated B cells 
via CD20 binding and due to the dissolved actin block and enhanced microtubule 
formation integrate their transgene into the host cell genome (Figure 35). 
   
Figure 35: Hypothetical model for the mechanism of MVαCD20-HIV transduction of quiescent B 
cells. The MV glycoproteins of MVαCD20-HIV vectors exhibit residual interaction with CD46 and SLAM, 
which leads to dephosphorylation of cofilin and moesin, resulting in actin dynamics and enhanced 
stable microtubule formation. Entry of MVαCD20-HIV vector particles into resting B cells occurs through 
CD20. After membrane fusion, the post-entry block in resting B cells, consisting of static cortical actin, Discussion 
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is dissolved through the activation of cofilin. Moesin inactivation enhances formation of stable 
microtubules. Together, this enables uncoating, reverse transcription and nuclear localisation with 
transgene integration (transduction). 
 
This mechanism relies on cytoskeleton rearrangement in absence of B cell activation. 
Alternatively, contact of vector particles with quiescent cells may result in mitogenic 
activation. It has been previously shown that lentiviral vectors engineered to display 
cytokines, like interleukin-7, thrombopoietin or stem cell factor on their surface can 
induce mitogenic stimuli in resting lymphocytes or haematopoietic stem cells and 
thus enable lentiviral vector transduction (Verhoeyen et al., 2003; Verhoeyen et al., 
2005). 
How about CD20 as signaling molecule? Although the anti-CD20 monoclonal 
antibody rituximab, which is routinely used for the treatment of e.g. non-Hodgkin`s 
lymphoma (Cheson and Leonard, 2008), is successfully used in immunotherapy, 
knowledge about the physiological function of CD20 is still limited. A natural ligand 
has not been identified and CD20 knockout mice are basically unaffected (Cragg et 
al., 2005). However, there is increasing evidence for a physiological role of CD20 as 
a regulator of cell growth and differentiation (Cragg et al., 2005; Riley and 
Sliwkowski, 2000). Recent data indicate that human CD20 acts as a capacitance or 
store-operated cation (SOC) channel involved in B cell antigen receptor (BCR) signal 
transduction, triggered to open when the intracellular stores are depleted (Li et al., 
2003; Walshe et al., 2008; Janas et al., 2005). It is known that B cell activation 
requires sustained elevation of cytoplasmic free calcium, achieved through a 
combination of its release from intracellular stores and influx of extracellular calcium 
via membrane channels (Cragg et al., 2005).  
Some CD20-specific mAbs, like 1F5, provoke G0 phase to G1 phase transition and 
induce elevated cytoplasmic free calcium levels (Cragg et al., 2005). The amino acid 
sequences of the variable chains of the αCD20-scAb used in this thesis (Bucheit et 
al., 2003) and that of the antibody 1F5 are ~88% identical. Walshe et al. (Walshe et 
al., 2008) suggest the following mechanism of anti-CD20 mAb mediated calcium flux: 
In the resting state, CD20 and BCR are separated. Following ligation of CD20 by 
anti-CD20 monoclonal antibodies and hyper-cross-linking, CD20 molecules cluster 
together and associate with BCR. This tight clustering of CD20/BCR complexes 
mediates BCR downstream signaling leading to release of calcium from intracellular 
stores. This release of intracellular calcium results in open CD20 channels causing Discussion 
 
  90
an influx of extracellular calcium, which leads to transition from the G0 phase to the 
G1 phase of the cell-cycle (Craxton et al., 2007). The multivalent CD20 binding as it 
occurs with lentiviral vector particles possibly further potentiates this effect that 
requires cross-linking of CD20 molecules (Janas et al., 2005). 
Indeed, the activation markers CD69, CD86 and CD71 became upregulated when 
resting B cells where incubated with MVαCD20-HIV vectors but not with VSV-G-HIV 
vectors (3.5.1). Moreover, pre-incubation of unstimulated B cells with CD20-targeted 
MV-HIV vectors allowed a low but significant level of transduction by VSV-G-HIV 
vector particles (3.5.2). Thus, the CD20-targeted MV-HIV vector particles must have 
induced an activating stimulus in the resting B cells which made them susceptible for 
transduction by VSV-G-HIV particles.  
Hence, an alternative mechanism for the transduction of unstimulated B cells by 
MVαCD20-HIV vector particles involves binding and hyper-cross-linking of CD20 
molecules by the vector particles, which leads to CD20/BCR clustering. This results 
in influx of extracellular calcium and finally B cell activation. Such B cells are then 
susceptible for completion of reverse transcription, nuclear import and chromosomal 
transgene integration (transduction) by lentiviral vectors (Figure 36). 
However, further experiments are needed to confirm these two hypothetical models 
(Figure 35; Figure 36) and to decide which molecular events are more relevant or if a 
combination of both takes place. For example, calcium influx into B cells after or 
during transduction with MVαCD20-HIV vector particles will have to be measured. 
Furthermore, different steps in the moesin and cofilin pathways can be blocked, to 
see if these pathways are indeed involved in the transduction of quiescent B cells.  
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Figure 36: Hypothetical model for the stimulation of quiescent B cells by MVαCD20-HIV vectors. 
In the resting state, CD20 and BCR are separated (a) whereas after CD20-binding by MVαCD20-HIV 
particles the CD20 molecules cluster and associate with BCR (b). The tight clustering of CD20/BCR 
complexes, which is potentiated through hyper-cross-linking of CD20 molecules by MVαCD20-HIV 
particles, results in clustering of the protein-tyrosine kinase Syk which activates the phospholipase Cγ 
that generates inositol trisphosphate (IP3). Through IP3 interaction with IP3 receptors (IP3R) calcium 
from intracellular stores (iCa
2+) is released (c). This release of iCa
2+ results in SOC channel opening 
(including CD20) causing an influx of extracellular calcium (eCa
2+), prolonging the calcium flux which 
functions as an activating stimulus making the B cells susceptible for transgene integration mediated 
by MVαCD20-HIV vector particles (d). (modified after Walshe et al. 2008, JBC (Walshe et al., 2008))   
 
4.4 Outlook 
Whatsoever the molecular mechanism is that allows B cell transduction by MVαCD20-
HIV particles, obviously, MV glycoproteins are especially suited for pseudotyping of 
lentiviral vectors as both viruses mediate pH-independent fusion and induce Discussion 
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cytoskeleton rearrangements in lymphocytes. Such vectors will enable a number of 
novel applications ranging from the genetic modification of B cells for investigating 
basic questions in immunology to therapeutic strategies such as the treatment of 
inherited B cell disorders or lymphomas. Until now, lymphocytes had to be stimulated 
for transduction with lentiviral vectors, which can lead to unwanted changes in 
lymphocyte subsets.  
The MV-HIV vectors that were developed in this thesis are based on glycoproteins 
derived from a MV vaccine strain (3.1.1). By applying the same cytoplasmic tail 
truncations, we also generated HIV-1 vectors pseudotyped with the glycoproteins 
derived from the wildtype MV strain IC-B, recombinant clone IC323 (Takeda et al., 
2000), that does not use CD46 as natural receptor. Such pseudotypes selectively 
enter SLAM-positive cell types (Funke et al., in revision). Presumably due to the 
absence of syncytia formation in the packaging cells, about ten-fold higher titers were 
obtained with these pseudotypes compared to the vaccine strain MV pseudotypes 
described in this thesis. Therefore, even more effective retargeted MV-HIV vectors 
may become available in future, using wildtype MV glycoproteins as display platform.  
Moreover, as the MV fusion process is pH-independent, in principle, every cell 
surface molecule can be targeted by displaying the respective ligand or scAb on a 
native receptor blind H protein. Therefore, it should now be possible to tailor lentiviral 
vectors for highly selective gene transfer into any target cell population, including 
quiescent lymphocytes, with an unprecedented degree of efficiency (Baum, 2008). 
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5 Summary 
Lentiviral vectors mediate gene transfer into dividing and most non-dividing cells. One 
exception are e.g. quiescent lymphocytes. Thereby, they stably integrate the transgene into 
the host cell genome. For this reason, lentiviral vectors are a promising tool for gene therapy. 
However, safety and efficiency of lentiviral mediated gene transfer still needs to be 
optimised. Ideally, cell entry should be restricted to the cell population relevant for a 
particular therapeutic application. Furthermore, lentiviral vectors able to transduce quiescent 
lymphocytes are desirable. Although many approaches were followed to engineer retroviral 
envelope proteins, an effective and universally applicable system for retargeting of lentiviral 
cell entry is still not available. Just before the experimental work of this thesis was started, 
retargeting of measles virus (MV) cell entry was achieved. This virus has two types of 
envelope glycoproteins, the hemagglutinin (H) protein responsible for receptor recognition 
and the fusion (F) protein mediating membrane fusion. For retargeting, the H protein was 
mutated in its interaction sites for the native MV receptors and a ligand or a single-chain 
antibody (scAb) was fused to its ectodomain.  
 
It was hypothesised that the retargeting system of MV can be transferred to lentiviral vectors 
by pseudotyping human immunodeficiency virus-1 (HIV-1) derived vector particles with the 
MV glycoproteins. As the unmodified MV glycoproteins did not pseudotype HIV-1 vectors, 
two F and 15 H protein variants carrying stepwise truncations or amino acid (aa) exchanges 
in their cytoplasmic tails were screened for their ability to form functional MV-HIV 
pseudotypes. The combinations Hc∆18/Fc∆30, Hc∆19/Fc∆30 and Hc∆24+4A/Fc∆30 led to 
most efficient pseudotype formation with titers above 10
6 transducing units (t.u.)/ml on 
HT1080 cells, using concentrated vector particles. Thereby, the F cytoplasmic tail was 
truncated by 30 aa, just leaving 3 aa and the H protein cytoplasmic tail was truncated by 18, 
19 or 24 residues with four added alanines after the start methionine in the latter case. 
Western blot analysis indicated that particle incorporation of the MV glycoproteins was 
enhanced upon truncation of their cytoplasmic tails. With the MV-HIV vectors high titers on 
different human cell lines expressing one or both MV receptors were obtained, whereas MV 
receptor-negative cells remained untransduced. Titers were enhanced using an optimal H to 
F plasmid ratio (1:7) during vector particle production. Stability of gene transfer was verified 
by reverse transcriptase inhibition and long-term cultivation.  
Based on the described pseudotyping with the MV glycoprotein variants, HIV-1 vector 
particles retargeted to the epidermal growth factor receptor (EGFR) or the B cell surface 
marker CD20 were generated. For the production of the retargeted vectors MVαEGFR-HIV and 
MVαCD20-HIV, respectively, Fc∆30 together with a native receptor blind Hc∆18 protein, 
displaying at its ectodomain either the ligand EGF or a scAb directed against CD20 were Summary 
 
  94
used. With these vectors, gene transfer into target receptor-positive cells was several orders 
of magnitude more efficient than into control cells. High target versus non-target cell 
discrimination with almost complete absence of background transduction of non-target cells 
was also demonstrated in mixed cell populations, where the CD20-targeting vector 
selectively eliminated CD20-positive cells upon suicide gene transfer. Remarkably, 
transduction of activated primary human CD20-positive B cells was much more efficient with 
the MVαCD20-HIV vector than with the standard pseudotype vector VSV-G-HIV. Even more 
surprisingly, MVαCD20-HIV vectors were able to transduce quiescent primary human B cells, 
which until then had been resistant towards lentiviral gene transfer.  
 
The most critical step during the production of MV-HIV pseudotypes was the identification of 
H protein cytoplasmic tail mutants that allowed pseudotyping while retaining the fusion helper 
function. In contrast to previously inefficient targeting strategies, the reason for the success 
of this novel targeting system must be based on the separation of the receptor recognition 
and fusion functions onto two different proteins. Furthermore, with the CD20-targeting vector 
transduction of quiescent B cells was demonstrated for the first time. Own data and literature 
data suggest that CD20 binding and hyper-cross-linking by the vector particles results in 
calcium influx and thus activation of quiescent B cells. Alternatively this feature may be 
based on a residual binding activity of the MV glycoproteins to the native MV receptors that is 
insufficient for entry but induces cytoskeleton rearrangements dissolving the post-entry block 
of HIV vectors.  
Hence, in this thesis efficient retargeting of lentiviral vectors and transduction of quiescent 
cells was combined. This novel targeting strategy should be easily adaptable to many other 
target molecules by extending the modified MV H protein with appropriate specific domains 
or scAbs. It should now be possible to tailor lentiviral vectors for highly selective gene 
transfer into any desired target cell population with an unprecedented degree of efficiency. Summary (German, long) 
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6  Summary (German, long) 
Lentivirale Vektoren sind von Lentiviren, wie beispielsweise dem Humanen Immundefizienz 
Virus-1 (HIV-1) abgeleitet. Im Gegensatz zu diesen sind sie allerdings replikations-
inkompetent, das heißt, sie können keine Nachkommen erzeugen. Sie können aber die 
genetische Information für ein therapeutisches Gen oder ein Markergen in Zielzellen 
transferieren, ein Prozess, der sich Transduktion nennt. Lentivirale Vektoren können sowohl 
mitotisch aktive wie auch die meisten mitotisch inaktiven Zellen transduzieren. Eine 
Ausnahme bilden z.B. ruhende Lymphozyten. Dabei integrieren sie das Transfergen stabil 
ins Genom der Wirtszelle. Aus diesem Grund sind lentivirale Vektoren sehr gut für die 
Gentherapie geeignet. Allerdings muss die Effizienz und die Sicherheit des lentiviral 
vermittelten Gentransfers noch optimiert werden, ehe eine breite klinische Anwendung 
möglich ist. Zum Beispiel sollte der Zelleintritt auf die Zielzellpopulation einer bestimmten 
therapeutischen Anwendung beschränkt werden können. Außerdem wären lentivirale 
Vektoren, die ruhende Lymphozyten transduzieren können, wünschenswert. 
Das Wirtszellspektrum (Tropismus) lentiviraler Vektoren wird durch ihr Hüllprotein bestimmt. 
Durch Einbau von heterologen Hüllproteinen anderer umhüllter Viren, ein Prozess der sich 
Pseudotypisierung nennt, kann der lentivirale Tropismus verändert werden. Eines der ersten 
und bis jetzt am meisten genutzten Hüllproteine für die Pseudotypisierung ist das 
Glykoprotein (G) des vesikulären Stomatitisvirus (VSV). Auf Grund der Stabilität und des 
breiten Tropismus von VSV-G-HIV Vektoren werden diese als „Goldstandard“ bezeichnet, an 
dem andere lentivirale Pseudotypen gemessen werden. In den vergangenen 15 Jahren 
wurde intensiv auf dem Gebiet des gezielten Zelleintritts (targeting) retroviraler und 
lentiviraler Vektoren geforscht. Allerdings gibt es bis heute noch kein effizientes und 
universell anwendbares targeting-System. Es wurden z.B. verschiedene Polypeptide, wie 
Wachstumsfaktoren, Hormone oder einkettige Antikörperfragmente (single-chain antibodies; 
scAb) an die extrazelluläre Domäne des retroviralen Hüllproteins (envelope protein; Env) 
fusioniert. Durch die Präsentation der verschiedenen Moleküle auf Env, sollte anstatt des 
natürlichen Rezeptors ein ausgewähltes Zelloberflächenprotein den Zelleintritt vermitteln. 
Obwohl die meisten dieser chimären Envs an das jeweilige Zielmolekül binden konnten, 
konnte diese Bindung keinen effizienten Zelleintritt der Vektoren vermitteln.  
Dagegen kann der Zelleintritt des Masernvirus (MV) sehr effizient umgeleitet werden. Dieses 
besitzt zwei glykosylierte Hüllproteine, das Hämagglutinin (H)-Protein, welches mit den MV-
Rezeptoren CD46 und signaling lymphocyte activation molecule (SLAM) interagiert und das 
für die pH-unabhängige Membranfusion zuständige F-Protein. Um gezielten Zelleintritt 
vermitteln zu können, wurde das H-Protein in den Rezeptorerkennungsregionen mutiert und 
ein scAb oder ein Ligand auf seiner Ektodomäne präsentiert.  Summary (German, long) 
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Die vorliegende Arbeit basiert auf der Hypothese, dass das effiziente targeting-System von 
MV auf lentivirale Vektoren übertragen werden kann, indem vom HIV-1 abgeleitete Vektoren 
mit den MV-Hüllproteinen pseudotypisiert werden.  
Dazu mussten in einem ersten Schritt MV-Glykoproteine mit verkürzten zytoplasmatischen 
Domänen auf ihre Fähigkeit lentivirale Vektoren zu pseudotypisieren getestet werden. 
Basierend darauf, sollten MV-HIV Vektoren hergestellt werden, die gezielten Zelleintritt in 
Zellen vermitteln, die den epidermalen Wachstumsfaktor-Rezeptor (EGFR) oder das B-Zell-
spezifische Oberflächenprotein CD20 exprimieren. Die Selektivität dieser Vektoren sollte mit 
Rezeptor-positiven und -negativen Zelllinien, in einzelnen Ansätzen sowie in Mischkulturen, 
verifiziert werden. Die CD20-spezifischen Vektoren sollten des Weitern auf ihre Fähigkeit 
getestet werden, Gentransfer in primäre humane CD20-positive B-Zellen zu vermitteln. 
Schließlich sollte überprüft werden ob durch den neuen Eintrittsweg über CD20 nun auch 
ruhende B-Zellen transduziert werden können, die bis dahin resistent gegen lentiviral 
vermittelten Gentransfer waren.  
 
Da sich zunächst mit den unmodifizierten MV-Hüllproteinen keine MV-HIV Pseudotypen 
erzeugen ließen, wurde angenommen, dass Sequenzen in den zytoplasmatischen Domänen 
der beiden Glykoproteine die Pseudotypisierung von lentiviralen Vektoren verhindern. Es gibt 
mehrere Beispiele in der Literatur, die eine entscheidende Rolle der zytoplasmatischen 
Domäne im lentiviralen Hüllproteineinbau induzieren. Aus diesem Grund wurden zwei F- 
Protein und 15 H-Proteinvarianten mit stufenweise gekürzten zytoplasmatischen Domänen 
und Aminosäureaustauschen auf ihrer Fähigkeit getestet, lentivirale Vektoren effizient zu 
pseudotypisieren. Die Kombinationen Hc∆18/Fc∆30, Hc∆19/Fc∆30 und Hc∆24+4A/Fc∆30 
erwiesen sich als am geeignetsten. Die entsprechenden ankonzentrierten Pseudotyp-
Vektoren zeigten Titer von über 10
6 transduzierenden Einheiten pro Milliliter (transducing 
units/ml; t.u./ml) auf HT1080 Zellen. Dabei war eine Verkürzung der zytoplasmatischen 
Domäne des F-Proteins um 30 Aminosäuren und des H-Proteins um 18, 19 oder 24 
Aminosäuren notwendig, wobei im letzten Fall vier Alanine nach dem Start-Methionin addiert 
wurden. Westernblot-Analysen zeigten, dass die Inkorporation der MV-Glykoproteine in die 
Vektorpartikel durch die Kürzung ihrer zytoplasmatischen Domänen verstärkt wurde.  
Während andere lentivirale Vektoren, z.B. vom Simianen Immundefizienz Virus abgeleitet, 
mit der gleichen Effizienz wie HIV-1 Vektoren mit den identifizierten H- und F-
Proteinmutanten pseudotypisiert werden konnten, wurden vom Murinen Leukämievirus 
(MLV) abgeleitete γ-retrovirale Vektoren nicht von diesen und auch von keiner der anderen 
getesteten MV-Glykoproteinvarianten effizient pseudotypisiert. Der beste Titer (3x10
3 t.u./ml) 
wurde mit der Kombination Hc∆24+4A/Fc∆24 erreicht. Alle weiteren Experimente wurden 
daher mit HIV-1 Vektoren durchgeführt.  Summary (German, long) 
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Erwartungsgemäß vermittelten MV-HIV Vektoren effizienten Gentransfer in MV-Rezeptor-
positive Zelllinien während MV-Rezeptor-negative Zellen untransduziert blieben. 
Interessanter Weise konnte ihr Titer durch Einstellen eines optimalen H- zu F- 
Plasmidverhältnisses in den vektorpartikelproduzierenden Zellen deutlich verbessert werden. 
Die Titration des Plasmidverhältnisses ergab, dass im Idealfall siebenmal mehr F-Plasmid 
als H-Plasmid eingesetzt werden muss. Dadurch wurde eine zehnfache Titererhöhung im 
Vergleich zu Vektorpartikeln, bei denen für die Produktion gleiche Mengen der beiden 
Plasmide eingesetzt wurden, erreicht. Hierbei ist erwähnenswert, dass auch in MV-infizierten 
Zellen mehr F- als H-Protein mRNA produziert wird. Durch Inhibition der Reversen 
Transkription konnte Pseudotransduktion, das heißt Proteintransfer von den vektorpartikel-
produzierenden Zellen zu den Zielzellen, anstelle der Integration des Transfervektors, 
ausgeschlossen werden. Des Weiteren konnte durch Langzeitkultivierung die Stabilität des 
Gentransfers und der Genexpression bestätigt werden. 
Nachdem die Pseudotypisierung der lentiviralen Vektoren mit MV-Hüllproteinen etabliert war, 
sollten basierend darauf in einem nächsten Schritt lentivirale targeting-Vektoren erzeugt 
werden. Zu diesem Zweck wurde als targeting-Domäne der epidermale Wachstumsfaktor 
(EGF) bzw. ein gegen das B-Zell-spezifische Oberflächenmolekül CD20 gerichteter scAb auf 
einem Hc∆18-Protein, das in den MV-Rezeptorerkennungsregionen mutiert ist und damit 
keinen Zelleintritt über die MV-Rezeptoren CD46 und SLAM vermitteln kann, präsentiert. 
Zusammen mit Fc∆30 konnten so die targeting-Vektoren MVαEGFR-HIV und MVαCD20-HIV 
hergestellt werden. Diese transduzierten effizient CHO Zelllinien, die genetisch so verändert 
worden waren, dass sie den EGFR oder CD20 exprimieren, während die parentalen CHO-K1 
Zellen sowie CHO-CD46 und CHO-SLAM Zellen nicht transduziert wurden. Dadurch wurde 
die Nutzung des ausgewählten Zelloberflächenmoleküls für den Zelleintritt nachgewiesen. 
Auch Zelllinien, die natürlicherweise CD20 exprimieren wurden selektiv von den MVαCD20-HIV 
Vektoren mit Titern von über 10
6 t.u./ml transduziert, sowohl in einzelnen Ansätzen, wie auch 
in Mischkulturen von CD20-positiven und CD20-negativen Zelllinien. Ebenso wie der Titer 
der MV-HIV Vektoren, konnte auch der Titer der MVαCD20-HIV Vektoren erhöht werden, 
indem ein optimales Verhältnis der MV-Hüllprotein-kodierenden Plasmide während der 
Vektorpartikelproduktion eingesetzt wurde. Im Gegensatz zu den MV-HIV Vektoren lag hier 
das optimale H:F Plasmidverhältnis bei 1:3 und nicht bei 1:7. Somit wird in Relation mehr H-
Protein benötigt, wenn ein scAb an seine Ektodomäne fusioniert ist, was vermutlich auf eine 
verringerte Oberflächenexpression solcher H-Proteine zurückzuführen ist.  
Die Selektivität des von MVαCD20-HIV Vektoren vermittelten Gentransfers wurde in 
Mischkulturen aus CD20-positiven und -negativen Zellen untersucht. Dabei zeigte sich, dass 
MVαCD20-HIV Vektoren nach Transfer eines Suizidgens selektiv CD20-positive Zellen abtöten 
können, während co-kultivierte CD20-negative Zellen unbeeinflusst weiter wachsen. Somit Summary (German, long) 
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wurde nachgewiesen, dass ein therapeutisches Gen selektiv durch diese Vektoren 
übertragen werden kann und sich dessen Wirkung auf die Zielzellpopulation beschränkt. 
Für eine klinische Anwendbarkeit solcher targeting-Vektoren ist die Transduktion primärer 
humaner Zellen bedeutend, was oftmals eine größere Herausforderung darstellt als der 
Gentransfer in Zelllinien. Weil CD20 exklusiv auf B-Zellen exprimiert ist, wurden diese als 
Zielzellpopulation verwendet. Auch wenn lentivirale Vektoren viele mitotisch inaktive 
Zellarten transduzieren können, brauchen ruhende Lymphozyten einen aktivierenden 
Stimulus, der sie aus der G0-Phase des Zellzykluses mindestens in die G1b-Phase 
transferiert. Aus diesem Grund wurden die B-Zellen nach ihrer Isolierung aus frischen 
humanen peripheren blutmononukleären Zellen zunächst mit einem Zytokincocktail aktiviert, 
bevor sie mit MVαCD20-HIV Vektoren und als Kontrolle VSV-G-HIV Vektoren inkubiert wurden. 
Überraschender Weise vermittelten die MVαCD20-HIV Vektoren einen sehr viel effizienteren 
Gentransfer in aktivierte primäre humane B-Zellen als VSV-G-HIV Vektoren. Nach einer 
einzelnen Transduktionsrunde und einer verwendeten Multiplizität der Infektion (MOI) von 2 
wurden 70% der aktivierten primären humanen B-Zellen vom MVαCD20-HIV Vektor 
transduziert, während VSV-G-HIV Vektoren mit der gleichen MOI nur in 20% der Zellen ihr 
Transfergen übertrugen. Auch unter Verwendung einer MOI von 150 konnten VSV-G-HIV 
Vektoren nur 40% der B-Zellen transduzieren, wobei Pseudotransduktion bei einer solch 
hohen MOI nicht ausgeschlossen werden kann. Dies zeigt das herausragende Potential der 
MVαCD20-HIV Vektoren für die Transduktion dieses Zelltyps.  
Des Weiteren war der Gentransfer sehr selektiv: In einer Mischkultur aus CD20-positiven 
primären humanen B-Zellen und CD20-negativen primären humanen T-Zellen wurden 
nahezu ausschließlich die B-Zellen vom MVαCD20-HIV Vektor transduziert, obwohl diese stark 
unterrepräsentiert waren. Dagegen diskriminierten VSV-G-HIV Vektoren nicht zwischen den 
beiden Zellpopulationen, die mit gleicher Effizienz transduziert wurden. Durch eine zwei 
Schritte  Alu-PCR konnte die chromosomale Integration der vom MVαCD20-HIV Vektor 
übertragenen Transfervektorsequenzen nachgewiesen werden, wodurch Pseudotrans-
duktion als Ursache für die hohe Transduktionsrate ausgeschlossen wurde.  
Auf Grund der effizienten Transduktion der aktivierten primären humanen B-Zellen stellte 
sich die Frage, ob MVαCD20-HIV Vektoren auch unstimulierte, ruhende B-Zellen transduzieren 
können. Überraschender Weise konnten MVαCD20-HIV Vektoren unstimulierte B Zellen mit 
einer Effizienz von ~20% transduzieren, während den Erwartungen entsprechend, VSV-G-
HIV Vektoren selbst bei einer 100-fach höheren MOI keinen Gentransfer in diese Zellen 
vermitteln konnten. 
Ruhende B-Zellen, die von MVαCD20-HIV Vektoren transduziert worden sind, wiesen eine 
höhere Expression der Aktivierungsmarker CD69, CD86 und CD71 auf als untransduzierte 
oder mit VSV-G-HIV Vektoren inkubierte Zellen. VSV-G-HIV Vektoren konnten ruhende B-Summary (German, long) 
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Zellen mit einer geringen aber signifikanten Effizienz transduzieren, wenn diese mit MVαCD20-
HIV Vektoren co-inkubiert wurden. Zusammengenommen spricht dies dafür, dass die B-
Zellen durch Inkubation mit MVαCD20-HIV Vektoren einen aktivierenden Stimulus erhalten, der 
sie dann suszeptibel für lentiviral vermittelten Gentransfer macht.  
 
In dieser Arbeit wurde basierend auf der Pseudotypisierung von lentiviralen Vektoren mit den 
MV-Hüllproteinen ein effizientes targeting-System entwickelt. Als kritischster Schritt für die 
Pseudotypisierung erwies sich die Identifizierung von H-Proteinmutanten, deren 
zytoplasmatische Domäne einerseits die Pseudotypisierung von HIV-1 Vektoren erlaubte, 
andererseits aber noch die Fusionshelfer-Funktion besaß. Im Gegensatz zu früheren 
ineffizienten Strategien basiert der Erfolg des hier beschriebenen Systems wahrscheinlich 
auf der Verteilung der Funktionen Rezeptorerkennung und Membranfusion auf zwei 
unterschiedliche Proteine.  
Parallel zu dieser Arbeit wurde ein auf dem Sindbis-Virus Hüllprotein basierendes targeting-
System in der Arbeitsgruppe von David Baltimore entwickelt. In diesem wurde ein komplettes 
Antikörpermolekül zusammen mit dem Sindbis-Virus Hüllprotein, welches blind für seine 
natürlichen Rezeptoren war, in lentivirale Vektoren eingebaut. Der Nachteil dieses Systems 
beruht vor allem auf der pH-abhängigen Fusion des Hüllproteins. Dieses ist darauf 
angewiesen, dass der Vektor nach Antigenbindung endozytiert wird, damit es die 
Membranfusion in Endosomen mit einem niedrigen pH durchführen kann.  
Kurz nachdem Teile dieser Arbeit veröffentlicht wurden, publizierte auch die Arbeitsgruppe 
um François-Loïc Cosset Ergebnisse, welche die Pseudotypisierung von HIV-1 Vektoren mit 
MV-Glykoproteinen beschreiben. Auch wenn sie ein H-Protein mit einer stark 
beeinträchtigten Fusionshelfer-Funktion als besten Pseudotypisierungskandidaten 
identifizierten, bestätigen sie die hier gezeigten Ergebnisse, dass die Kürzung der 
zytoplasmatischen Domänen des H- und des F-Proteins Pseudotypisierung von lentiviralen 
Vektoren ermöglicht.  
Das auf den MV-HIV Vektoren basierende targeting-System ermöglicht sogar erstmalig die 
Transduktion ruhender B-Zellen. In ruhenden Lymphozyten bildet kortikales Aktin einen Post-
Eintrittsblock für HIV-1 Vektoren. Es wurde publiziert, dass die MV-Hüllproteine nach Kontakt 
mit T-Zellen Zytoskelettumordnungen auslösen, die auch das kortikale Aktin betreffen. 
Dementsprechend beruht ein hypothetisches Modell für die Transduktion ruhender B-Zellen 
auf residualer Bindung der MV-Glykoproteine an ihre nativen Rezeptoren. Dies bewirkt 
keinen Zelleintritt, aber könnte für den Gentransfer in ruhende Zellen notwendige 
Zytoskelettumordnungen verursachen. Des Weitern lösen MVαCD20-HIV Vektoren durch 
CD20-Bindung und -Verlinkung vermutlich einen Kalziumeinstrom und damit B-
Zellaktivierung aus, was die B-Zellen suszeptibel für lentivirale Vektoren macht. Für das 
zweite Modell spricht unter anderem, dass B-Zellen die von dem MVαCD20-HIV Vektor Summary (German, long) 
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transduziert wurden, eine erhöhte Expression der Aktivierungsmarker CD69, CD86 und 
CD71 aufwiesen.  
Das in dieser Arbeit entwickelte targeting-System erlaubt erstmalig einen effizienten, 
gezielten Zelleintritt lentiviraler Vektoren in Kombination mit Gentransfer in ruhende 
Lymphozyten. Darüber hinaus sollte es leicht auf jedes beliebige Zielmoleküle übertragbar 
sein, indem entsprechende Liganden oder scAbs an die Ektodomäne des modifizierten H-
Proteins fusioniert werden. Schon in dieser Arbeit wurden zwei vollkommen unterschiedliche 
Zelloberflächenproteine, wie der EGFR und CD20, zum Zelleintritt verwendet. Entsprechend 
sollte jetzt die Generierung lentiviraler Vektoren für den selektiven Gentransfer in jede 
beliebige Zielzellpopulationen mit einem bis jetzt noch nie dagewesenen Grad an Effizienz 
möglich sein. 
 
 Summary (German, short) 
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7  Summary (German, short) 
Lentivirale Vektoren können sowohl mitotisch aktive wie auch die meisten mitotisch inaktiven 
Zellen transduzieren. Eine Ausnahme bilden z.B. ruhenden Lymphozyten. Dabei integrieren 
sie das Transfergen stabil ins Genom der Wirtszelle. Aus diesem Grund sind lentivirale 
Vektoren sehr gut für die Gentherapie geeignet. Allerdings müssen die Effizienz und 
Sicherheit des lentiviral vermittelten Gentransfers weiter optimiert werden. Zum Beispiel 
sollte der Zelleintritt auf die Zielzellpopulation einer bestimmten therapeutischen Anwendung 
beschränkt sein. Außerdem wären lentivirale Vektoren, die ruhende Lymphozyten 
transduzieren können, wünschenswert. Allerdings gibt es bis heute, trotz intensiver 
Forschung auf dem Gebiet des gezielten Zelleintritts (targeting), noch kein effizientes und 
universell anwendbares targeting-System für lentivirale Vektoren. Der Zelleintritt des 
Masernvirus (MV) kann dagegen sehr effizient umgeleitet werden. Dieses besitzt zwei 
Hüllproteine, das Hämagglutinin (H)-Protein, welches Bindung an die MV-Rezeptoren 
vermittelt, und das für die Membranfusion verantwortliche F-Protein. Um gezielten Zelleintritt 
vermitteln zu können, wird das H-Protein in den Rezeptorerkennungsregionen mutiert und 
ein einkettiges Antikörperfragment (scAb) oder ein Ligand an seine Ektodomäne fusioniert.  
 
Die vorliegende Arbeit basiert auf der Hypothese, dass das effiziente targeting-System von 
MV auf lentivirale Vektoren übertragen werden kann, indem vom Humanen Immundefizienz 
Virus-1 (HIV-1) abgeleitete Vektoren mit den MV-Hüllproteinen pseudotypisiert werden. Da 
sich zunächst mit den unmodifizierten MV-Hüllproteinen keine MV-HIV Pseudotypen 
erzeugen ließen, wurden 15 H- und zwei F-Proteinvarianten mit stufenweise gekürzten 
zytoplasmatischen Domänen und Aminosäure(AS)austauschen auf ihre Fähigkeit getestet, 
HIV-1 Vektoren zu pseudotypisieren. Die Kombinationen Hc∆18/Fc∆30, Hc∆19/Fc∆30 und 
Hc∆24+4A/Fc∆30 führten zur effizientesten Pseudotypisierung mit Titern der 
ankonzentrierten Partikel von über 10
6 transduzierenden Einheiten (t.u.)/ml. Dabei war eine 
Verkürzung der zytoplasmatischen Domäne des F-Proteins um 30 AS und des H-Proteins 
um 18, 19 oder 24 AS notwendig, wobei im letzten Fall vier Alanine nach dem Start-
Methionin addiert wurden. Westernblot-Analysen zeigten, dass die Inkorporation der MV-
Hüllproteine in die Vektorpartikel durch die Kürzung der zytoplasmatischen Domänen 
verstärkt wurde. Erwartungsgemäß spiegelten MV-HIV Vektoren auf unterschiedlichen MV 
Rezeptor-positiven und -negativen Zelllinien den Tropismus des MV wider. 
Interessanterweise konnte ihr Titer durch Einstellen eines optimalen Plasmidverhältnisses 
von H zu F (1:7) in den vektorpartikelproduzierenden Zellen deutlich verbessert werden. Die 
stabile Integration des Transfergens wurde durch Inhibition der Reversen Transkription und 
durch Langzeitkultivierung verifiziert. Summary (German, short) 
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Als nächstes wurden HIV-1 Vektoren hergestellt, die zum Zelleintritt den epidermalen 
Wachstumsfaktor-Rezeptor (EGFR) bzw. das B-Zell-spezifische Oberflächenmolekül CD20 
nutzten. Dafür wurde Fc∆30 zusammen mit einem Hc∆18-Protein, das für seine nativen 
Rezeptoren verblindet wurde und an seiner Ektodomäne den Liganden EGF oder ein scAb 
gegen CD20 präsentiert, zur Produktion der targeting-Vektoren MVαEGFR-HIV und MVαCD20-
HIV eingesetzt. Die Verwendung des EGFR bzw. von CD20 für den Zelleintritt konnte mit 
Rezeptor-positiven bzw. -negativen Zelllinien bestätigt werden. Dass CD20-negative Zellen 
nicht transduziert wurden, wurde in Mischkulturen demonstriert, in denen der MVαCD20-HIV 
Vektor nach Suizidgentransfer selektiv CD20-positive Zellen eliminierte. Bemerkenswerter 
Weise wurden aktivierte primäre humane B-Zellen vom MVαCD20-HIV Vektor mit einer deutlich 
höheren Effizienz transduziert als vom Standard-Pseudotypvektor VSV-G-HIV. Noch 
überraschender war, dass MVαCD20-HIV Vektoren ruhende B-Zellen transduzierten, die sich 
bis dato als resistent gegen den lentiviralen Gentransfer erwiesen hatten. 
  
Als kritischster Schritt der MV-HIV Produktion erwies sich die Identifizierung von H-
Varianten, die einerseits Pseudotypisierung erlaubten, andererseits aber noch die 
Fusionshelfer-Funktion besaßen. Im Gegensatz zu früheren ineffizienten targeting-Strategien 
basiert der Erfolg des in dieser Arbeit entwickelten Systems wahrscheinlich auf der 
Verteilung der Funktionen Rezeptorerkennung und Membranfusion auf zwei unterschiedliche 
Proteine. Sogar die Transduktion ruhender B-Zellen ist nun möglich. Der zugrundeliegende 
Mechanismus könnte auf residualer Bindung der MV-Hüllproteine an die MV-Rezeptoren 
beruhen. Dies bewirkt keinen Zelleintritt, aber könnte für den Gentransfer in ruhende Zellen 
notwendige Zytoskelettumordnungen verursachen. Alternativ oder zusätzlich könnten 
MVαCD20-HIV Vektoren durch CD20-Bindung und -Verlinkung einen Kalziumeinstrom und 
damit B-Zellaktivierung auslösen. 
Das in dieser Arbeit entwickelte targeting-System erlaubt erstmalig einen gezielten und 
effizienten Zelleintritt lentiviraler Vektoren in ruhende Lymphozyten. Dies kann als Basis 
dienen, dieses System auf beliebige andere Zielmoleküle zu übertragen, indem 
entsprechende Liganden oder scAbs an die Ektodomäne des modifizierten H-Proteins 
fusioniert werden. References 
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9 Abbreviations 
α anti- 
αCD20-scAb single-chain  antibody directed against human CD20 
A absorption  or  amper 
aa amino  acids 
Ac acetate 
Amp ampicillin 
APS ammonium  peroxydisulfate 
ATCC  American Type Culture Collection 
ATP adenosine-5'-triphosphate   
AZT azidothymidine 
BCR  B cell antigen receptor 
°C degree  Celsius 
ca. circa 
CD34TK39  fusion protein composed of TK39 and a truncated version of CD34 
CMV cytomegalovirus 
ct cytoplasmic  tail 
DMEM  Dulbecco`s modified Eagle medium 
DMSO dimethyl  sulfoxide 
DNA deoxyribonucleic  acid 
DNase I  deoxyribonuclease I 
DTT dithio-1,4-threithol 
ECACC European  Collection of Cell Cultures 
ECL enhanced  chemiluminescence 
E. coli Escherichia  coli 
EDTA ethylene-diamine-tetra-acetate 
e.g. for  example 
EGF epidermal  growth  factor 
EGFR  epidermal growth factor receptor 
Env envelope  protein 
et al.  and others 
F fusion  protein 
FACS  fluorescence activated cell sorting Abbreviations 
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FCS  fetal calf serum 
FIP fusion-inhibiting  peptide 
FITC fluorescence  isothiocyanate 
g  gram or gravitational acceleration 
gag  group specific antigen 
GALV  gibbon ape leukaemia virus   
GCV gancyclovir 
GFP  green fluorescent protein 
h hour 
H hemagglutinin  protein 
HEPES 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HIV-1  human immunodeficiency virus-1 
HRP horseradish  peroxidase 
ICLC  Interlab Cell Line Collection 
IL interleukin 
kD kilodalton 
l liter 
LB Luria-Bertani 
LTR  long terminal repeat 
m milli- 
M Molar 
mAb monoclonal  antibody 
MFI  mean fluorescence intensity 
µ micro- 
min minute 
MLV  murine leukaemia virus 
MOI  multiplicity of infection 
MoMLV  Moloney murine leukaemia virus 
MOPS morpholinepropanesulfonate 
MPSV  myeloproliferative sarcoma virus 
MV measles  virus 
n nano- 
NEB  New England Biolabs 
OD optical  density Abbreviations 
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p.a. pro  analysis 
PBS phosphate  buffered  saline 
PCR  polymerase chain reaction 
PE R-Phycoerythrin 
pol polymerase 
Ψ  psi-packaging signal of retroviral genomic RNA 
RNA ribonucleic  acid 
rpm revolutions  per  minute 
RPMI  culture medium developed in the “Roswell Park Memorial Institute” 
RT room  temperature 
scAb single-chain  antibody 
SDS  sodium dodecyl sulfate 
sec second 
SFFV  spleen focus forming virus 
SIVmac  simian immunodeficiency virus 
SLAM  signaling lymphocyte activation molecule 
SOC channel  store-operated cation channel 
SSPE  subacute sclerosing panencephalitis 
TEMED tetramethylethylenediamine 
TK39 hypersensitive  mutant of the herpes simplex virus thymidine kinase 
Tris tris(hydroxymethyl)aminomethane 
t.u. transducing  units 
U unit 
UV ultraviolet 
V volt 
VSV-G  glycoprotein of vesicular stomatitis virus Appendix 
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10 Appendix 
10.1 Plasmid map of pCG-F 
 
10.2 Plasmid map of pCG-H 
 Appendix 
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10.3 Plasmid map of pCMV∆R8.9 
 
10.4 Plasmid map of pHR`-CMV-GFP 
 Appendix 
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10.5 Plasmid map of pMD.G2 
 
10.6 Plasmid map of pSEW 
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10.7 Plasmid map of pCG-H-αCD20 
 
10.8 Plasmid map of pCG-H-αEGFR 
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10.9 Plasmid map of pS-CD34TK39-W 
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